From 739040998f631c0a0e8d22c3136447633df94f4d Mon Sep 17 00:00:00 2001 From: chibongho Date: Wed, 3 Apr 2024 10:35:30 -0400 Subject: [PATCH 01/10] O3-3003 (fix) slow queries with many JOINs by upgrading mariadb to version 10.11.7 (#800) --- docker-compose.yml | 9 ++------- 1 file changed, 2 insertions(+), 7 deletions(-) diff --git a/docker-compose.yml b/docker-compose.yml index a81dd4ee8..ce8cf45cf 100644 --- a/docker-compose.yml +++ b/docker-compose.yml @@ -45,14 +45,9 @@ services: # MariaDB db: - image: mariadb:10.8.2 + image: mariadb:10.11.7 restart: "unless-stopped" - command: - - mysqld - - --character-set-server=utf8 - - --collation-server=utf8_general_ci - - --optimizer-search-depth=0 # makes queries with many JOINs not over-optimized, see: - # https://mariadb.com/docs/server/ref/mdb/system-variables/optimizer_search_depth/ + command: "mysqld --character-set-server=utf8 --collation-server=utf8_general_ci" healthcheck: test: "mysql --user=${OMRS_DB_USER:-openmrs} --password=${OMRS_DB_PASSWORD:-openmrs} --execute \"SHOW DATABASES;\"" interval: 3s From 78b3848f6083be882a7d2b9cd5ab15346bb3beeb Mon Sep 17 00:00:00 2001 From: Ian <52504170+ibacher@users.noreply.github.com> Date: Tue, 9 Apr 2024 16:21:49 -0400 Subject: [PATCH 02/10] Rename ampath_poc_adult_return_visit_form_v1.6_core-demo -> Adult HIV Return Visit Form --- .../ampath_poc_adult_return_visit_form_v1.6_core-demo.json | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/distro/configuration/ampathforms/ampath_poc_adult_return_visit_form_v1.6_core-demo.json b/distro/configuration/ampathforms/ampath_poc_adult_return_visit_form_v1.6_core-demo.json index 1c51c3784..094b3b2a4 100644 --- a/distro/configuration/ampathforms/ampath_poc_adult_return_visit_form_v1.6_core-demo.json +++ b/distro/configuration/ampathforms/ampath_poc_adult_return_visit_form_v1.6_core-demo.json @@ -1,5 +1,5 @@ { - "name": "ampath_poc_adult_return_visit_form_v1.6", + "name": "Adult HIV Return Visit Form", "uuid": "xxxx", "description": "Ampath POC adult return visit form", "version": "1", From 2a71eb10ea6651a93735ccf94c3dc4d8dfe9cdea Mon Sep 17 00:00:00 2001 From: Ruhanga <41738040+Ruhanga@users.noreply.github.com> Date: Thu, 18 Apr 2024 12:50:13 +0300 Subject: [PATCH 03/10] O3-3078: Removed and replace Lab Order Entry form with configured Lab Order basket. (#804) --- .../lab_order_entry_form-core_demo.json | 308 ------------------ .../concepts/convsets-core_demo.csv | 2 +- 2 files changed, 1 insertion(+), 309 deletions(-) delete mode 100644 distro/configuration/ampathforms/lab_order_entry_form-core_demo.json diff --git a/distro/configuration/ampathforms/lab_order_entry_form-core_demo.json b/distro/configuration/ampathforms/lab_order_entry_form-core_demo.json deleted file mode 100644 index 72f55618a..000000000 --- a/distro/configuration/ampathforms/lab_order_entry_form-core_demo.json +++ /dev/null @@ -1,308 +0,0 @@ -{ - "name": "Laboratory Test Orders", - "description": "Simple lab order entry form", - "version": "2.2", - "published": true, - "retired": false, - "encounter": "Consultation", - "pages": [ - { - "label": "Lab Orders", - "sections": [ - { - "label": "Add Test Orders", - "isExpanded": "true", - "questions": [ - { - "type": "obsGroup", - "label": "Test orders", - "questionOptions": { - "concept": "ad2218e0-4bb1-11ed-bdc3-0242ac120002", - "rendering": "group" - }, - "questions": [ - { - "label": "Tests Ordered", - "id": "order1", - "type": "testOrder", - "questionOptions": { - "rendering": "repeating", - "orderSettingUuid": "INPATIENT", - "orderType": "testorder", - "selectableOrders": [ - { - "concept": "851AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Mean corpuscular volume", - "conceptMappings": [] - }, - { - "concept": "163695AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Crystals type in urine sediment by light microscopy test", - "conceptMappings": [] - }, - { - "concept": "1338AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Lymphocytes (%) - microscopic exam", - "conceptMappings": [] - }, - { - "concept": "161447AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Stool microscopy with concentration", - "conceptMappings": [] - }, - { - "concept": "729AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Platelets", - "conceptMappings": [] - }, - { - "concept": "163686AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Yeast presence in urine sediment by light microscopy", - "conceptMappings": [] - }, - { - "concept": "1325AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Hepatitis C test - qualitative", - "conceptMappings": [] - }, - { - "concept": "161448AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Kinyoun's stain for coccidians", - "conceptMappings": [] - }, - { - "concept": "160735AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Bacteriuria test", - "FIELD3": " urine", - "conceptMappings": [] - }, - { - "concept": "1015AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Hematocrit", - "conceptMappings": [] - }, - { - "concept": "163688AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Spore presence in urine test", - "conceptMappings": [] - }, - { - "concept": "163687AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Yeast hyphae presence in urine sediment by light microscopy test", - "conceptMappings": [] - }, - { - "concept": "1016AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Red cell distribution width", - "conceptMappings": [] - }, - { - "concept": "163689AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Trichomonas vaginalis presence in urine sediment by light microscopy", - "conceptMappings": [] - }, - { - "concept": "163426AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Combined % of monocytes", - "FIELD3": " eosinophils and basophils", - "conceptMappings": [] - }, - { - "concept": "655AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Total bilirubin", - "conceptMappings": [] - }, - { - "concept": "161450AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Stool fat test", - "FIELD3": " semi-quantitative", - "conceptMappings": [] - }, - { - "concept": "678AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "White blood cells", - "conceptMappings": [] - }, - { - "concept": "717AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Total protein", - "conceptMappings": [] - }, - { - "concept": "857AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Blood urea nitrogen", - "conceptMappings": [] - }, - { - "concept": "163683AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Erythrocytes presence in urine sediment by light microscopy test", - "conceptMappings": [] - }, - { - "concept": "161445AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Urine routine and microscopy", - "conceptMappings": [] - }, - { - "concept": "163699AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Urea measurement (calculated)", - "conceptMappings": [] - }, - { - "concept": "21AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Haemoglobin", - "conceptMappings": [] - }, - { - "concept": "654AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Serum glutamic-pyruvic transaminase", - "conceptMappings": [] - }, - { - "concept": "160225AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Sickle cell screening test", - "conceptMappings": [] - }, - { - "concept": "159430AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Hepatitis B Surface Antigen Test", - "conceptMappings": [] - }, - { - "concept": "163684AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Leukocytes presence in urine sediment by light microscopy", - "conceptMappings": [] - }, - { - "concept": "161449AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Stool test for reducing substance", - "conceptMappings": [] - }, - { - "concept": "653AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Serum glutamic-oxaloacetic transaminase", - "conceptMappings": [] - }, - { - "concept": "790AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Serum creatinine (umol/L)", - "conceptMappings": [] - }, - { - "concept": "163696AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Casts presence in urine sediment by light microscopy test", - "conceptMappings": [] - }, - { - "concept": "887AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Serum glucose", - "conceptMappings": [] - }, - { - "concept": "304AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Stool exam", - "conceptMappings": [] - }, - { - "concept": "785AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Alkaline phosphatase", - "conceptMappings": [] - }, - { - "concept": "159362AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Fecal occult blood test", - "conceptMappings": [] - }, - { - "concept": "679AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Red blood cells", - "conceptMappings": [] - }, - { - "concept": "1336AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Neutrophils (%) - microscopic exam", - "conceptMappings": [] - }, - { - "concept": "163692AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Epithelial casts presence in urine sediment by light microscopy test", - "conceptMappings": [] - }, - { - "concept": "1018AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Mean corpuscular hemoglobin", - "conceptMappings": [] - }, - { - "concept": "1017AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Mean cell hemoglobin concentration", - "conceptMappings": [] - }, - { - "concept": "161431AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Sickling test only", - "conceptMappings": [] - }, - { - "concept": "161488AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Renal function panel", - "conceptMappings": [] - }, - { - "concept": "953AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Liver function tests", - "conceptMappings": [] - }, - { - "concept": "161451AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Stool test", - "conceptMappings": [] - }, - { - "concept": "163697AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Urine microscopy panel", - "conceptMappings": [] - }, - { - "concept": "1019AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Complete blood count" - }, - { - "concept": "161481AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Prothrombin time" - }, - { - "concept": "161482AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "International Normalized Ratio (INR)" - }, - { - "concept": "161157AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "ECG: 12-Lead Electrocardiogram" - }, - { - "concept": "12AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "label": "Chest X-Ray (CXR)" - } - ] - } - }, - { - "type": "encounterLocation", - "label": "Facility name (site/satellite clinic required):", - "id": "location", - "required": "true", - "questionOptions": { - "rendering": "ui-select-extended" - } - } - ] - } - ] - } - ] - } - ], - "processor": "EncounterFormProcessor", - "uuid": "xxxx", - "referencedForms": [] -} diff --git a/distro/configuration/concepts/convsets-core_demo.csv b/distro/configuration/concepts/convsets-core_demo.csv index b34b8f840..d87a48e33 100644 --- a/distro/configuration/concepts/convsets-core_demo.csv +++ b/distro/configuration/concepts/convsets-core_demo.csv @@ -1,3 +1,3 @@ Uuid,Void/Retire,Same as mappings,Fully specified name:en,Fully specified name:fr,Short name:en,Short name:fr,Description:en,Description:fr,Data class,Data type,Answers,Members,_version:1,_order:1001 1114AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,,CIEL:1114;AMPATH:1114;PIH:1335,Vital signs,Signes vitaux,Vital Signs,Signes vitaux,Convenience set. Listing of vital signs.,,ConvSet,N/A,,5085AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;5086AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;5088AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;5090AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;5089AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;5087AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;5092AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;1343AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;5242AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;5283AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,, -ad2218e0-4bb1-11ed-bdc3-0242ac120002,,,Laboratory tests,Essais en laboratoire,Lab tests,Essais en laboratoire,Convenience set for all lab tests/panels,,ConvSet,N/A,,851AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163695AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;1338AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;161447AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;729AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163686AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;1325AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;161448AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;160735AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;1015AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163688AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163687AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;1016AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163689AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163426AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;655AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;161450AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;678AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;717AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;857AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163683AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;161445AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163699AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;21AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;654AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;160225AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;159430AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163684AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;161449AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;653AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;790AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163696AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;887AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;304AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;785AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;159362AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;679AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;1336AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163692AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;1018AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;1017AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;161431AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;161488AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;953AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;161451AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;163697AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA;1019AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,, \ No newline at end of file +1748a953-d12e-4be1-914c-f6b096c6cdef,,,Tests Orderability,Tests Orderability,Possibilité de commande des tests,Possibilité de commande des tests,,,ConvSet,Coded,,"Urobilinogen;Lymphocytes (%) - microscopic exam;Neutrophils (%) - microscopic exam;Hepatitis C test - qualitative;Spore presence in urine test;Yeast hyphae presence in urine sediment by light microscopy test;Yeast presence in urine sediment by light microscopy;Leukocytes presence in urine sediment by light microscopy;Erythrocytes presence in urine sediment by light microscopy test;Combined % of monocytes, eosinophils and basophils;Renal function panel;Stool test;Stool fat test, semi-quantitative;Stool test for reducing substance;Kinyoun's stain for coccidians;Stool microscopy with concentration;Urine routine and microscopy;Sickling test only;Bacteriuria test, urine;Sickle cell screening test;Hepatitis B Surface Antigen Test;Fecal occult blood test;Complete blood count;Mean corpuscular hemoglobin;Mean cell hemoglobin concentration;Red cell distribution width;Hematocrit;Liver function tests;Serum glucose;Blood urea nitrogen;Mean corpuscular volume;Serum creatinine (umol/L);Alkaline phosphatase;Platelets;Total protein;Red blood cells;White blood cells;Total bilirubin;Serum glutamic-pyruvic transaminase;Serum glutamic-oxaloacetic transaminase;Stool exam;Haemoglobin;Urea measurement (calculated);Urine microscopy panel;Casts presence in urine sediment by light microscopy test;Crystals type in urine sediment by light microscopy test;Epithelial casts presence in urine sediment by light microscopy test;Trichomonas vaginalis presence in urine sediment by light microscopy",, From 37522dab462b6aa346412f869efca545a54d7b1f Mon Sep 17 00:00:00 2001 From: Dennis Kigen Date: Fri, 19 Apr 2024 23:00:18 +0300 Subject: [PATCH 04/10] (feat) O3-2972: Validate number fields whose concepts don't allow decimal values (#805) --- .../TestResultsEntryFormv2-core_demo.json | 62 ++++--------------- 1 file changed, 13 insertions(+), 49 deletions(-) diff --git a/distro/configuration/ampathforms/TestResultsEntryFormv2-core_demo.json b/distro/configuration/ampathforms/TestResultsEntryFormv2-core_demo.json index b9adca07f..f9a4736b0 100644 --- a/distro/configuration/ampathforms/TestResultsEntryFormv2-core_demo.json +++ b/distro/configuration/ampathforms/TestResultsEntryFormv2-core_demo.json @@ -1,6 +1,6 @@ { "name": "Laboratory Test Results", - "version": "2", + "version": "3", "published": true, "retired": false, "encounter": "Lab Results", @@ -119,6 +119,7 @@ "required": false, "id": "ManualEntryPlatelets", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "729AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -172,6 +173,7 @@ "required": false, "id": "ManualEntryNeutrophilsMicroscopic", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "1336AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -210,6 +212,7 @@ "required": false, "id": "ManualEntryMCV", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "851AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -324,6 +327,7 @@ "required": false, "id": "ManualEntryLymphocytesMicroscopic", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "1338AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -459,6 +463,7 @@ "required": false, "id": "ManualEntryCombinedPercentageMonocytesEosinophilsBasophils", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "163426AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -543,6 +548,7 @@ "required": false, "id": "ManualEntryAmylase", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "1299AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -802,6 +808,7 @@ "required": false, "id": "manualEntrySerumSodium", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "1132AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -878,6 +885,7 @@ "required": false, "id": "manualEntryTotalProtein", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "717AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -911,6 +919,7 @@ "required": false, "id": "manualEntrySerumGlucosemgdl", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "887AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -1020,6 +1029,7 @@ "required": false, "id": "manualEntrySerumGlutamicOxaloaceticTransaminase", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "653AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -1058,6 +1068,7 @@ "required": false, "id": "manualEntryAlkalinePhosphastase", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "785AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ @@ -1214,60 +1225,13 @@ "answers": [] } }, - { - "label": "Amylase (IU/L)", - "type": "obs", - "required": false, - "id": "manualEntryAmylase", - "questionOptions": { - "rendering": "number", - "concept": "1299AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", - "conceptMappings": [ - { - "relationship": "SAME-AS", - "type": "IMO ProcedureIT", - "value": "601338" - }, - { - "relationship": "BROADER-THAN", - "type": "LOINC", - "value": "1798-8" - }, - { - "relationship": "SAME-AS", - "type": "CIEL", - "value": "1299" - }, - { - "relationship": "SAME-AS", - "type": "IMO ProcedureIT", - "value": "31004384" - }, - { - "relationship": "SAME-AS", - "type": "PIH", - "value": "3054" - }, - { - "relationship": "SAME-AS", - "type": "SNOMED CT", - "value": "64435009" - }, - { - "relationship": "SAME-AS", - "type": "AMPATH", - "value": "1299" - } - ], - "answers": [] - } - }, { "label": "Serum Carbon Dioxide CO2 (mmol/L)", "type": "obs", "required": false, "id": "manualEntrySerumCarbonDioxide", "questionOptions": { + "disallowDecimals": true, "rendering": "number", "concept": "1135AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA", "conceptMappings": [ From 3a024d238d4d9e8c20ad95fcf109feb8cd976035 Mon Sep 17 00:00:00 2001 From: Ian <52504170+ibacher@users.noreply.github.com> Date: Mon, 22 Apr 2024 18:20:53 -0400 Subject: [PATCH 05/10] Switch to React form engine --- frontend/spa-assemble-config.json | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/frontend/spa-assemble-config.json b/frontend/spa-assemble-config.json index cc3c61d48..b29aaa4b8 100644 --- a/frontend/spa-assemble-config.json +++ b/frontend/spa-assemble-config.json @@ -5,7 +5,7 @@ "@openmrs/esm-login-app": "next", "@openmrs/esm-primary-navigation-app": "next", "@openmrs/esm-home-app": "next", - "@openmrs/esm-form-entry-app": "next", + "@openmrs/esm-form-engine-app": "next", "@openmrs/esm-generic-patient-widgets-app": "next", "@openmrs/esm-patient-allergies-app": "next", "@openmrs/esm-patient-attachments-app": "next", From 75cac3383bc61b2c1dbf01f21b923e2bd196d1ba Mon Sep 17 00:00:00 2001 From: Vineet Sharma Date: Thu, 25 Apr 2024 17:27:40 +0300 Subject: [PATCH 06/10] (feat) Add translations for adult form (#807) --- ... visit form_translations_en-core_demo.json | 701 ++++++++++++++++++ ... visit form_translations_fr-core_demo.json | 701 ++++++++++++++++++ 2 files changed, 1402 insertions(+) create mode 100644 distro/configuration/ampathformstranslations/Ampath POC adult return visit form_translations_en-core_demo.json create mode 100644 distro/configuration/ampathformstranslations/Ampath POC adult return visit form_translations_fr-core_demo.json diff --git a/distro/configuration/ampathformstranslations/Ampath POC adult return visit form_translations_en-core_demo.json b/distro/configuration/ampathformstranslations/Ampath POC adult return visit form_translations_en-core_demo.json new file mode 100644 index 000000000..e70e2651c --- /dev/null +++ b/distro/configuration/ampathformstranslations/Ampath POC adult return visit form_translations_en-core_demo.json @@ -0,0 +1,701 @@ +{ + "uuid": "4e321497-2934-473d-9539-cf00b41f825e", + "form": "Adult HIV Return Visit Form", + "description": "English Translations for 'Ampath POC adult return visit form'", + "language": "en", + "translations": { + "1": "1", + "2": "2", + "3": "3", + "4": "4", + "Encounter Details": "Encounter Details", + "Visit date:": "Visit date:", + "Provider:": "Provider:", + "Facility name (site/satellite clinic required):": "Facility name (site/satellite clinic required):", + "Pre-Clinic Review": "Pre-Clinic Review", + "Pre-clinic Review": "Pre-clinic Review", + "Was this visit scheduled?": "Was this visit scheduled?", + "Scheduled visit": "Scheduled visit", + "Unscheduled visit early": "Unscheduled visit early", + "Unscheduled visit late": "Unscheduled visit late", + "If unscheduled, actual scheduled date": "If unscheduled, actual scheduled date", + "Patient covered by NHIF:": "Patient covered by NHIF:", + "Yes": "Yes", + "No": "No", + "What is the patient's NHIF status?": "What is the patient's NHIF status?", + "Indicate if the patient has been remitting monthly contributions towards the NHIF medical cover.": "Indicate if the patient has been remitting monthly contributions towards the NHIF medical cover.", + "Active": "Active", + "Inactive": "Inactive", + "What other insurance do you have?": "What other insurance do you have?", + "Indicate if the patient has another medical cover.": "Indicate if the patient has another medical cover.", + "None": "None", + "Employer based health insurance": "Employer based health insurance", + "Individual private health insurance": "Individual private health insurance", + "Linda mama services": "Linda mama services", + "Zuri health insurance": "Zuri health insurance", + "Other": "Other", + "Clinical History": "Clinical History", + "Social History": "Social History", + "Civil status:": "Civil status:", + "Cohabitating": "Cohabitating", + "Divorced": "Divorced", + "Married monogamous": "Married monogamous", + "Married polygamous": "Married polygamous", + "Separated": "Separated", + "Single": "Single", + "Widowed": "Widowed", + "Discordant couple:": "Discordant couple:", + "Unknown": "Unknown", + "N/A": "N/A", + "Partner Notification Service": "Partner Notification Service", + "Partner notification": "Partner notification", + "Sexual partner tested?": "Sexual partner tested?", + "Do you have a new sexual partner?": "Do you have a new sexual partner?", + "Name of new sexual partner:": "Name of new sexual partner:", + "Prevention With Positives": "Prevention With Positives", + "Prevention with positives: At risk population:": "Prevention with positives: At risk population:", + "Client of sex worker": "Client of sex worker", + "Commercial sex worker": "Commercial sex worker", + "Discordant couple": "Discordant couple", + "IV drug use": "IV drug use", + "MSM": "MSM", + "Prevention with positives: PWP services:": "Prevention with positives: PWP services:", + "Condom promotion/provision": "Condom promotion/provision", + "Couple counseling": "Couple counseling", + "Needle exchange": "Needle exchange", + "Targeted risk reduction": "Targeted risk reduction", + "Hospitalization History": "Hospitalization History", + "Recent hospitalizations": "Recent hospitalizations", + "Was the patient hospitalized since last visit?": "Was the patient hospitalized since last visit?", + "If yes reason for hospitalization:": "If yes reason for hospitalization:", + "Reason for hospitalization:": "Reason for hospitalization:", + "Reproductive History": "Reproductive History", + "How many pregnancies have you had?": "How many pregnancies have you had?", + "How many pregnancies have you delivered (more than 24 weeks)?": "How many pregnancies have you delivered (more than 24 weeks)?", + "Reproductive age status:": "Reproductive age status:", + "Menstruating": "Menstruating", + "Postmenopausal": "Postmenopausal", + "Amenorrhea": "Amenorrhea", + "LMP:": "LMP:", + "Is the patient pregnant?": "Is the patient pregnant?", + "EDD:": "EDD:", + "Reason patient not pregnant?": "Reason patient not pregnant?", + "Pregnancy not suspected": "Pregnancy not suspected", + "Pregnancy test is negative": "Pregnancy test is negative", + "Using hormonal contraceptive": "Using hormonal contraceptive", + "postpartum < 6 weeks": "postpartum < 6 weeks", + "Actual date of delivery:": "Actual date of delivery:", + "Gestation in weeks:": "Gestation in weeks:", + "Pregnancy outcome:": "Pregnancy outcome:", + "Abortion/Miscarriage/Terminated": "Abortion/Miscarriage/Terminated", + "Live birth (Preterm)": "Live birth (Preterm)", + "Live birth (Term)": "Live birth (Term)", + "Family Planning Profile": "Family Planning Profile", + "Is the client using condoms?": "Is the client using condoms?", + "Family planning, detailed": "Family planning, detailed", + "Select modern contraception method:": "Select modern contraception method:", + "Bilateral tubal ligation": "Bilateral tubal ligation", + "3-year implant": "3-year implant", + "5-year implant": "5-year implant", + "IUCD copper": "IUCD copper", + "IUCD hormonal": "IUCD hormonal", + "Injectables (Depo)": "Injectables (Depo)", + "Combined hormone oral contraceptive pills": "Combined hormone oral contraceptive pills", + "Projestin only pills": "Projestin only pills", + "Vasectomy": "Vasectomy", + "Lactational amenohhrea method": "Lactational amenohhrea method", + "Diaphram/Cervical cap": "Diaphram/Cervical cap", + "Emergency contraceptive pills": "Emergency contraceptive pills", + "Periodic abstinence": "Periodic abstinence", + "Undecided": "Undecided", + "Approximate start date (If FP is 3-year implant/5-year implant/Injectables/Vasectomy/IUCD Copper/IUCD Hormonal/Bilateral tubal ligation)": "Approximate start date (If FP is 3-year implant/5-year implant/Injectables/Vasectomy/IUCD Copper/IUCD Hormonal/Bilateral tubal ligation)", + "Cancer Screening": "Cancer Screening", + "Cervical cancer screening done:": "Cervical cancer screening done:", + "Cervical cancer screening test result:": "Cervical cancer screening test result:", + "Positive": "Positive", + "Negative": "Negative", + "Cervical cancer result date:": "Cervical cancer result date:", + "If cervical cancer is positive, is patient on treatment?": "If cervical cancer is positive, is patient on treatment?", + "Completed": "Completed", + "If patient on treatment, indicate below:": "If patient on treatment, indicate below:", + "Cryotherapy": "Cryotherapy", + "Chemotherapy": "Chemotherapy", + "Hysterectomy": "Hysterectomy", + "Radiotherapy": "Radiotherapy", + "Thermo-coagulation/Loop Electrosurgical Excision Procedure": "Thermo-coagulation/Loop Electrosurgical Excision Procedure", + "GBV Screening": "GBV Screening", + "Within the past 3 months, have you been hit, slapped, kicked or physically hurt by someone in any way?": "Within the past 3 months, have you been hit, slapped, kicked or physically hurt by someone in any way?", + "Are you in a relationship with a person who physically hit you?": "Are you in a relationship with a person who physically hit you?", + "Are you in a relationship with a person who threatens, frightens or insults you or treats you badly?": "Are you in a relationship with a person who threatens, frightens or insults you or treats you badly?", + "Are you in relationship with a person who forces you to participate in sexual activities that make you feel uncomfortable?": "Are you in relationship with a person who forces you to participate in sexual activities that make you feel uncomfortable?", + "Have you ever experienced any of the above with someone you do not have a relationship with?": "Have you ever experienced any of the above with someone you do not have a relationship with?", + "Adult Vaccination": "Adult Vaccination", + "Immunization history:": "Immunization history:", + "Hepatitis B": "Hepatitis B", + "Flu": "Flu", + "Tetanus booster": "Tetanus booster", + "Breastfeeding": "Breastfeeding", + "Child breastfeeding?": "Child breastfeeding?", + "Medication History": "Medication History", + "ART History": "ART History", + "Is the patient on ART?": "Is the patient on ART?", + "Reason for use:": "Reason for use:", + "Treatment": "Treatment", + "PEP": "PEP", + "Prep": "Prep", + "PMTCT": "PMTCT", + "If patient started ART since last visit, enter start date:": "If patient started ART since last visit, enter start date:", + "Line of ART patient is taking:": "Line of ART patient is taking:", + "First line regimen": "First line regimen", + "Second line regimen": "Second line regimen", + "Third line regimen": "Third line regimen", + "Patient's ART regimen, adults:": "Patient's ART regimen, adults:", + "DTG50mg/3TC300mg/TDF300mg": "DTG50mg/3TC300mg/TDF300mg", + "TDF300mg/3TC300mg/EFV600mg": "TDF300mg/3TC300mg/EFV600mg", + "TDF300mg/3TC300mg/EFV400mg": "TDF300mg/3TC300mg/EFV400mg", + "NVP200/ZDV300/3TC150": "NVP200/ZDV300/3TC150", + "ABC600mg/3TC300mg": "ABC600mg/3TC300mg", + "3TC300mg/TDF300mg": "3TC300mg/TDF300mg", + "3TC150mg/ZDV300mg": "3TC150mg/ZDV300mg", + "Emtri200mg/TDF300(Truvada)": "Emtri200mg/TDF300(Truvada)", + "Aluvia(Kaletra)200mg/LPV50mg": "Aluvia(Kaletra)200mg/LPV50mg", + "Atazanavir300/Ritonavir100": "Atazanavir300/Ritonavir100", + "FTC200mg/RPV25mg/TDF245mg(Eviplera)": "FTC200mg/RPV25mg/TDF245mg(Eviplera)", + "Dolutegravir 50mg": "Dolutegravir 50mg", + "Abacavir300mg": "Abacavir300mg", + "Efavirenz 200mg": "Efavirenz 200mg", + "Lamivudine150mg": "Lamivudine150mg", + "Raltegravir 400mg": "Raltegravir 400mg", + "Zidovudine300mg": "Zidovudine300mg", + "Darunavir 600mg": "Darunavir 600mg", + " Ritonavir 100mg": " Ritonavir 100mg", + " Ritonavir 80mg": " Ritonavir 80mg", + "Etravirine 100mg": "Etravirine 100mg", + "ART adherence": "ART adherence", + "Morisky Adherence": "Morisky Adherence", + "Do you ever forget to take your medicines? (0=No, 1=Yes)": "Do you ever forget to take your medicines? (0=No, 1=Yes)", + "Are you sometimes not keen about taking your medications? (0=No, 1=Yes)": "Are you sometimes not keen about taking your medications? (0=No, 1=Yes)", + "Do you stop taking medicine at times when you feel worse? (0=No, 1=Yes)": "Do you stop taking medicine at times when you feel worse? (0=No, 1=Yes)", + "If you feel better, do you sometimes stop taking your medicine? (0=No, 1=Yes)": "If you feel better, do you sometimes stop taking your medicine? (0=No, 1=Yes)", + "Morisky 4 total score:": "Morisky 4 total score:", + "Morisky score rating:": "Morisky score rating:", + "Did you forget to take your medicine yesterday? (0=No, 1=Yes)": "Did you forget to take your medicine yesterday? (0=No, 1=Yes)", + "Do you sometimes stop taking medicine if you feel like your symptoms are under control? (0=No, 1=Yes)": "Do you sometimes stop taking medicine if you feel like your symptoms are under control? (0=No, 1=Yes)", + "Do you ever feel under pressure about sticking to your treatment plan? (0=No, 1=Yes)": "Do you ever feel under pressure about sticking to your treatment plan? (0=No, 1=Yes)", + "How often do you have difficulty remembering to take all your medication? (0=Never/Rarely, 1/4=Once in a while, 1/2=Sometimes, 3/4=Usually,1=All the time)": "How often do you have difficulty remembering to take all your medication? (0=Never/Rarely, 1/4=Once in a while, 1/2=Sometimes, 3/4=Usually,1=All the time)", + "Morisky 8 total score:": "Morisky 8 total score:", + "Enhanced Adherence": "Enhanced Adherence", + "Has a home visit been done?": "Has a home visit been done?", + "If yes, number of visits:": "If yes, number of visits:", + "If yes, what were the findings:": "If yes, what were the findings:", + "If no, wish to refer to the social worker:": "If no, wish to refer to the social worker:", + "What are the support structures in place?": "What are the support structures in place?", + "Treatment supporter": "Treatment supporter", + "Support group": "Support group", + "Caregiver": "Caregiver", + "Family": "Family", + "Has directly observed treatment (DOT) been done?": "Has directly observed treatment (DOT) been done?", + "Number of directly observed treatment (DOT) done (days):": "Number of directly observed treatment (DOT) done (days):", + "Likely causes of poor adherence: (Choose all that apply)": "Likely causes of poor adherence: (Choose all that apply)", + "Stigma": "Stigma", + "School related stigma": "School related stigma", + "Home related stigma": "Home related stigma", + "Improper disclosure to child": "Improper disclosure to child", + "Inadequate supervision": "Inadequate supervision", + "Child refusing to take drugs": "Child refusing to take drugs", + "Pill related size": "Pill related size", + "Pill taste": "Pill taste", + "Pill color": "Pill color", + "Pill burden": "Pill burden", + "Disclosure": "Disclosure", + "Side effects": "Side effects", + "Alcohol": "Alcohol", + "Other drugs": "Other drugs", + "Mental health issues": "Mental health issues", + "Depression": "Depression", + "Caregiver changes": "Caregiver changes", + "Religious beliefs": "Religious beliefs", + "Inadequate treatment preparation": "Inadequate treatment preparation", + "Poor adherence": "Poor adherence", + "If other causes of poor adherence, explain:": "If other causes of poor adherence, explain:", + "Is patient enrolled in support group?": "Is patient enrolled in support group?", + "If no, wishes to enroll?": "If no, wishes to enroll?", + "If yes, name of support group:": "If yes, name of support group:", + "Has age appropriate disclosure been completed?": "Has age appropriate disclosure been completed?", + "Has a pill count been done?": "Has a pill count been done?", + "If yes, what are the findings:": "If yes, what are the findings:", + "Accurate": "Accurate", + "Missed doses": "Missed doses", + "Other possible causes of treatment failure:": "Other possible causes of treatment failure:", + "Inadequate dosing/dose adjustments": "Inadequate dosing/dose adjustments", + "Drug-drug interaction": "Drug-drug interaction", + "Drug-food interaction": "Drug-food interaction", + "Impaired absorption (such as chronic severe diarrhea)": "Impaired absorption (such as chronic severe diarrhea)", + "If drug causes treatment failure, indicate drug:": "If drug causes treatment failure, indicate drug:", + "Does this patient have other co morbidities?": "Does this patient have other co morbidities?", + "Convulsive disease": "Convulsive disease", + "Mental health disorders": "Mental health disorders", + "Diabetes": "Diabetes", + "Renal disease": "Renal disease", + "Liver disease": "Liver disease", + "Hypertention": "Hypertention", + "Has drug resistance test (DRT) been done?": "Has drug resistance test (DRT) been done?", + "If DRT result available, upload image:": "If DRT result available, upload image:", + "Has an MDT been done?": "Has an MDT been done?", + "If No, wish to refer?": "If No, wish to refer?", + "PCP Prophylaxis History": "PCP Prophylaxis History", + "Is the patient on any PCP prophylaxis?": "Is the patient on any PCP prophylaxis?", + "Septrin": "Septrin", + "Dapsone 100mg": "Dapsone 100mg", + "PCP prophylaxis adherence:": "PCP prophylaxis adherence:", + "Patient's adherence on PCP prophylaxis:": "Patient's adherence on PCP prophylaxis:", + "Good": "Good", + "Fair": "Fair", + "Poor": "Poor", + "Adherence (PCP) reasons for poor/fair:": "Adherence (PCP) reasons for poor/fair:", + "Felt well": "Felt well", + "Forgot": "Forgot", + "Gave away": "Gave away", + "Lost/ran out of pills": "Lost/ran out of pills", + "Stock out": "Stock out", + "Too ill": "Too ill", + "Travel problems": "Travel problems", + "Adherence (PCP): Other (specify):": "Adherence (PCP): Other (specify):", + "TB Prophylaxis History": "TB Prophylaxis History", + "Is the patient on any TB prophylaxis?": "Is the patient on any TB prophylaxis?", + "If yes select drug": "If yes select drug", + "Isoniazid 100mg (6H)": "Isoniazid 100mg (6H)", + "Isoniazid 300mg (6H)": "Isoniazid 300mg (6H)", + "Isoniazid 300mg and Rifapentine 300mg (3HP)": "Isoniazid 300mg and Rifapentine 300mg (3HP)", + "Rifampicin 150mg and Isonaizid 75mg (3RH)": "Rifampicin 150mg and Isonaizid 75mg (3RH)", + "Rifampicin 70mg and Isonaizid 50mg (3RH)": "Rifampicin 70mg and Isonaizid 50mg (3RH)", + "TB prophylaxis ever": "TB prophylaxis ever", + "If no, have you ever used the drugs in the past?": "If no, have you ever used the drugs in the past?", + "Start date of past TB prophylaxis treatment:": "Start date of past TB prophylaxis treatment:", + "End date of past TB prophylaxis treatment:": "End date of past TB prophylaxis treatment:", + "TB prophylaxis adherence": "TB prophylaxis adherence", + "Patient's adherence on TB prophylaxis:": "Patient's adherence on TB prophylaxis:", + "Adherence (TB Prophylaxis) reasons for poor/fair:": "Adherence (TB Prophylaxis) reasons for poor/fair:", + "Lost/Ran out of pills": "Lost/Ran out of pills", + "Adherence (TB Prophylaxis): Other (specify):": "Adherence (TB Prophylaxis): Other (specify):", + "Tuberculosis History": "Tuberculosis History", + "Is patient on TB treatment?": "Is patient on TB treatment?", + "Start date of TB treatment:": "Start date of TB treatment:", + "Tuberculosis treatment phase:": "Tuberculosis treatment phase:", + "Continuation phase": "Continuation phase", + "Retreatment phase": "Retreatment phase", + "Induction phase": "Induction phase", + "Retreated phase": "Retreated phase", + "Current TB regimen": "Current TB regimen", + "Current TB regimen:": "Current TB regimen:", + "RHZE": "RHZE", + "RHZ": "RHZ", + "RHE": "RHE", + "RH": "RH", + "EH": "EH", + "Ethambutol": "Ethambutol", + "MDR drugs": "MDR drugs", + "INH": "INH", + "Pyrazinamide": "Pyrazinamide", + "Streptomycin": "Streptomycin", + "Rifabutin": "Rifabutin", + "Rifampicin": "Rifampicin", + "tabs/day:": "tabs/day:", + "mg:": "mg:", + "mg/day:": "mg/day:", + "tabs:": "tabs:", + "TB treatment completion date:": "TB treatment completion date:", + "TB treatment defaulted year:": "TB treatment defaulted year:", + "Patient adherence to TB medications": "Patient adherence to TB medications", + "Patient adherence to TB medications:": "Patient adherence to TB medications:", + "Adherence (TB Treatment) reasons for poor/fair:": "Adherence (TB Treatment) reasons for poor/fair:", + "Adherence (TB Treatment): Other (specify):": "Adherence (TB Treatment): Other (specify):", + "Cryptococcal Secondary Prevention": "Cryptococcal Secondary Prevention", + "Cryptococcus Tx:": "Cryptococcus Tx:", + "Fluconazole 400mg": "Fluconazole 400mg", + "Other Medications": "Other Medications", + "Please add any other medications the patient is taking": "Please add any other medications the patient is taking", + "Other drugs:": "Other drugs:", + "Side Effects/Toxicity": "Side Effects/Toxicity", + "Any side effects attributable to any drug that the patient is currently taking:": "Any side effects attributable to any drug that the patient is currently taking:", + "If yes drugs suspected to be causing side effects": "If yes drugs suspected to be causing side effects", + "Drug:": "Drug:", + "If yes, tick all that apply:": "If yes, tick all that apply:", + "Anaemia": "Anaemia", + "Hepatitis": "Hepatitis", + "IRIS": "IRIS", + "Lactic acidosis": "Lactic acidosis", + "Lipo-dystrophy": "Lipo-dystrophy", + "Neuropathy": "Neuropathy", + "Persistent vomiting": "Persistent vomiting", + "Rash": "Rash", + "Steven-Johnson syndrome": "Steven-Johnson syndrome", + "Nausea": "Nausea", + "Burning sensation": "Burning sensation", + "Diarrhea": "Diarrhea", + "Headache": "Headache", + "Fatigue": "Fatigue", + "Jaundice": "Jaundice", + "Dizzy": "Dizzy", + "Abdominal pain": "Abdominal pain", + "Anxiety": "Anxiety", + "Nightmare": "Nightmare", + "Confusion/abnormal thinking": "Confusion/abnormal thinking", + "Insomnia": "Insomnia", + "Poor concentration/ memory problems": "Poor concentration/ memory problems", + "Paresthesia/painful neuropathy": "Paresthesia/painful neuropathy", + "Suicide ideation": "Suicide ideation", + "Severity of the reaction:": "Severity of the reaction:", + "Mild": "Mild", + "Moderate": "Moderate", + "Severe": "Severe", + "Action plan:": "Action plan:", + "Stopped drugs": "Stopped drugs", + "Substitute drugs": "Substitute drugs", + "Change drugs": "Change drugs", + "Switched drugs": "Switched drugs", + "How certain are you the drug(s) is/are the cause of the reaction?": "How certain are you the drug(s) is/are the cause of the reaction?", + "Certain": "Certain", + "Probable/likely": "Probable/likely", + "Possible": "Possible", + "Unlikely": "Unlikely", + "Conditional/unclassified": "Conditional/unclassified", + "Unassessable/unclassified": "Unassessable/unclassified", + "Vitals": "Vitals", + "Vital Signs": "Vital Signs", + "BP systolic:": "BP systolic:", + "BP diastolic:": "BP diastolic:", + "Pulse (Rate/min):": "Pulse (Rate/min):", + "Temp (C):": "Temp (C):", + "Weight (Kg):": "Weight (Kg):", + "Height (Cm):": "Height (Cm):", + "Sp02:": "Sp02:", + "BMI (Kg/m2):": "BMI (Kg/m2):", + "MUAC:": "MUAC:", + "Foetal heart rate:": "Foetal heart rate:", + "Fundal height:": "Fundal height:", + "Nutrition Assessment and Diagnosis": "Nutrition Assessment and Diagnosis", + "Nutrition status:": "Nutrition status:", + "Normal": "Normal", + "Overweight": "Overweight", + "Obese": "Obese", + "Severe acute malnutrition": "Severe acute malnutrition", + "Moderate acute malnutrition": "Moderate acute malnutrition", + "Current Symptoms": "Current Symptoms", + "TB Screening Questions": "TB Screening Questions", + "TB Symptoms:": "TB Symptoms:", + "Breathlessness": "Breathlessness", + "Chest pain": "Chest pain", + "Cough of any duration": "Cough of any duration", + "Fever for = 2 weeks": "Fever for = 2 weeks", + "New exposure to household contact with TB": "New exposure to household contact with TB", + "Noticeable weight loss": "Noticeable weight loss", + "Night sweats = 2 weeks": "Night sweats = 2 weeks", + "Abdomen swelling": "Abdomen swelling", + "Groin swelling": "Groin swelling", + "Joints swelling": "Joints swelling", + "Neck swelling": "Neck swelling", + "TB Status:": "TB Status:", + "No signs": "No signs", + "On TB treatment": "On TB treatment", + "Suspect": "Suspect", + "Confirmed": "Confirmed", + "Not assessed": "Not assessed", + "STI": "STI", + "Do you have any of the following:": "Do you have any of the following:", + "Genital ulcers": "Genital ulcers", + "Urethral discharge": "Urethral discharge", + "Vaginal discharge": "Vaginal discharge", + "STI partner notification:": "STI partner notification:", + "Adult WHO Staging": "Adult WHO Staging", + "If you are assigning a new WHO stage to patient today, select new WHO stage:": "If you are assigning a new WHO stage to patient today, select new WHO stage:", + "Select criteria for new WHO stage:": "Select criteria for new WHO stage:", + "Test Results": "Test Results", + "Chemistry Lab Tests": "Chemistry Lab Tests", + "Creatinine mmol/L:": "Creatinine mmol/L:", + "SGPT(ALT):": "SGPT(ALT):", + "AST:": "AST:", + "RBS mmol/L:": "RBS mmol/L:", + "FBS mmol/L:": "FBS mmol/L:", + "HbA1C %:": "HbA1C %:", + "LDL mmol/L:": "LDL mmol/L:", + "HDL mmol/L:": "HDL mmol/L:", + "TG mmol/L:": "TG mmol/L:", + "Cholesterol mmol/L:": "Cholesterol mmol/L:", + "Microalbumin test, urine mg/L:": "Microalbumin test, urine mg/L:", + "Urea mmol/L:": "Urea mmol/L:", + "CBC": "CBC", + "Hgb g/dL:": "Hgb g/dL:", + "WBC/mm3:": "WBC/mm3:", + "Platelets:": "Platelets:", + "ALC/ mm3:": "ALC/ mm3:", + "MCV:": "MCV:", + "CD4": "CD4", + "CD4 Count:": "CD4 Count:", + "CD4 %:": "CD4 %:", + "ART Drug Sensitivity Test": "ART Drug Sensitivity Test", + "ART drug sensitivity test (Upload image of the result):": "ART drug sensitivity test (Upload image of the result):", + "Viral Load": "Viral Load", + "Viral load:": "Viral load:", + "Urinalysis": "Urinalysis", + "Urinalysis:": "Urinalysis:", + "Pus cells:": "Pus cells:", + "Positive (+)": "Positive (+)", + "Strong positive (++)": "Strong positive (++)", + "Stronger positive (+++)": "Stronger positive (+++)", + "Protein:": "Protein:", + "Leucocytes:": "Leucocytes:", + "Ketone:": "Ketone:", + "Glucose:": "Glucose:", + "Nitrites:": "Nitrites:", + "Blood Grouping": "Blood Grouping", + "Blood type:": "Blood type:", + "A positive": "A positive", + "A negative": "A negative", + "B positive": "B positive", + "B negative": "B negative", + "O positive": "O positive", + "O negative": "O negative", + "AB positive": "AB positive", + "AB negative": "AB negative", + "A": "A", + "B": "B", + "AB": "AB", + "O": "O", + "TB Test": "TB Test", + "Genexpert test (Upload image of the result):": "Genexpert test (Upload image of the result):", + "Sputum gene xpert MTB:": "Sputum gene xpert MTB:", + "Indeterminate": "Indeterminate", + "Poor sample quality": "Poor sample quality", + "Sputum AFB smear:": "Sputum AFB smear:", + "1+": "1+", + "2+": "2+", + "3+": "3+", + "Sputum culture:": "Sputum culture:", + "Mycobacterium tuberculosis": "Mycobacterium tuberculosis", + "Non tuberculosis mycobacteria": "Non tuberculosis mycobacteria", + "TST (Mantoux test):": "TST (Mantoux test):", + "Strongly positive": "Strongly positive", + "Chest Xray": "Chest Xray", + "CXR code:": "CXR code:", + "Cardiomegaly": "Cardiomegaly", + "Cavitary": "Cavitary", + "Diffuse abn/non-miliary": "Diffuse abn/non-miliary", + "Infiltrate": "Infiltrate", + "Miliary": "Miliary", + "PI effusion": "PI effusion", + "Other Lab Tests": "Other Lab Tests", + "Test result, detailed": "Test result, detailed", + "Other test results, specify:": "Other test results, specify:", + "Assessment": "Assessment", + "Clinical Notes": "Clinical Notes", + "Please enter the clinical notes below:": "Please enter the clinical notes below:", + "Medication Plan": "Medication Plan", + "ART Plan": "ART Plan", + "ART plan:": "ART plan:", + "Continue regimen": "Continue regimen", + "Change dose": "Change dose", + "Change regimen": "Change regimen", + "Change formulation": "Change formulation", + "Drug substitution": "Drug substitution", + "Not on ARVS": "Not on ARVS", + "Restart": "Restart", + "Start ARVs": "Start ARVs", + "Stop all": "Stop all", + "Reason to start ART:": "Reason to start ART:", + "CD4 less than 500": "CD4 less than 500", + "WHO stage 3": "WHO stage 3", + "WHO stage 4": "WHO stage 4", + "Test and treat": "Test and treat", + "Adherence counselling completed": "Adherence counselling completed", + "ART change reason": "ART change reason", + "Reason for stopping/change/substitution/interruption:": "Reason for stopping/change/substitution/interruption:", + "Adherence concerns": "Adherence concerns", + "Clinical treatment failure": "Clinical treatment failure", + "Drug out of stock": "Drug out of stock", + "Due to new TB": "Due to new TB", + "Illness/hospitalization": "Illness/hospitalization", + "Immunologic failure": "Immunologic failure", + "Lost to follow-up": "Lost to follow-up", + "New drug available": "New drug available", + "Patient lacks finances": "Patient lacks finances", + "Planned Rx interruption": "Planned Rx interruption", + "Changing to adult regimen": "Changing to adult regimen", + "Pregnancy": "Pregnancy", + "Risk of pregnancy": "Risk of pregnancy", + "Other patient desicion": "Other patient desicion", + "Optimization": "Optimization", + "Toxicity": "Toxicity", + "Virologic failure": "Virologic failure", + "If toxicity, please provide cause:": "If toxicity, please provide cause:", + "If toxicity: Other (specify):": "If toxicity: Other (specify):", + "Eligible for ART": "Eligible for ART", + "Eligible for ART but not started:": "Eligible for ART but not started:", + "Patient refused": "Patient refused", + "Eligible for ART but not started: Other (specify):": "Eligible for ART but not started: Other (specify):", + "Plan treatment categories:": "Plan treatment categories:", + "ART regimen started, adult:": "ART regimen started, adult:", + "Indication for DTG based ART:": "Indication for DTG based ART:", + "ART intiation": "ART intiation", + "Substitution for EFV intolerance/toxicity": "Substitution for EFV intolerance/toxicity", + "Substitution for NVP": "Substitution for NVP", + "Substitution for ATV/r in PWID": "Substitution for ATV/r in PWID", + "Substitution for PI/r in 2nd line with TB disease": "Substitution for PI/r in 2nd line with TB disease", + "Alternative for virally suppressed 1st line PI/r based regimen": "Alternative for virally suppressed 1st line PI/r based regimen", + "Alternative regimen for pregnant/postpartum women": "Alternative regimen for pregnant/postpartum women", + "Other (specify):": "Other (specify):", + "PCP Prophylaxis Plan": "PCP Prophylaxis Plan", + "PCP prophylaxis plan:": "PCP prophylaxis plan:", + "Continue": "Continue", + "Not on PCP prophylaxis": "Not on PCP prophylaxis", + "Start": "Start", + "Stop": "Stop", + "PCP prophylaxis change reason": "PCP prophylaxis change reason", + "If change/stop, reason:": "If change/stop, reason:", + "Steven-johnson syndrome": "Steven-johnson syndrome", + "If toxicity, please provide cause: Other (specify):": "If toxicity, please provide cause: Other (specify):", + "If Start/Change, regimen:": "If Start/Change, regimen:", + "TB Prophylaxis Plan": "TB Prophylaxis Plan", + "TB prophylaxis plan:": "TB prophylaxis plan:", + "Not on TB prophylaxis": "Not on TB prophylaxis", + "stopping reason": "stopping reason", + "If stopping, reason:": "If stopping, reason:", + "Active TB": "Active TB", + "Lack of drugs": "Lack of drugs", + "Side effects (Adverse drug reaction)": "Side effects (Adverse drug reaction)", + "Lactic Acidosis": "Lactic Acidosis", + "TB prophylaxis regimen started:": "TB prophylaxis regimen started:", + "TB Treatment Plan": "TB Treatment Plan", + "TB Treatment Started, detailed": "TB Treatment Started, detailed", + "TB Treatment plan:": "TB Treatment plan:", + "Not on TB treatment": "Not on TB treatment", + "Start induction": "Start induction", + "Change to continuation": "Change to continuation", + "Re-dose": "Re-dose", + "Substitution": "Substitution", + "TB Plan Change Reason": "TB Plan Change Reason", + "If plan is to stop/change/re-dose/substitute, reason:": "If plan is to stop/change/re-dose/substitute, reason:", + "If restarting, reason:": "If restarting, reason:", + "Defaulted": "Defaulted", + "Failure": "Failure", + "MDR TB regimen": "MDR TB regimen", + "New treatment": "New treatment", + "Relapse/re-infection": "Relapse/re-infection", + "tbMedPickupSite": "tbMedPickupSite", + "Site of TB meds pick-up:": "Site of TB meds pick-up:", + "This AMPATH site": "This AMPATH site", + "Other Specify:": "Other Specify:", + "TB regimen started:": "TB regimen started:", + "Cryptococcal Treatment Plan": "Cryptococcal Treatment Plan", + "Crag test:": "Crag test:", + "Cryptococcal treatment plan": "Cryptococcal treatment plan", + "Additional Medication Orders": "Additional Medication Orders", + "Additional medication orders": "Additional medication orders", + "Drug": "Drug", + "Frequency": "Frequency", + "Once a day": "Once a day", + "Twice a day": "Twice a day", + "Three times a day": "Three times a day", + "Four times a day": "Four times a day", + "As needed": "As needed", + "If tabs, number": "If tabs, number", + "If caps, number": "If caps, number", + "If mg, number": "If mg, number", + "If ml, number": "If ml, number", + "Plan": "Plan", + "Family Planning Plan": "Family Planning Plan", + "Dispense condom today?": "Dispense condom today?", + "Continue modern contraception method?": "Continue modern contraception method?", + "Does patient wish to start modern contraception method?": "Does patient wish to start modern contraception method?", + "Are you planning to concieve in the next 3 months?": "Are you planning to concieve in the next 3 months?", + "Reason not on family planning": "Reason not on family planning", + "Wants to get pregnant": "Wants to get pregnant", + "Not sexually active now/Infrequent sex": "Not sexually active now/Infrequent sex", + "Fear of side effects/health risks": "Fear of side effects/health risks", + "Opposition/rejection from the male partner/other relatives": "Opposition/rejection from the male partner/other relatives", + "Complications of previous method(s) used": "Complications of previous method(s) used", + "Postpartum amenorrhea": "Postpartum amenorrhea", + "Breasfeeding": "Breasfeeding", + "Wants to wait untill the first baby is born": "Wants to wait untill the first baby is born", + "Wants to wait untill the desired number of children are born": "Wants to wait untill the desired number of children are born", + "Lack of knowledge": "Lack of knowledge", + "Complications caused by family planning method used:": "Complications caused by family planning method used:", + "If yes, modern contraception method chosen:": "If yes, modern contraception method chosen:", + "DC Outcome": "DC Outcome", + "Differentiated care plan:": "Differentiated care plan:", + "Continue in DC": "Continue in DC", + "Exit from DC": "Exit from DC", + "Reason for exit": "Reason for exit", + "Reason for exit:": "Reason for exit:", + "Self transfer out of facility": "Self transfer out of facility", + "High VL": "High VL", + "New OI/new chronic illness": "New OI/new chronic illness", + "Voluntary request to exit": "Voluntary request to exit", + "Other specify:": "Other specify:", + "Test Orders": "Test Orders", + "Test orders": "Test orders", + "Tests Ordered": "Tests Ordered", + "Test ordered: Other (specify):": "Test ordered: Other (specify):", + "Viral load justification:": "Viral load justification:", + "Routine VL": "Routine VL", + "Confirmation of treatment failure (repeat VL)": "Confirmation of treatment failure (repeat VL)", + "Clinical failure": "Clinical failure", + "Single drug substitution": "Single drug substitution", + "Baseline VL (for infants diagnsed through EID)": "Baseline VL (for infants diagnsed through EID)", + "Confirmation of persistent low level viremia (PLLV)": "Confirmation of persistent low level viremia (PLLV)", + "PMTCT patient category:": "PMTCT patient category:", + "Pregnant": "Pregnant", + "None of the above": "None of the above", + "Positive Health Diginity & Prevention Services": "Positive Health Diginity & Prevention Services", + "PHDP:": "PHDP:", + "Adherence counselling": "Adherence counselling", + "STI screening": "STI screening", + "Substance use": "Substance use", + "Disclosure to sex partner": "Disclosure to sex partner", + "Partner testing": "Partner testing", + "Condom distribution": "Condom distribution", + "Treatment of GBV injuries": "Treatment of GBV injuries", + "First line support (LIVES)": "First line support (LIVES)", + "Emergency contraceptives": "Emergency contraceptives", + "Referrals": "Referrals", + "Referrals made to the patient:": "Referrals made to the patient:", + "OVC": "OVC", + "ENT": "ENT", + "Cardiology": "Cardiology", + "Disclosure counselling": "Disclosure counselling", + "Hospitalization": "Hospitalization", + "Oncology": "Oncology", + "Mental health services": "Mental health services", + "Nutritional support": "Nutritional support", + "Psychosocial support": "Psychosocial support", + "TB/DOT program": "TB/DOT program", + "Surgery": "Surgery", + "Dermatology": "Dermatology", + "Social work": "Social work", + "Differentiated care program": "Differentiated care program", + "Ophthalmology ": "Ophthalmology ", + "Reproductive health ": "Reproductive health ", + "MDT Program": "MDT Program", + "Resistant clinic": "Resistant clinic", + "Legal counsel": "Legal counsel", + "Police department": "Police department", + "Child protection services": "Child protection services", + "Emergency shelter": "Emergency shelter", + "Referrals made to the patient: Other (specify):": "Referrals made to the patient: Other (specify):", + "If referred for hospitalization, choose location:": "If referred for hospitalization, choose location:", + "Local health centre/hospital": "Local health centre/hospital", + "MTRH": "MTRH", + "Reason for hospitalization": "Reason for hospitalization", + "Transfer Out": "Transfer Out", + "Transfer care to other centre": "Transfer care to other centre", + "Transfer care to other centre:": "Transfer care to other centre:", + "AMPATH": "AMPATH", + "Non-AMPATH": "Non-AMPATH", + "MCH": "MCH", + "Specify name of AMPATH clinic to which patient is being referred:": "Specify name of AMPATH clinic to which patient is being referred:", + "If Non-AMPATH specify where the patient is being referred:": "If Non-AMPATH specify where the patient is being referred:", + "Next Appointment": "Next Appointment", + "Medication pick up date:": "Medication pick up date:", + "Return to clinic date:": "Return to clinic date:" + } +} diff --git a/distro/configuration/ampathformstranslations/Ampath POC adult return visit form_translations_fr-core_demo.json b/distro/configuration/ampathformstranslations/Ampath POC adult return visit form_translations_fr-core_demo.json new file mode 100644 index 000000000..193e850f8 --- /dev/null +++ b/distro/configuration/ampathformstranslations/Ampath POC adult return visit form_translations_fr-core_demo.json @@ -0,0 +1,701 @@ +{ + "uuid": "515b2e59-29f2-455d-b170-7aca8ae979cc", + "form": "Adult HIV Return Visit Form", + "description": "French Translations for 'Ampath POC adult return visit form'", + "language": "fr", + "translations": { + "1": "1", + "2": "2", + "3": "3", + "4": "4", + "Encounter Details": "Détails de la rencontre", + "Visit date:": "Date de la visite:", + "Provider:": "Fournisseur:", + "Facility name (site/satellite clinic required):": "Nom de l’établissement (site/clinique satellite requis):", + "Pre-Clinic Review": "Examen préclinique", + "Pre-clinic Review": "Examen préclinique", + "Was this visit scheduled?": "Cette visite était-elle programmée ?", + "Scheduled visit": "Visite programmée", + "Unscheduled visit early": "Visite imprévue en avance", + "Unscheduled visit late": "Visite imprévue en retard", + "If unscheduled, actual scheduled date": "Si non planifié, date prévue réelle", + "Patient covered by NHIF:": "Patient couvert par le NHIF:", + "Yes": "Oui", + "No": "Non", + "What is the patient's NHIF status?": "Quel est le statut NHIF du patient ?", + "Indicate if the patient has been remitting monthly contributions towards the NHIF medical cover.": "Indiquez si le patient verse des cotisations mensuelles pour la couverture médicale du NHIF.", + "Active": "Actif", + "Inactive": "Inactif", + "What other insurance do you have?": "Quelle autre assurance avez-vous ?", + "Indicate if the patient has another medical cover.": "Indiquez si le patient bénéficie d’une autre couverture médicale.", + "None": "Aucun", + "Employer based health insurance": "Assurance maladie basée sur l'employeur", + "Individual private health insurance": "Assurance maladie privée individuelle", + "Linda mama services": "Services de maman Linda", + "Zuri health insurance": "Assurance maladie de Zouri", + "Other": "Autre", + "Clinical History": "Histoire clinique", + "Social History": "Histoire sociale", + "Civil status:": "Etat civil :", + "Cohabitating": "Cohabitation", + "Divorced": "Divorcé", + "Married monogamous": "Marié monogame", + "Married polygamous": "Marié polygame", + "Separated": "Séparé", + "Single": "Célibataire", + "Widowed": "Veuf", + "Discordant couple:": "Couple discordant :", + "Unknown": "Inconnu", + "N/A": "N / A", + "Partner Notification Service": "Service de notification des partenaires", + "Partner notification": "Notification du partenaire", + "Sexual partner tested?": "Partenaire sexuel testé ?", + "Do you have a new sexual partner?": "Avez-vous un nouveau partenaire sexuel ?", + "Name of new sexual partner:": "Nom du nouveau partenaire sexuel:", + "Prevention With Positives": "Prévention avec des positifs", + "Prevention with positives: At risk population:": "Prévention avec positifs : Population à risque :", + "Client of sex worker": "Client d'une travailleuse du sexe", + "Commercial sex worker": "Travailleuse du sexe", + "Discordant couple": "Couple discordant", + "IV drug use": "Consommation de drogues IV", + "MSM": "HSH", + "Prevention with positives: PWP services:": "Prévention avec des positifs: services PWP:", + "Condom promotion/provision": "Promotion/fourniture de préservatifs", + "Couple counseling": "Conseils de couple", + "Needle exchange": "Échange d'aiguilles", + "Targeted risk reduction": "Réduction ciblée des risques", + "Hospitalization History": "Antécédents d'hospitalisation", + "Recent hospitalizations": "Hospitalisations récentes", + "Was the patient hospitalized since last visit?": "Le patient a-t-il été hospitalisé depuis la dernière visite?", + "If yes reason for hospitalization:": "Si oui, motif de l'hospitalisation :", + "Reason for hospitalization:": "Raison de l'hospitalisation :", + "Reproductive History": "Histoire de la reproduction", + "How many pregnancies have you had?": "Combien de grossesses avez-vous eu?", + "How many pregnancies have you delivered (more than 24 weeks)?": "Combien de grossesses avez-vous accouchées (plus de 24 semaines)?", + "Reproductive age status:": "Statut d'âge reproductif:", + "Menstruating": "Menstruation", + "Postmenopausal": "Postménopause", + "Amenorrhea": "Aménorrhée", + "LMP:": "LMP:", + "Is the patient pregnant?": "La patiente est-elle enceinte ?", + "EDD:": "EDD:", + "Reason patient not pregnant?": "Raison pour laquelle la patiente n'est pas enceinte?", + "Pregnancy not suspected": "Grossesse non suspectée", + "Pregnancy test is negative": "Le test de grossesse est négatif", + "Using hormonal contraceptive": "Utiliser un contraceptif hormonal", + "postpartum < 6 weeks": "post-partum < 6 semaines", + "Actual date of delivery:": "Date réelle de livraison :", + "Gestation in weeks:": "Gestation en semaines:", + "Pregnancy outcome:": "Résultat de la grossesse:", + "Abortion/Miscarriage/Terminated": "Avortement/fausse couche/interruption de grossesse", + "Live birth (Preterm)": "Naissance vivante (prématuré)", + "Live birth (Term)": "Naissance vivante (à terme)", + "Family Planning Profile": "Profil de planification familiale", + "Is the client using condoms?": "Le client utilise-t-il des préservatifs ?", + "Family planning, detailed": "Planification familiale, détaillée", + "Select modern contraception method:": "Sélectionnez une méthode de contraception moderne:", + "Bilateral tubal ligation": "Ligature bilatérale des trompes", + "3-year implant": "implant de 3 ans", + "5-year implant": "implant de 5 ans", + "IUCD copper": "DIU cuivre", + "IUCD hormonal": "DIU hormonal", + "Injectables (Depo)": "Injectables (Depo)", + "Combined hormone oral contraceptive pills": "Pilules contraceptives orales hormonales combinées", + "Projestin only pills": "Pilules Projestin uniquement", + "Vasectomy": "Vasectomie", + "Lactational amenohhrea method": "Méthode d'aménorrhée lactationnelle", + "Diaphram/Cervical cap": "Diaphrame/Capuche cervicale", + "Emergency contraceptive pills": "Pilules contraceptives d'urgence", + "Periodic abstinence": "Abstinence périodique", + "Undecided": "Indécis", + "Approximate start date (If FP is 3-year implant/5-year implant/Injectables/Vasectomy/IUCD Copper/IUCD Hormonal/Bilateral tubal ligation)": "Date de début approximative (si la PF est un implant de 3 ans/un implant de 5 ans/des injectables/une vasectomie/un IUCD en cuivre/un IUCD hormonal/une ligature des trompes bilatérale)", + "Cancer Screening": "Le dépistage du cancer", + "Cervical cancer screening done:": "Dépistage du cancer du col de l'utérus effectué:", + "Cervical cancer screening test result:": "Résultat du test de dépistage du cancer du col de l'utérus:", + "Positive": "Positif", + "Negative": "Négatif", + "Cervical cancer result date:": "Date des résultats du cancer du col de l'utérus:", + "If cervical cancer is positive, is patient on treatment?": "Si le cancer du col de l’utérus est positif, la patiente est-elle sous traitement?", + "Completed": "Complété", + "If patient on treatment, indicate below:": "Si patient sous traitement, indiquez ci-dessous:", + "Cryotherapy": "Cryothérapie", + "Chemotherapy": "Chimiothérapie", + "Hysterectomy": "Hystérectomie", + "Radiotherapy": "Radiothérapie", + "Thermo-coagulation/Loop Electrosurgical Excision Procedure": "Procédure d'excision électrochirurgicale par thermocoagulation/anse", + "GBV Screening": "Dépistage de la VBG", + "Within the past 3 months, have you been hit, slapped, kicked or physically hurt by someone in any way?": "Au cours des 3 derniers mois, avez-vous été frappé, giflé, donné des coups de pied ou blessé physiquement par quelqu'un de quelque manière que ce soit?", + "Are you in a relationship with a person who physically hit you?": "Êtes-vous en couple avec une personne qui vous a frappé physiquement ?", + "Are you in a relationship with a person who threatens, frightens or insults you or treats you badly?": "Êtes-vous en couple avec une personne qui vous menace, vous effraie, vous insulte ou vous maltraite ?", + "Are you in relationship with a person who forces you to participate in sexual activities that make you feel uncomfortable?": "Êtes-vous en relation avec une personne qui vous oblige à participer à des activités sexuelles qui vous mettent mal à l'aise ?", + "Have you ever experienced any of the above with someone you do not have a relationship with?": "Avez-vous déjà vécu l’une des situations ci-dessus avec quelqu’un avec qui vous n’avez aucune relation?", + "Adult Vaccination": "Vaccination des adultes", + "Immunization history:": "Antécédents de vaccination:", + "Hepatitis B": "Hépatite B", + "Flu": "Grippe", + "Tetanus booster": "Rappel contre le tétanos", + "Breastfeeding": "Allaitement maternel", + "Child breastfeeding?": "Allaitement d'un enfant ?", + "Medication History": "Antécédents de médicaments", + "ART History": "Histoire de l'art", + "Is the patient on ART?": "Le patient est-il sous TAR ?", + "Reason for use:": "Raison d'utilisation :", + "Treatment": "Traitement", + "PEP": "DYNAMISME", + "Prep": "Préparation", + "PMTCT": "PTME", + "If patient started ART since last visit, enter start date:": "Si le patient a commencé le TAR depuis sa dernière visite, entrez la date de début:", + "Line of ART patient is taking:": "Le patient de la ligne de TAR prend:", + "First line regimen": "Régime de première intention", + "Second line regimen": "Régime de deuxième ligne", + "Third line regimen": "Régime de troisième ligne", + "Patient's ART regimen, adults:": "Schéma thérapeutique TAR du patient, adultes:", + "DTG50mg/3TC300mg/TDF300mg": "DTG50mg/3TC300mg/TDF300mg", + "TDF300mg/3TC300mg/EFV600mg": "TDF300mg/3TC300mg/EFV600mg", + "TDF300mg/3TC300mg/EFV400mg": "TDF300mg/3TC300mg/EFV400mg", + "NVP200/ZDV300/3TC150": "NVP200/ZDV300/3TC150", + "ABC600mg/3TC300mg": "ABC600mg/3TC300mg", + "3TC300mg/TDF300mg": "3TC300mg/TDF300mg", + "3TC150mg/ZDV300mg": "3TC150mg/ZDV300mg", + "Emtri200mg/TDF300(Truvada)": "Emtri200mg/TDF300(Truvada)", + "Aluvia(Kaletra)200mg/LPV50mg": "Aluvia(Kaletra)200mg/LPV50mg", + "Atazanavir300/Ritonavir100": "Atazanavir300/Ritonavir100", + "FTC200mg/RPV25mg/TDF245mg(Eviplera)": "FTC200mg/RPV25mg/TDF245mg(Eviplera)", + "Dolutegravir 50mg": "Dolutégravir 50 mg", + "Abacavir300mg": "Abacavir300mg", + "Efavirenz 200mg": "Éfavirenz 200 mg", + "Lamivudine150mg": "Lamivudine150 mg", + "Raltegravir 400mg": "Raltégravir 400 mg", + "Zidovudine300mg": "Zidovudine300 mg", + "Darunavir 600mg": "Darunavir 600 mg", + " Ritonavir 100mg": " Ritonavir 100 mg", + " Ritonavir 80mg": " Ritonavir 80 mg", + "Etravirine 100mg": "Étravirine 100 mg", + "ART adherence": "Adhésion au TAR", + "Morisky Adherence": "Adhésion à Morisky", + "Do you ever forget to take your medicines? (0=No, 1=Yes)": "Avez-vous déjà oublié de prendre vos médicaments ? ", + "Are you sometimes not keen about taking your medications? (0=No, 1=Yes)": "Parfois, vous n'aimez pas prendre vos médicaments ? ", + "Do you stop taking medicine at times when you feel worse? (0=No, 1=Yes)": "Arrêtez-vous de prendre des médicaments lorsque vous vous sentez moins bien ? ", + "If you feel better, do you sometimes stop taking your medicine? (0=No, 1=Yes)": "Si vous vous sentez mieux, arrêtez-vous parfois de prendre vos médicaments ? ", + "Morisky 4 total score:": "Score total de Morisky 4:", + "Morisky score rating:": "Note de Morisky:", + "Did you forget to take your medicine yesterday? (0=No, 1=Yes)": "Avez-vous oublié de prendre vos médicaments hier ? ", + "Do you sometimes stop taking medicine if you feel like your symptoms are under control? (0=No, 1=Yes)": "Arrêtez-vous parfois de prendre des médicaments si vous sentez que vos symptômes sont sous contrôle? ", + "Do you ever feel under pressure about sticking to your treatment plan? (0=No, 1=Yes)": "Vous arrive-t-il de vous sentir sous pression pour respecter votre plan de traitement? ", + "How often do you have difficulty remembering to take all your medication? (0=Never/Rarely, 1/4=Once in a while, 1/2=Sometimes, 3/4=Usually,1=All the time)": "À quelle fréquence avez-vous des difficultés à vous rappeler de prendre tous vos médicaments? ", + "Morisky 8 total score:": "Score total de Morisky 8:", + "Enhanced Adherence": "Adhérence améliorée", + "Has a home visit been done?": "Une visite à domicile a-t-elle été effectuée ?", + "If yes, number of visits:": "Si oui, nombre de visites :", + "If yes, what were the findings:": "Si oui, quelles ont été les conclusions:", + "If no, wish to refer to the social worker:": "Si non, souhaitez vous référer à l'assistante sociale :", + "What are the support structures in place?": "Quelles sont les structures de soutien en place ?", + "Treatment supporter": "Supporteur du traitement", + "Support group": "Groupe de soutien", + "Caregiver": "Soignant", + "Family": "Famille", + "Has directly observed treatment (DOT) been done?": "Un traitement sous observation directe (DOT) a-t-il été effectué?", + "Number of directly observed treatment (DOT) done (days):": "Nombre de traitements sous observation directe (DOT) effectués (jours):", + "Likely causes of poor adherence: (Choose all that apply)": "Causes probables d’une mauvaise observance: (Choisissez toutes les réponses qui s’appliquent)", + "Stigma": "Stigmate", + "School related stigma": "Stigmatisation liée à l’école", + "Home related stigma": "Stigmatisation liée à la maison", + "Improper disclosure to child": "Divulgation inappropriée à l'enfant", + "Inadequate supervision": "Surveillance inadéquate", + "Child refusing to take drugs": "Enfant refusant de prendre de la drogue", + "Pill related size": "Taille liée à la pilule", + "Pill taste": "Goût de la pilule", + "Pill color": "Couleur de la pilule", + "Pill burden": "Fardeau de la pilule", + "Disclosure": "Divulgation", + "Side effects": "Effets secondaires", + "Alcohol": "Alcool", + "Other drugs": "Autres médicaments", + "Mental health issues": "Problèmes de santé mentale", + "Depression": "Dépression", + "Caregiver changes": "Changements de soignant", + "Religious beliefs": "Croyances religieuses", + "Inadequate treatment preparation": "Préparation du traitement inadéquate", + "Poor adherence": "Mauvaise adhésion", + "If other causes of poor adherence, explain:": "Si d’autres causes de mauvaise observance, expliquez:", + "Is patient enrolled in support group?": "Le patient est-il inscrit dans un groupe de soutien?", + "If no, wishes to enroll?": "Si non, souhaitez-vous vous inscrire ?", + "If yes, name of support group:": "Si oui, nom du groupe de soutien:", + "Has age appropriate disclosure been completed?": "La divulgation adaptée à l’âge a-t-elle été effectuée?", + "Has a pill count been done?": "Un décompte des pilules a-t-il été effectué ?", + "If yes, what are the findings:": "Si oui, quels sont les résultats :", + "Accurate": "Précis", + "Missed doses": "Doses oubliées", + "Other possible causes of treatment failure:": "Autres causes possibles d’échec du traitement:", + "Inadequate dosing/dose adjustments": "Posologie/ajustements de dose inadéquats", + "Drug-drug interaction": "Interaction médicamenteuse", + "Drug-food interaction": "Interaction médicament-aliment", + "Impaired absorption (such as chronic severe diarrhea)": "Absorption altérée (telle qu'une diarrhée chronique sévère)", + "If drug causes treatment failure, indicate drug:": "Si le médicament entraîne un échec du traitement, indiquez le médicament:", + "Does this patient have other co morbidities?": "Ce patient présente-t-il d’autres comorbidités?", + "Convulsive disease": "Maladie convulsive", + "Mental health disorders": "Troubles de santé mentale", + "Diabetes": "Diabète", + "Renal disease": "Maladie rénale", + "Liver disease": "Maladie du foie", + "Hypertention": "Hypertension", + "Has drug resistance test (DRT) been done?": "Un test de résistance aux médicaments (DRT) a-t-il été effectué?", + "If DRT result available, upload image:": "Si le résultat DRT est disponible, téléchargez l'image:", + "Has an MDT been done?": "Une MDT a-t-elle été réalisée ?", + "If No, wish to refer?": "Si non, souhaitez-vous vous référer ?", + "PCP Prophylaxis History": "Historique de la prophylaxie PCP", + "Is the patient on any PCP prophylaxis?": "Le patient suit-il une prophylaxie PCP?", + "Septrin": "Septrin", + "Dapsone 100mg": "Dapsone 100 mg", + "PCP prophylaxis adherence:": "Adhérence à la prophylaxie PCP:", + "Patient's adherence on PCP prophylaxis:": "Adhésion du patient à la prophylaxie PCP:", + "Good": "Bien", + "Fair": "Équitable", + "Poor": "Pauvre", + "Adherence (PCP) reasons for poor/fair:": "Raisons d’observance (PCP) médiocre/passable:", + "Felt well": "Je me sentais bien", + "Forgot": "Oublié", + "Gave away": "Donné", + "Lost/ran out of pills": "Perdu/manque de pilules", + "Stock out": "En rupture de stock", + "Too ill": "Trop malade", + "Travel problems": "Problèmes de voyage", + "Adherence (PCP): Other (specify):": "Adhésion (PCP) : Autre (préciser) :", + "TB Prophylaxis History": "Historique de la prophylaxie antituberculeuse", + "Is the patient on any TB prophylaxis?": "Le patient suit-il une prophylaxie antituberculeuse?", + "If yes select drug": "Si oui, sélectionnez le médicament", + "Isoniazid 100mg (6H)": "Isoniazide 100mg (6H)", + "Isoniazid 300mg (6H)": "Isoniazide 300mg (6H)", + "Isoniazid 300mg and Rifapentine 300mg (3HP)": "Isoniazide 300 mg et Rifapentine 300 mg (3HP)", + "Rifampicin 150mg and Isonaizid 75mg (3RH)": "Rifampicine 150 mg et Isonaizid 75 mg (3RH)", + "Rifampicin 70mg and Isonaizid 50mg (3RH)": "Rifampicine 70 mg et Isonaizid 50 mg (3RH)", + "TB prophylaxis ever": "Prophylaxie antituberculeuse jamais réalisée", + "If no, have you ever used the drugs in the past?": "Si non, avez-vous déjà consommé ces drogues dans le passé?", + "Start date of past TB prophylaxis treatment:": "Date de début du traitement prophylactique antituberculeux antérieur:", + "End date of past TB prophylaxis treatment:": "Date de fin du traitement prophylactique antituberculeux antérieur:", + "TB prophylaxis adherence": "Adhésion à la prophylaxie antituberculeuse", + "Patient's adherence on TB prophylaxis:": "Adhésion du patient à la prophylaxie antituberculeuse:", + "Adherence (TB Prophylaxis) reasons for poor/fair:": "Raisons d’observance (prophylaxie antituberculeuse) médiocre/passable:", + "Lost/Ran out of pills": "Perdu/à court de pilules", + "Adherence (TB Prophylaxis): Other (specify):": "Adhésion (prophylaxie antituberculeuse) : Autre (préciser) :", + "Tuberculosis History": "Histoire de la tuberculose", + "Is patient on TB treatment?": "Le patient est-il sous traitement antituberculeux?", + "Start date of TB treatment:": "Date de début du traitement antituberculeux:", + "Tuberculosis treatment phase:": "Phase de traitement de la tuberculose:", + "Continuation phase": "Phase de poursuite", + "Retreatment phase": "Phase de retraitement", + "Induction phase": "Phase d'induction", + "Retreated phase": "Phase de retrait", + "Current TB regimen": "Régime actuel contre la tuberculose", + "Current TB regimen:": "Régime antituberculeux actuel:", + "RHZE": "RHZE", + "RHZ": "RHZ", + "RHE": "RHÉ", + "RH": "RH", + "EH": "hein", + "Ethambutol": "Éthambutol", + "MDR drugs": "Médicaments MDR", + "INH": "INH", + "Pyrazinamide": "Pyrazinamide", + "Streptomycin": "Streptomycine", + "Rifabutin": "Rifabutine", + "Rifampicin": "Rifampicine", + "tabs/day:": "comprimés/jour:", + "mg:": "mg:", + "mg/day:": "mg/jour:", + "tabs:": "onglets:", + "TB treatment completion date:": "Date de fin du traitement antituberculeux:", + "TB treatment defaulted year:": "Année d’abandon du traitement antituberculeux:", + "Patient adherence to TB medications": "Adhésion des patients aux médicaments antituberculeux", + "Patient adherence to TB medications:": "Adhésion des patients aux médicaments antituberculeux:", + "Adherence (TB Treatment) reasons for poor/fair:": "Raisons d’observance (traitement antituberculeux) médiocre/passable:", + "Adherence (TB Treatment): Other (specify):": "Adhésion (traitement antituberculeux) : Autre (préciser) :", + "Cryptococcal Secondary Prevention": "Prévention secondaire des cryptocoques", + "Cryptococcus Tx:": "Cryptocoque Tx:", + "Fluconazole 400mg": "Fluconazole 400 mg", + "Other Medications": "Autres médicaments", + "Please add any other medications the patient is taking": "Veuillez ajouter tout autre médicament que le patient prend", + "Other drugs:": "Autres médicaments :", + "Side Effects/Toxicity": "Effets secondaires/toxicité", + "Any side effects attributable to any drug that the patient is currently taking:": "Tout effet secondaire attribuable à tout médicament que le patient prend actuellement:", + "If yes drugs suspected to be causing side effects": "Si oui, médicaments suspectés de provoquer des effets secondaires", + "Drug:": "Médicament:", + "If yes, tick all that apply:": "Si oui, cochez toutes les réponses applicables:", + "Anaemia": "Anémie", + "Hepatitis": "Hépatite", + "IRIS": "IRIS", + "Lactic acidosis": "Acidose lactique", + "Lipo-dystrophy": "Lipo-dystrophie", + "Neuropathy": "Neuropathie", + "Persistent vomiting": "Vomissements persistants", + "Rash": "Éruption cutanée", + "Steven-Johnson syndrome": "Syndrome de Steven-Johnson", + "Nausea": "Nausée", + "Burning sensation": "Sensation de brulure", + "Diarrhea": "Diarrhée", + "Headache": "Mal de tête", + "Fatigue": "Fatigue", + "Jaundice": "Jaunisse", + "Dizzy": "Vertigineux", + "Abdominal pain": "Douleur abdominale", + "Anxiety": "Anxiété", + "Nightmare": "Cauchemar", + "Confusion/abnormal thinking": "Confusion/pensée anormale", + "Insomnia": "Insomnie", + "Poor concentration/ memory problems": "Mauvaise concentration/problèmes de mémoire", + "Paresthesia/painful neuropathy": "Paresthésie/neuropathie douloureuse", + "Suicide ideation": "Idées suicidaires", + "Severity of the reaction:": "Gravité de la réaction:", + "Mild": "Bénin", + "Moderate": "Modéré", + "Severe": "Grave", + "Action plan:": "Plan d'action:", + "Stopped drugs": "Drogues arrêtées", + "Substitute drugs": "Médicaments de substitution", + "Change drugs": "Changer de médicament", + "Switched drugs": "Médicaments changés", + "How certain are you the drug(s) is/are the cause of the reaction?": "Dans quelle mesure êtes-vous certain que le(s) médicament(s) est(sont) la cause de la réaction?", + "Certain": "Certain", + "Probable/likely": "Probable/vraisemblable", + "Possible": "Possible", + "Unlikely": "Peu probable", + "Conditional/unclassified": "Conditionnel/non classé", + "Unassessable/unclassified": "Inévaluable/non classifié", + "Vitals": "Vitalité", + "Vital Signs": "Signes vitaux", + "BP systolic:": "TA systolique:", + "BP diastolic:": "TA diastolique:", + "Pulse (Rate/min):": "Pouls (taux/min):", + "Temp (C):": "Température (C):", + "Weight (Kg):": "Poids (kg):", + "Height (Cm):": "Hauteur (cm):", + "Sp02:": "Sp02:", + "BMI (Kg/m2):": "IMC (Kg/m2):", + "MUAC:": "PB:", + "Foetal heart rate:": "Fréquence cardiaque fœtale:", + "Fundal height:": "Hauteur utérine:", + "Nutrition Assessment and Diagnosis": "Évaluation et diagnostic nutritionnels", + "Nutrition status:": "État nutritionnel:", + "Normal": "Normale", + "Overweight": "en surpoids", + "Obese": "Obèse", + "Severe acute malnutrition": "Malnutrition aiguë sévère", + "Moderate acute malnutrition": "Malnutrition aiguë modérée", + "Current Symptoms": "Symptômes actuels", + "TB Screening Questions": "Questions de dépistage de la tuberculose", + "TB Symptoms:": "Symptômes de la tuberculose:", + "Breathlessness": "Essoufflement", + "Chest pain": "Douleur thoracique", + "Cough of any duration": "Toux de toute durée", + "Fever for = 2 weeks": "Fièvre pendant = 2 semaines", + "New exposure to household contact with TB": "Nouvelle exposition à un contact familial avec la tuberculose", + "Noticeable weight loss": "Perte de poids notable", + "Night sweats = 2 weeks": "Sueurs nocturnes = 2 semaines", + "Abdomen swelling": "Gonflement de l'abdomen", + "Groin swelling": "Gonflement de l'aine", + "Joints swelling": "Gonflement des articulations", + "Neck swelling": "Gonflement du cou", + "TB Status:": "Statut de tuberculose:", + "No signs": "Aucun signe", + "On TB treatment": "Sur le traitement de la tuberculose", + "Suspect": "Suspect", + "Confirmed": "Confirmé", + "Not assessed": "Pas évalué", + "STI": "IST", + "Do you have any of the following:": "Avez-vous l'un des éléments suivants:", + "Genital ulcers": "Ulcères génitaux", + "Urethral discharge": "Écoulement urétral", + "Vaginal discharge": "Pertes vaginales", + "STI partner notification:": "Notification du partenaire STI:", + "Adult WHO Staging": "Stade OMS pour adultes", + "If you are assigning a new WHO stage to patient today, select new WHO stage:": "Si vous attribuez aujourd’hui un nouveau stade OMS au patient, sélectionnez un nouveau stade OMS:", + "Select criteria for new WHO stage:": "Sélectionnez les critères pour la nouvelle étape de l'OMS:", + "Test Results": "Résultats de test", + "Chemistry Lab Tests": "Tests de laboratoire de chimie", + "Creatinine mmol/L:": "Créatinine mmol/L:", + "SGPT(ALT):": "SGPT(ALT):", + "AST:": "AST:", + "RBS mmol/L:": "RBS mmol/L:", + "FBS mmol/L:": "FBS mmol/L:", + "HbA1C %:": "% d'HbA1C:", + "LDL mmol/L:": "LDL mmol/L:", + "HDL mmol/L:": "HDL mmol/L:", + "TG mmol/L:": "TGmmol/L:", + "Cholesterol mmol/L:": "Cholestérol mmol/L:", + "Microalbumin test, urine mg/L:": "Test de microalbumine, urine mg/L:", + "Urea mmol/L:": "Urée mmol/L:", + "CBC": "Radio-Canada", + "Hgb g/dL:": "Hb g/dL:", + "WBC/mm3:": "GB/mm3:", + "Platelets:": "Plaquettes:", + "ALC/ mm3:": "ALC/mm3:", + "MCV:": "VMC:", + "CD4": "CD4", + "CD4 Count:": "Nombre de CD4:", + "CD4 %:": "% CD4:", + "ART Drug Sensitivity Test": "Test de sensibilité aux médicaments ART", + "ART drug sensitivity test (Upload image of the result):": "Test de sensibilité aux médicaments ART (Télécharger l'image du résultat):", + "Viral Load": "Charge virale", + "Viral load:": "Charge virale:", + "Urinalysis": "Analyse d'urine", + "Urinalysis:": "Analyse d'urine:", + "Pus cells:": "Cellules de pus:", + "Positive (+)": "Positif ( )", + "Strong positive (++)": "Fort positif ( )", + "Stronger positive (+++)": "Positif plus fort ( )", + "Protein:": "Protéine:", + "Leucocytes:": "Leucocytes:", + "Ketone:": "Cétone:", + "Glucose:": "Glucose:", + "Nitrites:": "Nitrites:", + "Blood Grouping": "Groupement sanguin", + "Blood type:": "Groupe sanguin:", + "A positive": "Un positif", + "A negative": "Un négatif", + "B positive": "B positif", + "B negative": "B négatif", + "O positive": "Ô positif", + "O negative": "Ô négatif", + "AB positive": "AB positif", + "AB negative": "AB négatif", + "A": "UN", + "B": "B", + "AB": "UN B", + "O": "Ô", + "TB Test": "Test de tuberculose", + "Genexpert test (Upload image of the result):": "Test Genexpert (Télécharger l'image du résultat) :", + "Sputum gene xpert MTB:": "Sputum Gene Xpert MTB:", + "Indeterminate": "Indéterminé", + "Poor sample quality": "Mauvaise qualité des échantillons", + "Sputum AFB smear:": "Frottis d'expectoration BAAR:", + "1+": "1", + "2+": "2", + "3+": "3", + "Sputum culture:": "Culture des crachats:", + "Mycobacterium tuberculosis": "Mycobacterium tuberculosis", + "Non tuberculosis mycobacteria": "Mycobactéries non tuberculeuses", + "TST (Mantoux test):": "TST (test de Mantoux):", + "Strongly positive": "Fortement positif", + "Chest Xray": "Radiographie pulmonaire", + "CXR code:": "Code CXR:", + "Cardiomegaly": "Cardiomégalie", + "Cavitary": "Cavitaire", + "Diffuse abn/non-miliary": "Diffuse ab/non miliaire", + "Infiltrate": "Infiltrer", + "Miliary": "Miliaire", + "PI effusion": "épanchement IP", + "Other Lab Tests": "Autres tests de laboratoire", + "Test result, detailed": "Résultat du test, détaillé", + "Other test results, specify:": "Autres résultats de tests, précisez:", + "Assessment": "Évaluation", + "Clinical Notes": "Notes cliniques", + "Please enter the clinical notes below:": "Veuillez saisir les notes cliniques ci-dessous:", + "Medication Plan": "Régime de médicaments", + "ART Plan": "Régime TAR", + "ART plan:": "Plan TAR:", + "Continue regimen": "Continuer le régime", + "Change dose": "Changer la dose", + "Change regimen": "Changer de régime", + "Change formulation": "Changer la formulation", + "Drug substitution": "Substitution de médicaments", + "Not on ARVS": "Pas sous ARV", + "Restart": "Redémarrage", + "Start ARVs": "Commencer les ARV", + "Stop all": "Arrête tout", + "Reason to start ART:": "Raison pour commencer le TAR:", + "CD4 less than 500": "CD4 inférieur à 500", + "WHO stage 3": "Stade OMS 3", + "WHO stage 4": "Stade 4 de l'OMS", + "Test and treat": "Tester et traiter", + "Adherence counselling completed": "Conseils d’observance terminés", + "ART change reason": "Raison du changement de TAR", + "Reason for stopping/change/substitution/interruption:": "Raison de l’arrêt/changement/substitution/interruption:", + "Adherence concerns": "Problèmes d’adhésion", + "Clinical treatment failure": "Échec du traitement clinique", + "Drug out of stock": "Médicament en rupture de stock", + "Due to new TB": "En raison d'une nouvelle tuberculose", + "Illness/hospitalization": "Maladie/hospitalisation", + "Immunologic failure": "Échec immunologique", + "Lost to follow-up": "Perdu de suivi", + "New drug available": "Nouveau médicament disponible", + "Patient lacks finances": "Le patient manque de moyens financiers", + "Planned Rx interruption": "Interruption planifiée de la réception", + "Changing to adult regimen": "Passage au régime adulte", + "Pregnancy": "Grossesse", + "Risk of pregnancy": "Risque de grossesse", + "Other patient desicion": "Autre décision du patient", + "Optimization": "Optimisation", + "Toxicity": "Toxicité", + "Virologic failure": "Échec virologique", + "If toxicity, please provide cause:": "En cas de toxicité, veuillez en indiquer la cause:", + "If toxicity: Other (specify):": "Si toxicité : Autre (préciser) :", + "Eligible for ART": "Éligible au TAR", + "Eligible for ART but not started:": "Admissible au TAR mais non commencé:", + "Patient refused": "Patient refusé", + "Eligible for ART but not started: Other (specify):": "Admissible au TAR mais non commencé : Autre (préciser) :", + "Plan treatment categories:": "Catégories de traitement du plan:", + "ART regimen started, adult:": "Début du traitement antirétroviral, adulte:", + "Indication for DTG based ART:": "Indication du TAR à base de DTG:", + "ART intiation": "Initiation au TAR", + "Substitution for EFV intolerance/toxicity": "Substitution en cas d'intolérance/toxicité à l'EFV", + "Substitution for NVP": "Remplacement de NVP", + "Substitution for ATV/r in PWID": "Substitution pour ATV/r dans PWID", + "Substitution for PI/r in 2nd line with TB disease": "Substitution de PI/r en 2ème intention en cas de maladie tuberculeuse", + "Alternative for virally suppressed 1st line PI/r based regimen": "Alternative au régime de 1ère intention à base d'IP/r avec suppression virale", + "Alternative regimen for pregnant/postpartum women": "Régime alternatif pour les femmes enceintes/en post-partum", + "Other (specify):": "Autre précisez):", + "PCP Prophylaxis Plan": "Plan de prophylaxie PCP", + "PCP prophylaxis plan:": "Plan de prophylaxie PCP:", + "Continue": "Continuer", + "Not on PCP prophylaxis": "Pas sous prophylaxie PCP", + "Start": "Commencer", + "Stop": "Arrêt", + "PCP prophylaxis change reason": "Raison du changement de prophylaxie PCP", + "If change/stop, reason:": "Si changement/arrêt, raison:", + "Steven-johnson syndrome": "Syndrome de Steven-Johnson", + "If toxicity, please provide cause: Other (specify):": "En cas de toxicité, veuillez en fournir la cause: Autre (préciser):", + "If Start/Change, regimen:": "Si Début/Changement, régime:", + "TB Prophylaxis Plan": "Plan de prophylaxie contre la tuberculose", + "TB prophylaxis plan:": "Plan de prophylaxie contre la tuberculose:", + "Not on TB prophylaxis": "Pas sous prophylaxie antituberculeuse", + "stopping reason": "raison d'arrêt", + "If stopping, reason:": "En cas d'arrêt, raison:", + "Active TB": "tuberculose active", + "Lack of drugs": "Manque de médicaments", + "Side effects (Adverse drug reaction)": "Effets secondaires (réaction indésirable au médicament)", + "Lactic Acidosis": "Acidose lactique", + "TB prophylaxis regimen started:": "Début du régime de prophylaxie antituberculeuse:", + "TB Treatment Plan": "Plan de traitement de la tuberculose", + "TB Treatment Started, detailed": "Traitement antituberculeux commencé, détaillé", + "TB Treatment plan:": "Plan de traitement de la tuberculose:", + "Not on TB treatment": "Pas sous traitement antituberculeux", + "Start induction": "Commencer l'intégration", + "Change to continuation": "Passer à la suite", + "Re-dose": "Re-doser", + "Substitution": "Substitution", + "TB Plan Change Reason": "Raison du changement au régime PC", + "If plan is to stop/change/re-dose/substitute, reason:": "Si le plan consiste à arrêter/modifier/re-doser/substituer, raison:", + "If restarting, reason:": "Si redémarrage, raison :", + "Defaulted": "Par défaut", + "Failure": "Échec", + "MDR TB regimen": "Régime antituberculeux multirésistant", + "New treatment": "Nouveau traitement", + "Relapse/re-infection": "Rechute/réinfection", + "tbMedPickupSite": "tbMedPickupSite", + "Site of TB meds pick-up:": "Lieu de retrait des médicaments antituberculeux:", + "This AMPATH site": "Ce site AMPATH", + "Other Specify:": "Autre précisez:", + "TB regimen started:": "Le régime antituberculeux a commencé:", + "Cryptococcal Treatment Plan": "Plan de traitement cryptococcique", + "Crag test:": "Essai de falaise:", + "Cryptococcal treatment plan": "Plan de traitement contre les cryptocoques", + "Additional Medication Orders": "Commandes de médicaments supplémentaires", + "Additional medication orders": "Commandes de médicaments supplémentaires", + "Drug": "Médicament", + "Frequency": "Fréquence", + "Once a day": "Une fois par jour", + "Twice a day": "Deux fois par jour", + "Three times a day": "Trois fois par jour", + "Four times a day": "Quatre fois par jour", + "As needed": "Comme requis", + "If tabs, number": "Si onglets, numéro", + "If caps, number": "Si majuscules, nombre", + "If mg, number": "Si mg, nombre", + "If ml, number": "Si ml, numéro", + "Plan": "Plan", + "Family Planning Plan": "Plan de planification familiale", + "Dispense condom today?": "Distribuer un préservatif aujourd'hui?", + "Continue modern contraception method?": "Continuer la méthode de contraception moderne ?", + "Does patient wish to start modern contraception method?": "La patiente souhaite-t-elle commencer une méthode de contraception moderne?", + "Are you planning to concieve in the next 3 months?": "Envisagez-vous d'avoir un enfant dans les 3 prochains mois ?", + "Reason not on family planning": "Raison non sur la planification familiale", + "Wants to get pregnant": "Veut tomber enceinte", + "Not sexually active now/Infrequent sex": "Pas sexuellement actif actuellement/Rapports sexuels peu fréquents", + "Fear of side effects/health risks": "Peur des effets secondaires/risques pour la santé", + "Opposition/rejection from the male partner/other relatives": "Opposition/rejet du partenaire masculin/d'autres proches", + "Complications of previous method(s) used": "Complications des méthodes précédentes utilisées", + "Postpartum amenorrhea": "Aménorrhée post-partum", + "Breasfeeding": "Allaitement", + "Wants to wait untill the first baby is born": "Veut attendre la naissance du premier bébé", + "Wants to wait untill the desired number of children are born": "Veut attendre que le nombre d'enfants souhaité naisse", + "Lack of knowledge": "Manque de connaissances", + "Complications caused by family planning method used:": "Complications causées par la méthode de planification familiale utilisée:", + "If yes, modern contraception method chosen:": "Si oui, méthode de contraception moderne choisie:", + "DC Outcome": "Résultat DC", + "Differentiated care plan:": "Plan de soins différenciés :", + "Continue in DC": "Continuer à DC", + "Exit from DC": "Sortie de DC", + "Reason for exit": "Raison de la sortie", + "Reason for exit:": "Raison de la sortie :", + "Self transfer out of facility": "Auto-transfert hors de l'établissement", + "High VL": "CV élevée", + "New OI/new chronic illness": "Nouvelle OI/nouvelle maladie chronique", + "Voluntary request to exit": "Demande volontaire de sortie", + "Other specify:": "Autre précisez:", + "Test Orders": "Commandes tests", + "Test orders": "Commandes de test", + "Tests Ordered": "Tests commandés", + "Test ordered: Other (specify):": "Test ordonné : Autre (préciser) :", + "Viral load justification:": "Justification de la charge virale:", + "Routine VL": "CV de routine", + "Confirmation of treatment failure (repeat VL)": "Confirmation de l'échec du traitement (répétition de la CV)", + "Clinical failure": "Échec clinique", + "Single drug substitution": "Substitution d’un seul médicament", + "Baseline VL (for infants diagnsed through EID)": "CV de base (pour les nourrissons diagnostiqués par EID)", + "Confirmation of persistent low level viremia (PLLV)": "Confirmation d'une virémie persistante de bas niveau (PLLV)", + "PMTCT patient category:": "Catégorie de patients PTME:", + "Pregnant": "Enceinte", + "None of the above": "Aucune des réponses ci-dessus", + "Positive Health Diginity & Prevention Services": "Diginité Santé Positive", + "PHDP:": "PHPP:", + "Adherence counselling": "Conseils d’observance", + "STI screening": "Dépistage des IST", + "Substance use": "Consommation de substances", + "Disclosure to sex partner": "Divulgation au partenaire sexuel", + "Partner testing": "Tests des partenaires", + "Condom distribution": "Distribution de préservatifs", + "Treatment of GBV injuries": "Traitement des blessures liées à la VBG", + "First line support (LIVES)": "Assistance de première ligne (LIVES)", + "Emergency contraceptives": "Contraceptifs d'urgence", + "Referrals": "Références", + "Referrals made to the patient:": "Orientations faites au patient :", + "OVC": "OEV", + "ENT": "ORL", + "Cardiology": "Cardiologie", + "Disclosure counselling": "Conseils en matière de divulgation", + "Hospitalization": "Hospitalisation", + "Oncology": "Oncologie", + "Mental health services": "Services de santé mentale", + "Nutritional support": "Soutien nutritionnel", + "Psychosocial support": "Soutien psychosocial", + "TB/DOT program": "Programme TB/DOT", + "Surgery": "Chirurgie", + "Dermatology": "Dermatologie", + "Social work": "Travail social", + "Differentiated care program": "Programme de soins différenciés", + "Ophthalmology ": "Ophtalmologie ", + "Reproductive health ": "La santé reproductive ", + "MDT Program": "Programme MDT", + "Resistant clinic": "Clinique résistante", + "Legal counsel": "Conseiller juridique", + "Police department": "Service de police", + "Child protection services": "Services de protection de l'enfance", + "Emergency shelter": "Abri d'urgence", + "Referrals made to the patient: Other (specify):": "Références faites au patient : Autre (préciser) :", + "If referred for hospitalization, choose location:": "Si vous êtes référé pour une hospitalisation, choisissez le lieu:", + "Local health centre/hospital": "Centre de santé/hôpital local", + "MTRH": "MTRH", + "Reason for hospitalization": "Raison de l'hospitalisation", + "Transfer Out": "Transfert sortant", + "Transfer care to other centre": "Transférer les soins vers un autre centre", + "Transfer care to other centre:": "Transfert des soins vers un autre centre :", + "AMPATH": "AMPATH", + "Non-AMPATH": "Non-AMPATH", + "MCH": "L'HME", + "Specify name of AMPATH clinic to which patient is being referred:": "Précisez le nom de la clinique AMPATH vers laquelle le patient est référé:", + "If Non-AMPATH specify where the patient is being referred:": "Si Non-AMPATH, précisez où le patient est référé:", + "Next Appointment": "Prochain rendez-vous", + "Medication pick up date:": "Date de retrait des médicaments :", + "Return to clinic date:": "Date de retour à la clinique:" + } +} From 2a3d6091188f4dc7eb25e34c500a0582e09b5c9a Mon Sep 17 00:00:00 2001 From: dkayiwa Date: Fri, 26 Apr 2024 02:58:11 +0300 Subject: [PATCH 07/10] Bump webservicesrest to version 2.43.0-SNAPSHOT --- distro/pom.xml | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/distro/pom.xml b/distro/pom.xml index 032ab5158..a4bd16631 100644 --- a/distro/pom.xml +++ b/distro/pom.xml @@ -26,7 +26,7 @@ 2.0.0 2.6.4 2.7.0-SNAPSHOT - 2.41.0 + 2.43.0-SNAPSHOT 2.17.0 4.10.0 1.16.0 From 724a5d68bfd663c19a90d65774621b9c8dd88dd3 Mon Sep 17 00:00:00 2001 From: grace potma <67400059+gracepotma@users.noreply.github.com> Date: Fri, 26 Apr 2024 06:48:08 -0700 Subject: [PATCH 08/10] O3-2599: Fix majority of Lab Test metadata errors (#808) --- ...s_v4.2_autoexpand-4.2.2023-11-29_183847.zip | Bin 162501 -> 0 bytes ...s_v4.7_autoexpand-4.7.2023-12-20_235959.zip | Bin 0 -> 238824 bytes 2 files changed, 0 insertions(+), 0 deletions(-) delete mode 100644 distro/configuration/ocl/openmrs_BasicLabTests_v4.2_autoexpand-4.2.2023-11-29_183847.zip create mode 100644 distro/configuration/ocl/openmrs_BasicLabTests_v4.7_autoexpand-4.7.2023-12-20_235959.zip diff --git a/distro/configuration/ocl/openmrs_BasicLabTests_v4.2_autoexpand-4.2.2023-11-29_183847.zip b/distro/configuration/ocl/openmrs_BasicLabTests_v4.2_autoexpand-4.2.2023-11-29_183847.zip deleted file mode 100644 index 8c9a49dabef0743a0ee7e4dca7899205e9e1382f..0000000000000000000000000000000000000000 GIT binary patch literal 0 HcmV?d00001 literal 162501 zcmV*rKt#V#O9KQH000080CAOlR~KtdKuvlA0IFUi01E&B0A+Y^Z*p`lYIARH?7e-H z+cvT<{8d<~Iu)mmM?;VxLHgGHW9&GwYyEcZN%q;jd#;O;s1bK4QXwf%mC?B&KUPfgydKV3E`0uMKny(q*{LchO8)^Pon|0ia3pdhb@(EeRuhp>;&i}+iTFUqe+&x6=Jqau#zW2<+BV>|8@ zLRU_Bi-H%}dEo{F$Mu6C_$S-7^YOmHUN9gY30?1>+cOWBbnx9guYk>4lQgf#e^y0A z`S#!cQ~wqhS(JWdF9zour*-R1S?#`K9^>k>>^aP$`5dew`ONeFGn(nCE4@{h9f)NbaW9=F%*#qOFx@vqcpR z)2+|YJn%~1F5K+ttYd7q9?LrGxyc% z9R$fWx-S>A^`_lSMz3(0z9XfNkUrv*Y?c4wgWJ_W+nUGmkd50UoA@p^w!;qVw_eLP zuWx?-K_+t3{4N)FqU7oA>>!mwlk6#l*p=<}7C|Kujka^;IJd}sfx;J#KM1kygy^3? zNZ+gd+Cib>+l1s^35;G~JirdYw*OC=y0^+06!&EF2(2o&;*35&E3$_4J3P1Y1shXM zV{4fIX^rDqZoPj0dGJG_^uk}z{x8h6ZGY1Jh=*o_VCIJM`MhL9U{m5K~PbQ z)DLuxTBHbHt^WP%dUI^S9Qw7^d+8V0-^;5n^LRuh@pxND^WFbH|0T-BCc!u)oZg1; zyp7Wo$gX#j^)O9FQ!52ITCv9gJKajMZ}4++$95oGDnO`yi;|RyR}i$rxHg*Nu|$^s z5MYFD&#|w{rYvDr*yKA)}cW$UmuEx9DVgUuWj{U;LFK{^U9c0_# zJ_|?~>|s=!ODogtpcR@Qk|O{>4l}A4>AerRRbS*5LmJUd`E^4r7ryJwvCj&Yb7HNQ zWg>3Fr&hGH*GN5PNzT6mOyT2KaqCs!h0Z8qtA#SG!DI*1Khq=~OYf||(J|Ym4Fhfi zXZB(~xAy8OCm?=6w)7MTWr+lWt2e4YQndsqK%$jCT;Ira(z^u6vnGqIc8OJM*Hm|{ zgbBidYi}#1wpp8+*S671#h=sE5`Wc1t@PWwcmMeM<y^vmrR83}IadHp59-Q8mVYU5N!3ATybUrO*UgaZIz zP4fDUf!`MJOA^ao8W*-1)8p0=iz(yo+ei#el6VT+uz)jaBB&Cm=}R~C&00tc?cS1x_L9~{j{-qGB0U1) zm@S(r<;n?PLlgKR6>JxoZz%NqUsQig`-b*Bj*U-wK+VCS6Z%RAQ2PpU z2T%^?_IQ?LQWwzbgjM4ESv~o^&Y#@}zV?fRo_nl+M=>ksKnE9&Y9c~>9C}8)G-}?8 zUYcz-9pk4V*x&eRf`CY*0bD)KPeaYV9WTvd78l7#=BfD-7mJy7mo7&1u=n|)E*h}x z1w&x7~;k%#fF9o{z0^aTgWxH_2Dni;o79+|aih>}Y#&91wo}r2oE{d3{ zujkgcI0Mmd4JoglTSb(ObEz?92guc7-kYJ*+1+>T!VV#1s~n$?NQ+=|yuSMmKV??g zV!dP6H);~<5^ug>bbMyptlo6BfUur@e);7m8HpHUUxyWc7W=~^3j1U0-CG6v@QrGv z@wYg&lB|yYVUGrWncZE_WOi8)+81J$EV6{fbNm3LjMI9Rhp*AF%+m!6jIrTTl+ugi zc$CaoxDi|R63iHm8TT3)_6yG$1fK7Op4yD52m8oDZg(@LxkA6p7*O>F%osW==fG)Z z44Vkd7&q_@n=x&?)oaGM&Q?-G;7QFG?>uHqt%^b5MHWbbBEPG}%wfh1@{xeXS|)8G zGxce6FH9PsPC#id7cy!n^gsUzXJ_aSLEA$LhdPYE{SA$C6 zz=@#Jt3jphI%Yv-D{u9JO2=`wL8T`JmEKuECHaj|b8aZk%h3+n5rP(CKS{CXgWy#)0UFrS1SWjaKennji!pm*P*4Tps?sp0a&6 zO}=J%QR7V4=6G~{Wp&}N;`ZclK!G1!Jn#be4|hSRbZ}^6gbzWe;tG93sGbpo>RodV zoQhCAicr1KGmlW^yw!?Oy%23>*#w>}`4g_51)+kF%&bvf%opWokw%5}4PN@$;n36$ zJ<;{KXW|`9s&W_h0+Uh-1^4Is(YF@&=lLCnUEQCQ2uDpsh_TmGU`;6yyq~|beP!LH z`4ILQ^%KtWrPR+307p-lwORN^DHN={_YV;eL|>p}#_6nMuiI$szbBN^C>VIZ|N6cK zk|G_D^dKMTAup5PjR@!L(f#d2DB&~;rJ3!3pKBSuLemjw$LKC@Kw!(9%1UUe$0CCdEUnoht&(}Vq~*cre6$urmBX49y^Cy?EU;Xdc~}q1E=D3#PB*nrtx|kZ}sAJzm67NRp5~6UATJ2XzM5)E;v1hq4dBO zv$=Mr+l}4YueiGEF2mRy=n`P_EIPdAmvwWrwl@@vZnuRvvYd7d+6CLLB}cZXJ`e?JI{f7kB=BcRk(# zG~NI=0gW>Vx*?hiIU-+a4+Y$C?15+Fkl0-S4I3N~r+fO?&I&yPG&nE;Xkb>(ffE4@ zorqTaLbh>0Bj>GNK!fYk)sH@eXozDI8>0u3+qC64ah?Gq4h0F7qRsW(95^js#Wz*R#aLb2-)FkMDwxkm}iI$ zEnirmtgq^kSJRd^(N5qz>x0k*m(`SPgdV@Boz2T%lhmgQ_$G zFoR9Yd2kxesAnR9W4qWe&}d_?R-oay{+8#2gbtRSb+YTnAdR1k#SYA9sVDe8y367+ zS4B+uv!1z>zIKFY;e;bGOYB0y$GL=baOZAt1M&Cc% zi%CYE+s_s(rR1l>HJR-PLJ;iUshbw4a|tozj7A{}_7zXI;v`BbQ-xvoLx})89y}N8sIzDEM1~RN9`?>48Y-s4 z-Eoep7dWiDBPdQ~Sft8020G~(Vz~(jZ%RpaP&2TskDDAu)&cM3Zy$D(8TXa$BmJ$B zvAsjs6C{!+`08`*=)1Xn`{C_}*VdPt55N8fKS)VMT1i!&=AC|WwfGBWZmxih0uLj1 z;Q9_it!*uugNcnibO_=WSLhq!wvFIz`z7N}iA$c=Jxye}V$h^QSj< z1)`LQpur=?9vLOX!~HCw$H)jf@PhcNjs=fMftW$EicRbE${+*+tCxkW8DWB{^Jzl~ zkT+uF$vuv?*ME;HB~LJfqB0p<6XsTpzPHhJDV|gT`vypMKzfrcR}t}Bd$hEk(eqJu zA)n=0&Jw37%O}OUpdhG{au!)M2rNnOf3os94Q@}A`)bUzA^hL2cS6$~B2A5jAv8mQw(f*09!3%q z;8J4kSAc6DLbt;gE*T&PUUYS68XxT09`1f6p&pvd}91+Syo&z9|Zad4jlndZcWr619u3o?*Y!I6ouU= zqNk*e(Uw@cC=we3e)-3j+qWOu2+{$V*68WIa8r0uC&Yw*Efm%4I) zQl}MqrhurhGogamyqpUsDxrER;)kARrVXl^!+O;aH`!L|#&%?_P}z0UYN$SKI7Sa) zB6w%EXWCIj>NDL(QAB?YDaSXHLI&CX0Qoiv)I}0kgK5|GL!_LzLf@nud|M+@j?T-u zaH^DJQ-PGjuHpLItsK@Wnj;3aa3KhfPzc%Vv_yk`m$;6iuUs!+I?yTva3+-2QNm&x-OQTj z#hT)DKgB-PBj}fCU%7$@_{+psM~Y0pzh8X#xC=WRRf9d?#kM=3Sy{=Kq#`yWuBxm zA0@48sq#|x!bf=l_-3U>_M#8;!ovgP_^3mMD<2FPA9pXYx3faO@J+2mO=O?c6LUVC zn190OA|$kl;ZBLIOx6o=c)c@jusN~}M7VmEn1WAqQ>Afr1dOpgvB9)3Rg)ZF1y=e2 zSAZtepy`iATvbvvO?(v|>4#$xh>~=8n{#$a2&2sfRp~*eaqH-VYf6kOa!9)2Lf<21 z@$pF{2>AbY3J_t)DyGXQ2|};Olz1``0C;DS$#xcNgxHtJ++AY)1~K<_O+zUqw5Xwu z*6U`Yrzur}$L%&+{7IAN=KCZYD{G^JxO0@Xah*C(t66G0$rcqXk>y#o7^MtvJ*P&) zeVW|I7QAga3v~cPWSEbsaUz%;Vlc$Snnkl2d}o*eROvTB@eJ2T)-1k@?jwNwtlP}#47=&c?I^%oisqf2`?=`0oni0y`Jp^DPR;nZv-hIcU4lS5vWWr zZG|pi`pFB8Tv)?8g+YLV0isP|)K$ItV9z7=K_-W|LcdH7*ybi2sxT|(z=`fuIuW7e zOhV(9hMc#0Ee*GB!@l;Jx>94KzHwG(>Ua@T`S_Z;Me=wUS#OfE%F`v41P7ZUei%3c zDD1w@j$0LBvvI*%v^phNfRGZm>W1X$UXpzhXzC=c*{`bB`$*<&d@K6zqB;`tTU1bi zV8M47M$Cc8Jb9TFmCM<@%4r9Vku{2nB8dyu7$;CS784DYPaFST5205hIImn&zN_c1=j6UgQwBnWN8 znf$Fx)~uh&b}br**wT;=dfjwLN0g3eBzL(;C&$#G@k7$c(%qe~8Q|f%%9NsB=vopA zy7tR&?|!+teNBz%S2yooz5T7VG>gJ*(*xfiB~I|*lnG^*br14nxv!WnP^TlL@+ksQ zsXP zn$?xR)g+2Ieke_crPt4-u8uF929i%q5tB~2qq08%KVQd^&p?C1%VfoWf;OPTlgy$WPGXwr4p$=haeep;Q_ZN?m=1`FCEI9= zG?Aa%UPxm3CBO(Strbe%L4zQ0Y`c@;%Le<%Js>HixkBGygc%S~LkQr&sSu(D5Kd@1 z9i@%8S^)$J1A7}lI8qVdoC84I%<=*ZxJ9`!<4yn(gal%DGR5ponpM?OdIBVXOt+oP zeG~@pNflT+jl!ct)hJbh4ZMLz@fQ1T-hcf3>CNjeZNR~36I*TU6Wr4)d{o={Ry4~e zE!3%a*H2hvd$L-fulO#t@*1;5>9Pb+GmXB{!{;mq`~uG;n%A2zJJao;k&7r!N$C>w_9vjIE@sVY zI#-lTc|f)c$ovA1lYu}nA>i*HZ(sl8?FZ}jf8pi44E?;@KlQKE?0qdp6?zxh17e3ER-I+62O~EmU7Nj2R_K{#M@FjuAXfW_ za^OVGj#%X%LWt4csC#&;S+hIa=kCZ0q$#8Hy5V#8n{t#F!(?PdBUtocz3zFTSbMrT zT{9dzv{kJ(dZE{WF0ttJC@%6;7Hu666sWMuV|f*TiaPf3GLWdY0bk(+>!m!7@z&kWt{VMG`720->UvN((gG=43&v_YJZ<4vx zHw_f28i+q4MZQSUZ8DQ~ln8CqTUF?bT_j#z?@{SMM^CFIP&&lAzt@Uwg?cQr!WK%b zTd7(HV$R>lymhR-Nq=b&ReT(` zDaX)7J*~?@sSp)>JWBusBfE_f++#|xgpyX4^tBfbB}7#8ah9j@NNh?*kKb{>K}JPe z;(ST6yEHDZeot7PJGspmx?YdjBP#s(TXOYM>XZmVZ1>jm^^u_Oe<>C;3Qoq2(CM)S z?;}CkzmM-CFyC)R$=LdoE~EvYu;=ub9LH{wa|MucA1(bA$c~`oKUi-^ah+Eo2Z?W7)?f!xhP>rn&V>7XA}@L5~%sSlZ%qJkI}=;>eJ=sJ~XQ zBdGh0u_E18grFYtL(uqN>dszrIs%9E*Q9p@4gaMoqK6^O+oB!=x6g07pyj_Tviqd0 z_6y*^>+{PJiuBCm!fNwMQcC*!vWPu=eotWZhA-C7MK1NcgkhgOtu7L2T2UkQyHF#u zH_g{~NfD!g0Z_(PRG&irv5=?5;=ndq3Q^M$q%TI^+|Z7fQF&h{4-J$1HrjMFD1Azb zl?IYHilkT;KVZ89Kk$(Ocg7g@bkzZE%6)XVa__=qr354i$vXwJ4% z)mGJ1qbJcMNGz_#RjTV*dzq^vC+owHM&u-=GUrs*9e!6Cn$ik+K7hkZh?Tqq zMaAX8UNsWDz+@1*AqrI$^45bfM(6-V)m))pii*lZBlYq8T1^2DPOXmT*R}CH$7tr| z9`^iN`J1uLXx&fP(^WbDH z%X-^`R5My3eh+)~YFXcNH(Hk17)whe(d(vD3)0~N=y+Z?`#VC(67k$0 z-VaSn#G@om*wsxsmv>GM2oCz{>IY(ogqTPgw+nRi^)v|)Cv4JDNaMhPh`z>DA|jqv zyj;{RDrIB@q1PJ(v`dC?KvDPcv=OIGL?;AF_g z#Q6i8mviC7^M`sW0_YVR?SHz5!Fnn8&g zx%dBCASZI^-=l#39eVU{QeTNI_Rkppb}_pVIqbH_ZXosvXT0_E(ArEDkLfS2=hI)t z>=I!g_hoqk$o9c#((ur##PmxT?246dxs;^9Rpo4U+XtF^#qE+5N=TAwXiAcf7^qf~ zPT1Ow?0@;o$tcibIT@h4tBrPgwyO&Y4>LM(5N74AHHqo2`Xl-meoh)`|0DIUW^3$G9EA-7` zH`4a0Zu&$yaH_TL*0#E1x~OCuZ}r;ho+ES+uKT>~Mq%JHMPb}di#R?u48sltR3Of^ z8;7B6mC*~M&=#A4w1;7wzeYv(FbrF4_t74O(btq5pg;f$WmV+aUAkPWP$_I6zLxGC zX6O-o4Zq|?6;t8P36i>oY+7(n13j%?hm+_LJPocKiH5co-Bc$^04?Z^kf`pG7dNrQ$Tk_24NUrze73^3=Rgi?O<1q^E<83FXI5MTHtAqAH&z2 z2PemmVHQ7Tn{BYShrN330~~G_ov*z;J1zor+*#gX{c%28S$r2Acc5qcVmBOduAS2r zWfRz5m+^K2#pIrQB{qKo=Uu@$he0anj0Y(6!4B*M>OLZ)rl=X@!1)bJ%c3 zJoo6DbKq3ZJz}1Fc;e=fxsk$GK>mAfNCS&~0oJr6RUA029EyJC#`$9*1E;;Q0= zdV+ z)5crP$lTtlzvb7*qB|nMKL;{@d5X{65f5}a)lAo(>Q3`6(hM{DtxnAg6xeWb1}AC&J;?FjvZzSnTzq=O1|jW zU&fKSn4H+o7o&Zbbt7|W)Vf||{!-~P2etf!%(WqNTU~Y#02vv07u?5A6dQ zEjL%_8#4EeAannkbKq2D?$^lNFM9sX{XReAf z=&A{fBXc6EYH5f#AoITVVgv$2y{z<^>xeZlj?4*Ga)l9NG;Q=Gu6VL{r40e9Iv4f= znS)4HGldeP!#8UPnLC6u`Lfq%t|Q9GG%|Nc(1|ZvN`{;bnIrSjEH69w%<&U4*N4oV zZpa*k7{+%*<|qtNOA)9}EA$PSn}{^0vvLlcip()b=BA@r+IXuMnY*=HbM>-2QW4;s z1DW5Pp)IMkU0)y?@B8&*WsHrj?8hWW(p-nhi}#tGWYC*_@X1q$T%|hP&dBlh%!1KGRMY| z`Ar9(xw41A6Eg3L%sC8F;bwo}1tAWDPRJYvhZvOFLC9QKp>N3CF@nsUYtDgFk-5W> zx#2U_A(`bRB@R@7rYit~uH@cs+ z^5vp3K&34(O(66AK66zI%_n4j05Vs1dj>$}4M+fXSvO=3gG1X!hefjpEA$PS+eVPN z&5`+uou1i544Iqm^W4T;&B&Z=XMhrE1}Hf)160=L`NLus7s*Hl%|DCM=?Hv|kbpTP z6E;D*D(C!G8!uiFoX+B(}fQ^cLaTiNVwz@tFjmDa5d*Op7 zWl3s1#;u3#=*vb!^OPF7XhGm{ED!P`y1}sY-Vu@jsHFaLd-RPl+3*%s@xNvGVw%*y8T{lLt2AO{D- zG|EPD%2a@@C*Z&qtGNBW)f!M8K|H24(5STkE?(T{qa|#=HY6Ilp>pdz8WL@k*q5^e zfidrEsd8h40<bctoL{60vu5#!M;k+ycg*jM#rK26)`>I}Y1IgMF3SKUqa;BTF#Io?W%|C_cYI)(MeO3IuCRo}OU`J?-!d-=ElxcSUAF zdX6dw^f4(wlDEAz@w@-&C6pvbLQ-3cT~+z7(?~jrGp>4XF$#=kq-fA}4>H=>3W%oRp2=KhK9In-F)?tz+#bTHUeTF+)Z$Tg+Qpto((gID^ zj%gz<2n3{hONo-%3qDa54t>M}C`yJ{EUJZyfT$`uKAz1Gh~3*>?%7?Gj-D2zrF7sf zJ1Pu_s(ssI(%?yXK~YXc*OlSAz{W;<5@>tleJO1FACu| zpj4uzH7W90eX=3fRF?r(H%A(aS)N|MtC!h1uejKwi5gU>P$(Jrwi|eMC!9+M2X0F> z&`vA#4Ci{D37iYFat@q`bLm7B=X&PTq2;{QjdQotp*`u*gm>i8#DO^XOI$2w)*Za( z(JUEV&6maETQY)|JIYG9l11e)Cl`S)VBe05?BL-GIn)Sz0S|xq_0w$&96o@(#9TbUPc698>wgg^O0h3e{6Jm26Q?HoJ0tu1F4dzpnvK@s*G98gP3+x` zY@^b+Cv3ELh1R$yTjs!imjE!ZCW~yuGOZ~ZdrkwLMpJ81E&wSnt)zq><1uw{kK-yH zRaVMAlw|*26icah+q)3&_Qqg%``h(S0F>)JZv;TCqMiOS21S=FZorXl=-{wZw=g!? zcgbOnb76(P85Bkw=N@;QJEvxGd)#sEp>r4%65i@ID7JeNc&=2sxQ}5_;)7TPf^R9Vt}F)UmmDCf(sAKMIz^XEkzU|3+WK2u5SmcZukWLgA{%0c>w zs1}Pgn!ZT66FB{i`UvCqDsk|G+_TfK>C zT|KEH@s;+5)ZAz(=lU|w(>N01aMsZR54kl@7l)_6d+?kDkJa`}JDS8-L7;xv3`Feh z`=8Qsu703u?D?n`0})&K%4r}r>91uVw(_0jV=!>47*zG1iowVxzMe)4Mko?&o%i{e z1MT`BD&zN6cm-Z*NqpCV!*)p%j37r|YB#jCL|~iYjjMcJY_P&Hj)SXcf#;8+iER&~N8|uja)3l=6gZ9p-`yEs;n5_#8V-ZWl{fL-An?ZsPacy1!5aBF zUi{gnNG4?DO@hhr${yR%6-J=H!_m;c^1=xUoT2Ru>!LDew=9+B39bX&8s^DLXY#Op z>sd*^5Ka94PwUG1PxvFvHE}&G#C31NkP znFth*8n6-Aw44X0842}FgaGz2pMNc9uU;#GSHxMH1G08(^zxakgpXN#q?HhaVztce znRcxNWvApmSP4LqVED8d3H_}fMM(&hB!G?3(^k*)`wK?SLmb_Aun&5QL4#0i!Xd}d zU<6!1v^&ru*gC&N$uNz(SU5)eKA*%K!NNhU7EWKRPbC&bo-9g#C7IV)G|#M#a1<*` z#XiB&j&PJKeg#-Wc;I@(3BxXMln(X*932El#T9x7M@=*!W7BdToD4^u8jjl7I2@I; zS1TO#T$gO%sOLK}I7%-c1xF942lTO;#>L?v)OT$G?yzaBEYGe+`8by4A2~$jurh+* z4%fFpn%IGCQ5ACh;{{sU5gmdbx@lN2|HSe$OE6B7EdDMn-$IL2=s1)IBc%Y`5#CW)|?&6F_wLZ7jcfQ3|l$8&lY3qQS zgtlFqM%nnGNUAE%o^LcTwK=wm+WfHqzz8$Tf^Qs09ewj;ZFI9XR=94jE#SUz{ed6Q zDtBsYgAWdHATJ`?X@!1S8x+?Xur}DVoCl{_8}&@Y_dqrpwl><>tJT_Y!*I*mz_LO% zSY5}adp!QDl?~9eHhwE;4kz&CE{n3!l0^?5ZhY9p5!}UXvo_5sbvuP#c*B7_LG95e z3_8HNEAq08;eXZw2#yk|RicWPJze!_BT}%k?ibZ!mPFR&-1ehAc`LKs%;Q*A?9Ji8alOS)S4U0$D{}-$};a0%?<2 z>??zbp8!oqK(kUEd*O!t!VL$+wn-O2!w36drFRE3%@z6uXt0TLC74w!q0j#`FoRjK z66_Mw#Y);3s~5@;w3S=v*42?3?>}5U1D5%FGLF*Y5DX4IEH=6l=4z7TUPR#$N|YGB zOl3WzOs?1hM?qH)a0(?#0AtlkcmMtE&o}Sd2%e4M~q7*QMzC|kiy-P?bSs#jteW= z>{<9es|^21URe3JXbsfM1YnIE4_`>t;fuh-HTY1YRmUcQ-Jx`FJs3HmbHLeRbA`U) zVH1_U=&YOrr{ZB;<6&gFMMfKMb>rc!(!s7Ri(-VUXF6G|br0C*<0C>EK?&G`#+J?4 zBu!a|s4v*q7E56=!eVRuBRfNpqDEEm*1jNPF%I>&8yQXveY-cE+B;}y*}>UO#tbyr zk}EAuol=Z_)^KUfr?64sYtgP%u;PsUJd2~O99UZ$8AR~BNJ{DRGmFwUYEbH^SX`IffD-XU^4A6)o0Co%wGk^{qRU24b2D8EY7f1BD&}sQE z%sH5|Xkq3@)8;L%l*|Dq`EaP^6_F+l|Nb0d>%&y zb;(iR;p%b7VaSEl7rG1>qAoZJ+Q%CZkdIvwD)?X$5P8$BPAl{chM0(OqO)=ioC-r6 z4nutNFht5*-7sV;x!0|K*%1Nu8DPlEx&!@kzRCtZ41(ZB)1Jm`JMiNo3Wrj%1Z4GV z0d{q4l~H!LkT!>MRVRaeK_55}aTVx8>w9F4qnXTW;3~UC^~4p2gJ5?X-chbmWlOdB z=Qr)!5+P(eI*L`A@but72s^t?=5!y*{Z*h_G*EGV7f+qr&}Y&!X(da`g!yXkfir zz%_n_!cQtw=?U%lIcu*9W8kM~Gy(&QeXX3qIGD1G;c3z_(UAWLC^ass2$0?^D(>NX zTF>B#rtx@vg8Y+}*D$bL6qBg_3_NMR{3uS-78ezI!iM^=p*q=?K>|DQeMCB9LpyW> z@313VVTHb7L)!>8v^h3BG1Zn$#IT|HfH665^w(Z7k}S$>!1 z$24#S2qorpzPTGpND2JMXb;-8N(v=HNa%bcqak#9+g6hj;HbF}Isxiwg>p)Pa8CY4 z*prgON57{~4hRtr#b58E!^Onyf6pSINz6U}Tk-%#Qf|GPM%K@AqoRWi*bAcqNE2+O zhA?bWr7MlauxSfa38vB;UVoHRCUdQ;Ory@E88&X={SurJK$$;6>~Gqwz{ei@JD`6@ z6ZSLSTyfanSQeg*+>mHVIbIll0D{|MBPpq!1Qyc_jEg*L?YN6D3GjuKFtP(w_wJTN z|0V@XD$c0!MXfZNS)3G6l^08Ep4`oNI!?pXqShAxx+)&h0O9gE4Rk4!vW}pgfL%v} zUwrx`Y50pZjb|}4EknG%RzGZM%Cg#Idn}u6dlRw8Dl^8j#JW$a#eI?{qiH^`6W*%( zh@Hd?;}QJd%9io{A{#GO4kdWT(K1gaQMTk4?iUZydYEhj`k|*vg*xOZwQ2|rPf1qG zmC2EKBU7+%F<}$ZzsC;y#dX==s2*EivbQb~_IG4$BvviGhTE68$Qo_^Jh8Su?r$dK z-(fX&>zDeQV6SbddanA**JJD3d@4R~uo;TkvLvi2sIOZaDa;=L9~;zPaqF3EPvW}P zMnH4%?Qc!e`edBR*3;nM9kqTT*&Ym#G9B-bJ=iMq^>y~RyB_a!_CRD1uywb3dmwv& z`L#xO4|)l{L`Bb3;Sza%vE2n%*7H7h3l3jkdk}cGAE+HVtHGFf-TQs)tk5rqj)M&N zb6`^b{7-Y|(0PdOhMwU7{8q;5_2#(lcC(Lw$Z8qT%jbzWqQ2_9iUIvR8`F~nc;oMX zI^4HI8or&qQ%gKPDr2b+mJ(^Wem=+WfnqeR>8#BrO7$}q#38MUY5Pb^B(!0}i8Opf zpB{jZOJF3;^Pea4#CrA;kZxLM5?1m8pwv^QfmFl(3es>U)f*S~E8DItNQm!ZseR-) zs<^DjaxRgEbLmq}1?jQE=>lGPbuxG&;PAGhkJ*wbyzY3G`64 z&Fu&D5IcR{e!ltA0xz^g=$M8Vp4dIEjXe|ttFlxd1p{}`y3$~8tDHq?YDKerkyQih zH(IiQYF?&->sV=NEDP1R_(|jH(ztFnjf-r@_tkOEd@!jqN!?gr-wXnD7s&8PWj$x<}_<0tD%NFF(=IDs36 zVjKHzYe)(JEA&AhoFbH1XAiMb*80Ad@U){Ft?X~04$K)j8i5-}ppl=G=q}57Igt)dfcJ~hg2_WxY~={(5rl&E zygT1+Wya8K<8n>PI0ywyHOoi271K-#ASa2e39Z{Ap^w;sG7zsDeFwBsIgUO7M$J}? z%d-kLQ`M5E3@K-f4y20TL7S zgxR#52PcCOpFt7FbZe$o_UeQpUKl!Ct(lPTyYe%1cH;;z@-7;FiFe_M+<<;X%R|M} zI4fzq&#C~^$eKr4e1tuXd?ExYQNV@>&pv?%=&smD?YB%v2HWVs`o_W_>Tp= z_+VS{LO!&=%8#X$#XNlJ^UGJ|s(#Q^oShCIMT;`7o5ze-wStz`IGMl$p!uMbWZqmR zo+Z)XU&X&N`v2`$h`BfZxAlMFB_7fmlM_pP!LF_CJ7cRZi}Z?Stp1nv|52+)%2{O` z^OHsQ7_i0e1Y5`eV>@(lC)h#yE`lN47Ru&Q|PwnU|P0hZPjwKwsc=9Pn(epQE#URi%^5;_jXE>0MT2Az8TT_B^Z ze$fLULkaa7go-4#;F32G^3*lC5{VG<*GT69{@gOf3d$1n*zKjWB0&R(sUgdnn2ARDnd zxH8eeZkTtY+@!+=5Od9TBP}WvTde<;^=t+c)<6G5<98fvO@Tqyx=qDFcm)NXFC3p9 zzwR!Maj?K;(dM@J8@CUQvx0T6S#jg)0=e9{G?Hh_ZG!B&t-viQQKjnF0mCl3AM;(Ti%lISQi`DD*YV8u#w?^XKvg@XpZ@3^7b$GjTskx+ih-D!oM!3r~7 z7g61Ik@4VEd#>)g7zEg`kGYk-S^)(JM-foSPp#A~k4^;?um4yi-*TQkau|$okXT<> zm`Wn!6pE@B-~nh7^e&a!qmU8y$D+mS7&tnFw_yzhgbC{SQ)J!q0%mPg^|5@J>LlC^ zTv@r^^+7JHf>q33SXMrdGj`1Vkkd9bGul5V$>1h@%Zf?7@_*4A`NUdetIjo9R4oeD z)}~DEvSgBsBDg2d!&P^skvzetLLL$oz7m#u6|6(WHVn0WSFOV9!9D^h-(7__SLmGz zH_?>_)op1Q4^CF$tS?Pq+lB*wTiL5ug}ZpWkcSgW4H&qr?U;CxneTdJ|6i5_rJm_r3i@> zC291%ji5^m$#aSCOMu92ZjI}tcT`^WbtvaemDg8C>yFDUrolzPi_K}p+uyEt zs`o}P0^#yGz{~Hni#@#E)|h4%RWvkRV|1ilvyD9+ z+s?$cZA@%VY}>YNOl;elOeVH%+h5On*ZtFfdiCn(^r=&4*WSCT8=Z1%Ez#`CZO&G# zQ%jew0Env+EtIK2{FdXog3hof3(2ni3U_avd0Q7nQ3Nsft&qgzqjrf-Y?+7OtvlM{ zQ$2*(yJUSV_M2p4LHf3CV%q4-^k?@HD>TF+zU|;gy|iq&*&12FBC|w;2e^Y)e&H!K z812|}DfpYx{63V5GM;&K*>-JAu@CqG?Sd}I%*@nMKO-w0Q*x{u_;Wce;T<6PnUVBv z8#OU?Z1s*RCpmsr^=YX!#Hw(x9ptP}EMNh;iclnFevx&ZI z;_!Q7r!yDW21_jTVp^~o9FhRX#Dt}4i(N8Wkr+-rh1pu32{s-18zXM&)FEp^cnZcg z;YM+LRWFIvwC>P%cul#qsvs@&p9@Yj zP<#8@KU&v*k)yWs9<);F4lS}&44R`B=N+3XoaRFCIvGBSRM+`FM`=P!ZlHr86$C*W zut3LhJGilNfEn3)SYz>n39_yt8V2G*2z=G44(izu9Qd2KWOqqztCy>V@ zdnIlOrVDb@HyYo-d=%7-o|ia_Fqj0RZi(rspu(#JFwmf{+$YAY~S+1z*4eLH_i`k~Y2zRUCriL8s*(G6<^H2Jh;LS@vFE6G6O0^ORZgV|8*K z*HmQD+{>!6q!^I#XUP3|vA6VgRf+&n4# z<2y``t|$%uj~M)!rJVAsGLsrm%f+-8S}4fejb;m*+u~*y3!C1oMGD*F7a@sixjGU1 zC+ZR4m8NKg`<+=y;m=FHkQHi8vz!D{Gm~cRB7m2;e2&~TE5nA+*pyI(`+CWlsZa@4 zHFrd82rp+o;Z*Y=+jC*Jswo%w>avv73U*Zp3vQG>thV*+1yNOQ@6{jN|5|*XZrXUG zdaP75ZpFB)+T)QnchKpXgde)S(52ZKlobJQ8y2EdL9lo^664G)uzJdFb&O4Gd*@i0 zSGv$YrjCuSO5e_IZH&>A-HjK!fUYGELVn>Wwy$OZl+4di#z5UM&#zRQt;VS{)uY9) z_VFtlh#BW^A?h9u8(o$Hw{;sQYvql~8{_h|6LM_kPp;!K3;x=y)sYxRuVS3)6s@>% zE2woVsvTdAQ1=U$%bY2N2 zFnRhjZjLX6@#AAXpo_D|Gv%i)pJ6&0JP>g|maaYvO-*h!zrosB&J@O&Bsiq87~on_|$kNPB${E z2RFn$q0`o13%>x@v`MgRxvDBvr@eF%)@r>s>RJm9Ri18DO$yhYRlbXd}C6p`1#SK=f!f; zyp>9IHbJL1z9h`ML8~Ryt0uf|#jcS;f0j3rC7G zb|G9Q#+D`;s!j)2)Oj}JKqFAIcCS8?=!=NZ)tTP5i1J5LgjPsHhzhmMxG=^#|AN>x z9Ogg;2E44O5_>W=iv)B^^5Pv6FbxN zHZ`IZ)+=;117qx3U$0~XXqP$72^SSH*4h%`;SQwQw3;-AKQU2N!pOLiV5uh%`SM^Z zsB>;j0v}f)E>NZ;a)h=~D38&mrJ#e*_ucGVIvRx$JP=mzlPAZ@>${Sz^Wh=-a%k+2- zk0cX=K0|E*sWst{bKv)EPH`Hct+|q%&=#$M3WHuCwX2yHL7kUO8Ut1j(BCM^M&%Tr@F>cH z$2;T{OAQ01y;ACN%{YXR<)UV70-%hHh*wK}rS#=$3@D}QCZokIS+t^X*lon2jeczV zwmdw<)54(FVSG2NP90++4Y#MnwC}Bt*80E`uT;ztEdaYC3CSyJr8Ecn!8hG#7&AqD zP>{o3R;GQ;VgQ2^ZH*(TT$_NoT;|o7&`lsN@R5=`?Bly(gY8?R=G=%) zqrk@9THaDDGJG=Ylptu?dJA~U*~gKzRwigxD0RR5YC+^7`CtDV2LX;}vheKl6+AUdI6PIxGL<1i4s^X_!&U>TE z7+y`jnpgaC;6S;+(Oz3N*dP{#dI<5Rf7G=LBVGtBC4U?_z9~o$6Q!;B{lbL@23+IE zQRHJD!&THD+w|5i-=J=)$Gf17A#UE`y&_t^db^9a^b`%;QMK2-z}CHRb*pRrwYp+A z*bHk>6k6?rz2q4SRyr}{zmumU=yHJ)wDoiEkzZaY^PNvsam)t{;iM z`!pY8OA8WO1`%E!b!0XJC|zrF?wBdo+=OVG>-1$qK>4W@`A}C87GKu;s_r&; z7p_}`yeC6#^x+>dP=vycDMmiVOP#=?$wF;$FL5)NdK+xN2czPsSn{w1M=kyT`Uioo zQVv95QK`?SZnszy>oH?>iWE^fF2LaIBXR_y4ikhSzcWU*DB@&w%o?8LHTe&!0V(6d zCo#j-onvkjQboz!+KWRtgA7DZ{j9mh)uw8inpSN3O~w)jfwI7;$Pc+{^TxeB3^VAC zXoE9&8u9h=+DKdkuq`Ly&ZL&oprHJcGG$5<<;EnoHKVtCxKMA4*xo3?Y;g|(u~ZY`~!!i0$_Vw&BW+gn^ABY(`1>R?FHlz=5{xN8y_ez+5-{PDV2Ff>{G)bokl-2cjItQ;NX!~+ zhe%9qUJPY+klGCK>d__|0)0$o5<)?v7_zTxAEqlw3iJcYaVy-loZ*>qG988Y!EO?g zYu>2jDwaF8NEGI4bF6)eNeu>_MFBSF4DN;+S z@IoWhwfCJhypcg=(?Fv-$&x@|9Fc^DN^6X)>o7ZR+wy@54H5<}wW%QGq4zXMlm`>| znl}?TSCY%%t|_CE3=?>pAr8hD->cJj%qxq>U0uH35|QIYKXrMYG-yJz^DGlsLOo?k zjjIr-4Yrd|wFNH}<m_~O}F^mS2T zWaKxHrng^^TFsqhGvvhssP#5|i(UmSL=2Sh>uIAq_#owk?1+cXiWdR_mb&>J%Cvac zNWy14u3!s{oY&qYZn$n*1!4KCilOW|>32flWrx_SEiVW*TuE#}mSiob4}+-)Ho!em z>GgKelch^N<@NBu-t7r~>=vzheEH8g_Y>VswO(s=2*+WzBXBLFV2rIwdT%&9QEEoH zTsYBIHZ&KPQ{CZMOnsTKU46#{MStbdo%eCj9LwWok623mPmi5gBHMU`V1t^Vg_ja< zEah=zw2@;7C2-=DJ7`a24h(zb6$0gh=GY#%w7RYQokkcdlrnRyze!S2*8v7s2S|*q!)h%9W>xJB+a-dJI#? zfCy%cp;Ks)`7PC9GmfKI!(%D5kZlE9ZV64oOA`D21z&-k+%c}p$qzVO|54qM#u5 zX8ggW1OGJdIF}KlxvFHm!~r5Mu)8*L)$+osTQ3m8%x!`9ZMhZmks!qU#MdMD7^RjE zy^54RE(>?pSu!?{sGVMN^Sf>|g3cDAPc12#TYs6v?Vs9zfttwki>Q5&xINaHDNN*+ zr8r6|qY5|C>zickDiIg+w{gFSiqk)a6fw+S)&Bc6;fW2bZuA#fHhRC{gTwj2E1(2J z!iMrs^sHBx#7#x5aq|rsewX!z-yzpO^~p0z-{~$x54`b7F>T7ereCks*MG&ZVTqeXJ}!oIZ_qEV5eCZ(axV%6_1hw~K`$6#svi?Sw#XUUWf|M4gFm)#J@SjZ z7AKE))N`QJyG^S_@lC5nb)$Q2VT_w+PTkT{SKH0tgS4`8p?wkr^$Zipcl3nFir`-G z6~Zg9zw*OQYk%51FE(E@6v9_Bq|UqzB_QzTdObS#49>l9_;K?Ph$4?#qsv%%k#J`Z z#(`MK%j;AYcV0M~1m(uZ(3=Ex5aVtMmB-<~NN=p%|>|aSx6pF;~nIYnmbM_`r`~G*)8BPUW5$ z0s92Zc-tI(gF53R#Z9fQIXFI1xPb4)NIL%x6P!>CS|H2*nj|nJzq8)j1h)KT=x55& z2MEJ`g_9yV&mDNiufKi&C z>{{{T!cJRI0hDEMP4@hifNwd@YMlB1aW<1VznN>|i{OXy zyx@gZpe>YL;ggyTw+S85TLBLCdh}jKHL`UHSHgbr`4e~MUy1I)0#csD#2ahUur4(J zj!nM;t}D<7?$G3ee33#AF5xDfcmqXTZ&Rzi$&CO&azs2UCj(+nJe!KrAAMfbD>#WJ zU;_^K*oh{^vWqcAxO^#rExFPGH@VWyV2pmQ$L!3;mf`*W!}SGwpXB?+Z#AM@mRw{H zZ)L`A<8Goo6Nc`=$r5ojLgCJvyq_Y6`)) zELNuk5be_j<_gfP(;4(@0^OES0^NWq5IpN1FR*rk$6DmD$N&PU`yiHcMa{&geI1Pt7CH{ z53R!b<;`B&4zf;-;;Pgm@_LFJiz|S}8KndP$7H4#3u+eg>fA&>dhtb&NqDQvoB_tP z6yal0*ng-&nC?H2r}cs}s|A~1ij16yC)%tJtZ>o;K!z12A({eqPUEqg; z`@|`$bNa&S#tcXRPX1o+g@CW+n~xr}p&!~%H6&CiaAopkmkP!XXfa*U0zlq$>yD_?j?e*#uxt51~yK>bA+O0yqRW2XST{M4e-S_m9l#>{_PC=&(CQI6Yfrn0f2A zlejdiB(uhppNp40I!tMce~_zmGz@Flay>Xu@l(gv@es95Qw!ByYGg4Tj2@?&s7Es4np(;b6Lwq~kWIg=TFDMcO-G%!I(p^>o;MF*7`y-YP(*JSVj(@@91mc)M`g!}=-Ig&(Z`u6; z1}SzZ*m+Ss!Wug*`z2n;EXT~WI}1_mSPUTM%yHrD01Kz%tkFY<%^9Z_3i1KpSt*om zGI_wVZw2ED#I(FhN}TzrB6cbSDOj`}^NMSxsXE6!J|Q(9`qo5tj3wSJnAh1!ZsGIS zU2HEi&&EVga34PY`_SZOl${>@Pg8i-?E78V`Ud^Bcg1ddQyM1o;o{kv(ppXrJjog# zH$*8m$oFRkq=zJ_MBS3{XMF*U1J+D%@tDIqtiJESu|c+_H?v>|=Aho`M@|0VAXA#o zX~RDo(luwIg;k#oyAQMt%D&KO^5H`Z={E&N@t=oUe0ot4Liz(PprKQYkbrj*0vkGw z|Ct78AglWqV;s8Rp)usX?BX|(tj*pQ4Nz~{sy;);d(%`*qEw8g$6NLm6yZleNYO6W zDcssLq#(v&5_^aptBHKt0H%T@N891(>&wDaBl;ZHx2!qwLJ&Eg3nc7nA7=$uL6`>K z+qHvik1BD;VnJlVA6hTwO;plnhB#)d-Bj`?5(a%^k>aq?^wn7OEQpxiiFugfE{Sr9 zN+p5?BJW4xmP@>-jt;9xgL57Q>_gMz4hI0dz=XMzuJ~_&fkAGTNMLeeO6O)6dhbFy zvDdk|6E^wmQv7SO5neEpf!xX_GdjvDBY?(aZzWD@Km=xR+z=?cqa&CJ6W>875bdX< z8D*oQC+H@b|KoH+i?}a(AuyM-niXfVlMNc*gsZJJrmsMwByvOzD?sVQ@s!NX14BH( zwbs0MxPes)X{7iHV13aagK*COQBl;Pk)NLrRxMn$?QrgAMjv$b^ArpL`kFMg!|{U} zQxthS$xeXWu2QAx<0}eDhfD$p*k0!q@`XC1R1f9TTT1=Xoa-;aME_hZ*XHO#e#;%* z(}59;=*Zx171ph9dbK#RGwf(d+!C?ANoqr7g92t`n+Wh!rw@77+RTQxqa>FgAzoT< z02tKl7>@a76_+Aq#GyBPKt}chfv0_XHOS zrG*pEy>yLnMcA0=4ru1nv=H?ehjly-z|*Os0Ra^TM>LG)Mu+$ngg=jAJ`aRuLVz_D=R{oz zN>D=iFg#cMoPB$aGO00Qvj)?#fT2Z4z2!tTXbx7PSi~r7n8E}Em-kG1ao_|7AhF*} z8M@#I8mhZ-qaD3kT*V%-2wjLw_WLugcXRW%Y6kv&Q^WW8Z8!3Q(iGVMh#drW20^Bc zl5w9;pSh3dt3V8eFq@XM_wP*+hKJegD}QZ^s%mX*$i&lnfh{DX>?p69d67f28WK`? z*xhOIt&w1$lUK;N;@a!kLwpLq`SeDRY3^+ds#DjPGpzqJ$Y+{p;Q%zmsR~%*DiYQDa&et=wB1uy--#i zb)KXoT^nmr$MDAZ)`4jlRY-qdZsmUxD_t0iW{lz-neRDfs+yA_i8gN# z6;d-hrrJlSga%DF;4W5o8yV@u^4c(js}|=Cr4&Wj*`ivnuk^ z=xk*XwE%kOq3)q5fX2Z`xW|*%;bqQgaWh`c^(W+{Ou7$fT-!x|yZ9bn6CWoiUQgUk z#>ZMkkWoM%^=s?HIUjEYaJ2a13t-ADu~^L+5%G}cD&TFc1&uS4)oa7!Vn z5q}j41yz^~JVkExv~`*U`Dim)8>7w}Ay2w1^lTx%C=GZMW{eq^>2er*&UJ_}qA+25 zOX*N!W&iTGj-!B!s%aix`0#Or-2Z;kXtNcaA@Fny&g>$fh2W-2WXK*6_O!d%-*`WQ z?Ea|B`i^o%qUEvsG*Koiz6cxyZkRiua7Pt|2v~g--VIkB(JHk;IeA`Y(z1|+E;hJ_ zojzS)&6S$)Qug%p;2knYGMJfo%3B4xkhqIsQOc9T%dBaQscB{)&3`Sd^{U&s15FM{ z+f&fF6w?sDdNMf+Ji^PoT(x;pr=KJYG37gKH-4TZHz>CI0y0<-g_mBLZf~hnMWF zGFhr^x>t{CRC{z*xxspNLM?g`x) zODM(@+~r`(u-=?pCM=RI5Tj1R*g*N{&gXvmZwY@(+-D^b)X#`)ErI3W&y#R0b3+eD zL0MHNAlC^cLb>GpPd5qgKMe1;j}@dzdLV(?&PpJ0R}{yiH1U{KOAo*A zWkfELvCpx_g!T*n*F9lT*b8N{ZKPQ;eGz~=i=vc66vWrp0@Q3OJb^kffZ6{CGdT8t z&N>k&cFYijG5d%tH43W`gcgZlD4j8lpchF5k+@jMXiv-$i$8=T>n z6UxR+*J?vi*B2OKb=56%p4j3W70n&3R8{Lram}lDaM!3&U6ki1)PZ1I#ft)=tdw+_ zVh?`-YmCO^YlIAH4!l*?qo!PEu)(gew!{2J!uD*J*0OwHh(H5(E=RL)w2T&UKJ~7q z%E4Z`*_Zt6Fki1oRG(-gnXausDK)mlO`oUs3^$Vsz!nGHPg0{krzz5$JOhh<&^UW| zFZgu(`|+--1@>~araWRrH8XIs{8CPVMAuJYFB0*n#KVy4GZ@T2%nGlpUnA82^M3$8arUm>hvbcuK{@wckMw?ow^br=w z)$}TC0}|p(#MGqJ10xPu!d<`E@-xqdvD3wz(Uc$X@8X+|YgH&ZCr>x&o#hbm;pqZO zo*MGnCUTDQCQ5Ib%&#fMuYe>O#aqeXIYGvO;UcGs+A7Nzy zv_&q&KBJdN3xA=ZeW_}xfgo|yf+If9vC53t5)?czWo`?Nz~w-zs}4)i(kvG(rH+EBljznK6H8xWu&8=Uk75^nQjR1gEqt3)L(CGOcr}{u%9(cX19- z#d1kil!809a(Eg1CP)9(VtT-Ecau26Prm2kWQ=2`GNPHGGTv%jQQ@zHHYMM>=Q*uUvD$?Fl_OeCJC=K9^Sn=?7I^ZgakcwGM!UE zfUw(E;-K+QOY24OKs)*O6!(}$h ztyZ*C=ERApY^hcpuw1gL9v`(1;^od-W!6O%3`&rG==deEk)|jS5X)yj2%``wdVB=g zm4WH|l!}G?_y4UG?U4JobNO#}inB$fNo59)2uIJsCjC0V8zi-96Xxr!`&T~cSm&a} z&qM_Y<(JZX`4T}D!sNP(D`Q#3upkuvbWXa@A|U&&NR;_q|1SklCL%)8rALw*&G`4= zf=#$!N_suno6``hPeU0!lgkasOG=gtHke6QH_Oz=&Bi9AC`h%Qz8Udd;e%*oc)z+n zuG?cW3Dju?C8tgDie7jbD!82*#@TX}NQx2Ke2*#tH85iDx%1pl)<@Z8!lC|DI2U{t9iF! zilO*j#TBo%zf#8+r4nZM!nE-IMpmTtT3gcGZlZEBZ-8VZ;LJUgJRig-`wm|5#;$%` zu*jY)F8xn+%Ww9;DYxPVG{lT&HnZENKj~#HKE}?hhQ07q@+!p1Vm?SxadU;VyQ<() z_3=M~KTmkDzdZhcrSRG&*)6c$fni)O=;i~U_zb{(p!(!~pE+`v31h>e)uVgeR%Ky$ z1v0g?uj_ThuUZw!1K;GJWUOQwv~=VOBO|Jg)Uc-#D+Mr`Kq$SrUtEJfb`yw}Q-Jdq zO#*M3>?fh@GA+HjPA+#h(|FgjXL8vJiOk?aJbqZs{ck69~KppuBOBSzhJgLE~3B>{iIAj z*6b?qiiiGkdL|Wdq<}6g0GOTgoQDdCPhkFKEPDJC9a-*7#GffFnyt?FIJ5P1Tm*zk zcz%*pXIqKZ84L}CGVl40~=Sn-D_QbPsQPISt z@RW-~i_fcH9ylr$lVM1RNlJvVPcJ^~-IQ7Lbs$Y@{`~&k-0BvaNt5$;AOV`5DyTgM zZrp8V-CgB#uc+Efxf8*M4)Rc94pOnilk8(@U4Ba^X1$VU0lJoa)X=iNZB9s zodqe-<-TMs%cfalGSyAUs^j%~AJ-s*P2Y^_s1UTY8L@B98l4fFuzn|u4CP?uUU=%5??UQ~7#6l?HBKmVE-_<0{|zPy1gM&qO>kM`E4dLCxy z8MU5c^BONNhzh*{j!yoO9Ha0xoacVuDiravq1_S5pA+a$7Jd31Lglu*$EKOt7236< zpgFKPv{PO0_pVJ}9XmVB07M9BB!n7%VS^kfFL2}IhNsG3@AgX9O}}`bc{vl7Y0d+kz?SnED=i(~cBBAi{@c3(0I zr*Y0Jxv3Jmgt?4uqns68uA(jT31M|QR&wcjB-Qzs2zkU8Xy!Dqi@IpeOJ* z4Av@Eg+8j`Z*!!&#^?3{-%}WatPu={p2`?*eOk;13m$#CFZCno(8&aK`(H>^HW0U* z4h@;URV{M{XUs6toAkCkPkwq6TmvJY3Md`?t6ve+nO+f-lQ`KoEwA2uVI^@<2;uAN z^m`aHO&uY}AbOnMKJ}R!InZBN&b$m5Y1eCEdFT3}RNL6D2{r6zQ#Y$j61;16B*U%b zM9Or#2LnrL&5}p1_<@_lS%Ya7y&^8o$Zel{)gtg)FGk(ke+v1oDXK^rvh)qW^48s- zT%4%kZ#-da6=p~-x1@LsWi5R=Xw!NSX5txbt6jookQrbu29av*cbWhU6nZyWf?b@r z&w{2$Bu5l_lMV$sZpjDR(E5??V#o(aNDK>{eeSQXSi~NXlx!h(e;+?7BIQvdmNY1= zTWt20Nx*Kj{E@4VqQ^+k-w;bx-aFbd)O+LTxcxqEjs$qaOxa3}bJ{ou`1FEoF*H`@v0s{3 zvlf0Xt*@TcNg4{>F1b%w^vypS#vl|BARFdzZ{}x4r(e3FPB*;_uz(n`bpobo>JX z>lKX-XSE2_qVm+6k?;2A(O4_`lkKDHj zr&bmljkLX)Sp=@^Y>vNKnlr_6n8RO2-g*EA2=<=I@NUi0Yp4L-vbT1L0;&@9~@*t89w z+O}j5sFkA9>oFlnN8&)hPy^VVVr4iO40Q znc%u%>BpytKx%42Yifk0L2G6NR(-Dv3!-=2B&t*qVGa|Ll)#sM?!Oj#EPZfwbM4Hi zp~r|`LTF5{%U&xiEwTGm zOD$|*zR#rAD#0nKJM1{YmwOE5Fx+55mkD zZl_9ls}6P&>kD2 zvxc<|pmnshojF!AESCe>!+>Nidr>!VMnWh|#(>vCyP6JpCH z>tI`50z0D7M~`gI^xbfYWD0~9k;Dl+wKj2$dk<;dCN*F04U72Vl8K>8ei8ru++_8l ziBJS5%k5+BQnN~1$b$>|1BjvIQhqCcjw+9w$QEU5voJ-lLa>_@<7ph3mKrLeh-2<0 z5tp}bQu<+kl*xSS0DVMJ&Me(GjUejJif{{;F;fLJaBvD)=0@=lN#>pU6}~n0ci`P$ z!6T7bOHU&Ub$G4@fe5^M?(^UZoGw%pQOJAQ%1^n;>9enE3+q4L;E#;PEi=9<+zeRY z>-~*OS9mu+Cf(AF%1$G6nAw+5+ii3iKxDQlb*b3%Vae&&#dOPJge8^s;8myDX=v2)M8`I2aQ#WobpLme9@5@u^=a-;NA~1IWv4W9 z`ZnE=i$a?P5F$)!?!G^Juw^l%p}T{Rl|K&dpEQX{Z7svB5&ZonF%Bol^w)5xKXv4C zX^zt{G^SVgJJ!lFe$>qcSfIw_fGy_Q#=Yehig&$Kp1k_m%12Gnuml(bF6(cz#xA8e zZz5C7JM#yDz>#Gm*nZzm!BH+K9(}XH37YUtFT@uU>xHZ23_)*)a;Y7u(cB(u$vrh7 zAniE*c4L@+j1RmxcZO$p^d>ANpP^Efj&=5{W^l*G4DS~=cV>7#iInes3j;74;xtvp zz7787*oGcc%EFhDF;cf4=Adan$S36NsVBuBe=<3(xHLX5|D3ZsWITV^y?PL3d!Cou&+2fv+acv*veUEKJKUV$#m<}Op`gr! zrT;jAN$;_ap^Vn#>lqv)F}SZ65$${Z7gboGbInzOet?`_S31W{n6Y9TQ9Ut zVu1W*B%KZi0+<)o@?}kF{BF(Bnq~8*YWxYE+QV|4zs$#$yN#OTV>5deWefS&jmdt( zRdBk!P4;=h#sVR{BfI&dt5&$%-w}il#y0|-7M=b>||5}(XA_QVkH)|feU)bj& z5&}bnXyG=kXH@>zfy;~8a0?Dfe_rDJZk6l)^4sXTS>w*^M-tS_J;d5D1>00YqrF0M z9QH!B>hxdSBgxqR^hSA1m+Rfe=s71sCx&bt0V4Hvs0=iu9FkW*aDpYxJG^MV1+=2w9|` zlQ%2`;fn6hRt3z-`!KaViP^GbrD3ZT-lG>o-(g|32@_F!&x1)5vJde`Bpgxf#uOa4 z|LwWF<3KamII;+$#;Ml+I@ytZ-;cW5O73bn*;9a%$>Q2u8Kti7l-;8Ggv&IHrJOq1 zE#9T}pug7!)DEckdyaJf=E(PEyQ!@^%``qz=?iVc9Ja?*#8GCwQU?)>lL55cH^0pV zLRV`=7M{=XsD9JUrWgIF(;L`sFy_Y3C9t@a{vjrShIJN|Ctr?q25m?w9^bVME>6Z! zt9p*OxklP-?J^7QO8`G}Fu!Z(#MWr@n+V-#%kt%hnM!AOjtE4|X`|3aONW+srrnOf zwghIBCY>Q_u{Cj3NX_^%?;WGG71tN5zHKGjJCZL-PeYaMV&#U*s1nGI{;=zuvGz#s zg4=Vo?BCV7aAgQq)@&v^&p(t3`l)|WD9rG;41>|!%H*h1*vs{*o>Obkzh6!pu>wCXM@GAx!w&SI^16OuQ4pnhi@W$&L4D6k@luCQ)NTfENp!$>n&kx|NWx#b zBWRd-CzI;^p{5?lY6phY6w=F0Dz*Mefw~nhe|%~v}Z*9>eiI77XKXm~6OCkNI@! zZM5pUUnlZFurf+|&M(5AV@ms(dhYxSO3* z{&H}z;_U0|;L5~;`CFISDtbcS!OOQY%>l#4xF=UYrT7#3(BR_q@nU##a>MeQt)nO5 zd;$YzWt62)YbAj2dHB?kKWeyqYAI@kjTesR`O4;DUZ!4yoC3>KH@N)MJs~nfy&p^; zyjzC&9^wVXn}qzXVKo2o{^wOm(RAm(<8rl6#3Fh2FaL0L!!Ln(jy_Bu{HhWAD|6Lk zby-Gj%YBT`F_rHYoO_%HI)3oMLX~a*O%JsuC?mfL+tqdu-l)g^d^wn$JJTPV?e}1N zsc{~fE~4Ei=`{!DJt;*otpX@#{$Lb7IIqh8&2BoP|5veUO3LWY}J9*Q~F1G zPgM#@3VtRK)a&e;=C?rrQOfmg8(Ize?(B9BKQJUY=)bR7o25df{D>03>NvkX;^O5| z1y<4PC|Z>3=te2r^*?vZl!!Kd**|owKAd4E0P0eL{AHpC{UCKUa%$qB=^h-2*k4 zn09pFe!VKTKL0dEi0ELuV&p!B+Bd*D#rW@@ou|`-$0JV?vFdf9b5uK}pnHOzmy?{F zCf2%vp31lN(~+%JJG(GiYpl7xGCWjG2dMfiuiLrJ9Weh{rAXpxI5GKvJ!EQ zDCXvZ&%Mg5%(m~VEVTBjix#ExZm6NaxYaT@M&DluGs{JV(Oz<#djHH~8NxAZ z=l%J2qRQj3#kH=FgHH0yF@ioSLGwp!01Gv7me<2`gQyi0dcCJqfB;s%1r3XDeT6~t zaXT}YrvOj&_!=9`Jm3tcYGU_jC*BfL$hZOO0d_8P~5>^}Qh1Wp~+pEL7_ludV z-~%zg<&u$GniGjQ+L^JcKkCGQENI}H&wP=S$6cb(nqn`~vk;=gX}Saka~q+96lIVO zenRZwu-1%!&TnrCA*gn4Q~WPPd8pw!o^Ml>K?eOy2W3koNsjyJB20|f5Jf{LKO+_q zR-tc5m|?`n7Jt8=MWk@0*hdE-1S(Z*{T>sNIQmHuBy9}s15F&{Rl6btrH})7k%oFp z6!OvngpRxYmak&z86A87Nb9DE{$sac=xkyiKS*52kAt$fJ!}#$#%w;+w|kZ|k(GvE zxkeN;P-H9kTrj>Jcea4d8`yYMFJ!73^o>BjS`Jzv8EQlbI>RP%Orr5rZOs6epltqd5O{zQiE)S084UA7-9K9TVgE+$% zz3a5$tEY8ew&BF~Oehq9_=3L3oAmZ-U3Uq#{bX}CgWDLF%7v*CmK%Vo=J5$M{rXvo z_T8D|im_#y?wzOrmp*H8yQF|e2UfV%XfVvy+v6_Oc7>CN6oMK8gb)$G!_U`u*>o}> zML+<%L4nOYn$(14QBu;6AG=1ux;>gqhh>qI+L2o2i0Tv#abdu~>9k()8`Ksn*n^?B z@AO6alzj1C4ZhIpeE4*&P={T7YUz|T=ub8XCHrm`h+z>Pt^?~<|6+p_emw(_R!M*Q`vh-`8z(S zWjB^%)qYxr;7Og?uj0fQVTNaU(R?H#$jvm$9Uxq@dlRn7>K20^?EJp3GtQJ94x{#( zn$kJk)sb;k(UiR`g7c{t+t;I&`t4l05RCPz@?yioJL$9@c=db<(|&bru3L++eYiF* z3m?a(+;7~w68QNKI}AR2zv-@Z=rY6G^7?a0MYCn`6nhroDxQm1bbtMGs=EK~P|poZ z8xQfuC|;6)0a$F5)OYoys%~BjDPK}zaG9~DNq_f1nrs)+rrh2uP`(tH5=a8)Xl=l5 zn-g2*lFE&CURK1fvIst1^B7I|A5C8w5LNR%3<%O4OLt0lgEZ11-5^~{NjFO)64If7 zAky7kN_W>vH@MREUY_6o{W|B~GiT16o(e2PcAgxyQKh2~F1N)GIOegB56mj*B7J8S`w3Fx%V>=#=ts za_JP{+l?8+emX1tRqAPH36n+(RN_0m7||W+grR&Ejb{@Gf2N}4i5daq(ZcwXUab-_ zYgEE8Alv+J(3dh~zlvp9^bJkK4hL5rd5gb-VSg5J?&fp%#44~=O{fTGrC70?a}-*} zQ*o#t3(RxzKF4}L({|W)AUBlcS*FJ4a9Qts?`yZRJ>|}zvvNn3VLw{Urhpf@L)*hA z$FKS(_dB0PR!Vo6m<}v4Jc|s6yZY z2$?!8;hWBTGd&Behh4^h4-(;E;zCl~a<3L$i;(<`2wp7Uo@>MNP!oF*Yraa+NYo&Q zI7EZ0RgBq3ljW~~rtnB0B)NY68|CRbL)u>dfLr}w`lsHZj>|n&w#oh6#{I#-Y;ttB+?5&3G`VG)3 z)>%kc{KBU}teq+o#zk$+VzcRp!N%>XqczW^1_Da=xr=4!O5*$Tj%$!+er3>#XtQq~ z_rWVBEog8yqXaXGnd-AnU`|*ddH^yJ2Khgs3$EW$u+E^aPsxdAJ=0^JP3x-*>?3VQ z2d6Ys(Ip8-;eAH*7z+q}KD#vPgwjJvzU0gp8|CS)R$AbWn|p_j(j5pS;rcP)JVr5J zWuob5XN_Yuw!FkY2za?e_gL&7&xkNd=uwodWFlP^(GdJo#dD`fWZ7H$ZFc zF->z8_cIomg@4$s;g4hs*0|kOduJ&_{7H1UYFbPy1t*m3H=jTI`1y2vRK9T}Hh2|z zAy4oa5)&3-T>Nm;yWWDaIJxNmJlVlE?#MkY72kv5=Eu@5Y%ug3_WH-X$g1-$KWyLJ zvgGHL)z>U@eLAUo4ly(HxjgX4%quk3)p60#Tpy<7(SNTc-f^C|hMBt0|4Cne7`(BL z-DX;(TEH)926fz6Kh%B+)4Z{U0m($V194F4I-s50UGJ03lmzyv`e{(XN z+I$cW@@-r1F*BR3`6SQv-4+uo+_-v-3l<+sl3@{MjcEv@P~$=-GV{ajLBuB|e9q6) zCvtWF&9}{DXRZ+bHBium<1jKd8|#tYYVHPE>~))`W8mraT(_CpMLpYL`hag1q5ctF zLW%fII#W#6ttt+`_|i;mRN}Vmf>{_DP*A$b%=D~oI-lyf?w6%WX+w3R#fxOPI=EaRI~K0l-YHhG-|+?x_}8i(m`V&0`(-R_#Ua6A^h%Q4X{i2p5tG15jE}U% zOKMm6E&NyEf3}hv6LWfh+E?;CbbEYfOi3oQHp)sm)dP#60Ely`3ueEWo$1xx@A$PD zZLk%eH~oxj^Cd1mzqzQt+giJ`>_kfhC6&IR`hbW1is;fs;RkccQgsfULJpQq+3T3B zN}D*Dy1w#inQYFyY6GKYQ=)8i<~qtq7h6oC)(t&9*qjM@Swq%_%9c;_z?BKpU1(CJy`stWdEl~9-R&p`i-<{gD z{_G0s%zSdJF&@?HvF{C@*sXqDHgJ5ptIBU;(x2FUQ4zvkZd=!;>eUwdqsf5ntPf(N zeIwVqz%l=lDBZ4AqQT@UOY(v8VnF9liOTMTK?C{=PRVsL|2}@f5(l$FYKkiA*|Xfk zlu)6cr4C!=V*DF0=!kCZCtS0ah+Bh7W|(>?bPK3kxBq(!4rFKTf!u|@3R2n#lriLEbYEn%&yus_zIFfFx?4n{%_Eqs?S_A|fO$ft)$l+SxUEis5s zfv>bh9SI7nr6ioUpC=x2uOD-$R|u7p&ph9YACk0%PQdIhZ<5@h>K2-19innH{sw`9 zH##3h zYd+EQ@`ma@O8BYmCuJ9_(<6KExd(+LUfot#^pT{HiyBluv;y|!CcpcwZ=yEd9Yr0! zYj2t%)oapDr!Tb;mNUT8!r+5R;$xGmut(oFiYYB6A`T{^?ONIXyCm3xT-Wav#2x)ph}vd38v^e;R}_ifq>{vw zXC(YAtZXb{bLWYZ3s)OVB;wbKG$T4X-1-Oe4CSrmGGJ1Od-|HEJN_;-VgB1+l_#&%V9MTqI9Yi`yob43_}|&ZJWEiuAFcaT6uR_YD#Bcu7APsc zFIpV&yZ<(D9DD6*qoLgwH3b&671k5J<+AAub5|T_wVh@dOFVqN_ThkVv@hm$OQV$C z0d7Xp?He9iyU|1CvodvtK?nhzhaCr2r z(u%e~S8t90|CeyrhcHKuiSY_aNo|lzkieW)?%3==i)g-y>G?>UX=8w4s;XQ_x2IAC zo6VzkQdR6hi&m2CU7iX-zo;{#u6~JnA}>%|Gv@9MdRfm%i!HKXYSG4Rb}|f4FQ$bm z={ihAu1}mAu9ufa&s>(S1@=r7l%fQPdA`9@PhU$(!L{vh(TE#5st;HyrKv4cR0xx5 zwFWMq62y!pxcNhz8IEZ!$xrHR&lP#%>D7=^dA|D&Sasoz9IFg_clE1?!_hs}T3L^) zqIMBCg>G(f$I?6TFVb%3Ux-S8#aU*4{O&_;HNJI=_aUE|qS?GOj!h8xhQ)_~&?TuG z=@%kFe<3~$o9HTWp|{cte{FWrkHMnpBsrWJJ-5AGRez?cZE;>RkzHJFN;`9xEL49Z zV{?#QqS~AL*t)3GG{f$qLrKZ!`PFMIyfWCNXRB6PXD_qS;7}@;s3QbkcxlyXLv;f5 zEdAXlGpWQz76M|2Rs~=v2L+69li^A&)bt9<8G7b=m8R zw$AMsZH1lZ0m%Y=C|cm5w2UlPfygoC+v=YU$lXWca3&P9kIoO;vyv#mZz!J$kh5Rk z*vuW6?ghDSeD!|?kL()}eqGo4K1f5LOUy(%ooA>P+ejLFSD^M@vO=QrVo%@UWGDmN zfH|#jWSbf!=2bMiB~|Eog(8|2MY~Bca)G!f5#=qi^L`PxGVptArCJm&oVKEPpGNp4 z+JyLtzQ@FF5`VQG-BnNvo#Wl?2X8c|=kUaGae9RkJO^>8wEo)GFT+Rc-;jQ?C_i8! zm!*w_(OQtj+LrS~AXX2J#ovLDiqBdhUC?p3Qb!!o{fyBK$?Hl5$;(M)FX~dxA^T2jsdSxMH= zwVB^F(T6HaE}4*Tnv^#qQHLeik_uZmWjQrA^)qh^xf{E;Uy7hHt=;VF9(+8SR;wbas!Q!9#LKSXPBreJH=` zn5n52Hotq8cP4wvsN?J#ueW=u%>Q(}=jJ8-ZguV^Ao9`O;co7)OXKS&*ge;)Yi!Q~ zq!{^dJ1>*VMMVz>>3>2f1Q`qT8YA~heaA;kV@})HwhyI;TAHTO zki(h6T(gp=q3{VIT-%Ina0R`0Ag#eetq%Fd{Fzr&k{r)@X85S(tQUPazs~{v;GL31 z+T>;uhS_?165Gj>XTU_53aw2Wv|0{UnL7xCLXNfs*ZgezD7%#Ron_gmo@duNlG%>cR#ki6xBMJ zlTJ6Z8`wv?d!^j=-B*GIzebkOP*tYSWZ$EM<RulhfBb*0w!= zPK%+175Jun4Y;{1?MV2W)FCJXFC)~Mr+%{FV?8vi+fD6O&!c{V$mR2H$ny8Q%3l7D z?SEr(Lzem+u6Ed~WQHyY&(i`UgnHg&Wa;nb&II}>-|&Fu|9trjq~;W^ntkU)mjV?% zalXp!$pkLuYd?XQZN$ilqKR_dJEjfZz>+TH7sdVuIg*Wdq<>_Mx4%o}A)4p-)$LQY zMhZPxep(W6SH(=`QN4QAedOkhg)w{1MxIsts72eev-!A5c%Qt|o|dI#{hH|8Mc5~n z?mog_Y}puWlztz+RYDS?k{(RqlWEs>Dd<>u_?J0(Hxh|jbyw!z0F=RKd84t!;zZ8f zFillH{P_}A{I^@S*wGh;N5VjAD~%-b2PDBE^`SG|4gWwS|5da^ZfePdkXLr^>|CpMxgP;sW-T3B5utK z*pMUG9aklw-F#;{#ygHwI-c$gJA_>Z=!`wzf9%LLn;o(qFInL_JP48~rOey;shgm` zu0S)nW{Ip>^XFN&LJ-{N{2mFjAiwPr>!xS#2>gM$c zxXIn*l;Ns)7XRTlE_ksJw!j$>5$DC@cDVR^QGcKdB5KTu^&8RFKj~}(txvJ@LH5Dc zk~UOkg;G4_GCll?-Xd=A2FuEd*z$8|%YTX6FxMd~>K<~Q$W%*v3yFN;jO?b780`kp z1U|-=I#5!+4ERJtO1`yk`D?Rcp@)ZFwDxDXReZA)V*F-F!ntwFU)h6Oj8~#n=bg(8 zpQg~x({VOAr7@zeeFP;pRIVk1@NcA}598)^kjg(`Vn1HJ-j_>B49PF0-bMC38jd=vS71WV6Iwfs{)STt#WI0&(Y$|4V40h+I3LBd3S1RY3P&Zws}@)3LRc}I1nfi zW7I{_zNdZ7dHVRH3bEgOe?1XMcT_R3zIQ_fyTz4~#8aty4LE--LJ&3#TanQNgQ5gO0MtsQx$ z5L;a7M{c9V&Qc&AN1(~j#o4S%gB|h)1bpP~icbpm5;Ph=Yn&rsMrwb$*0~YFjoin0 zHH9)4i7delO!GtEUH^_vp!RQ#S@7Hm`NOh96X*N-pc3%dQCs%G&p4Cz##%QXXtj#1@=%YqYb;=w{(tldqbTVVZmpeA8g2Z)TKWmtppy57j!?ah_$f4k<&{2f^wAr(4%GfNyfW5Q1C2h4Lp))rPDENZFHQ`XZk&@1xL$u6NVizW`vBEaItYJ%Qt%G5w@dAL+`O?jV#^ ztUBkDVamg>``|BkAIY@7%<0p5#(z&E^C-(|x?5OA?qX?^%3P)-|Rv6`H3Lt$R* zt~P0XWDUiBz-wok&A~(?w?TeSBkf}zVEZrFN7*Yo4^vdH^=`;(XJ!o!S{<@4w>1qY zb1wPh^dtgc-@;+>_71u$C@Xy^oP#reryIZ4{JychQS%b-GI+(_+{2u>8B~sM(UT_c zcYdO6qtBZat348LGjiJ$d<);u9W$j;Y;QDKp0=?z3wsi{tlXJ%4-9I`LHG?X_}Y~H zY4T)}2Dn6DFvy_K+?~$$#-(G~d4A+@%deq{GpnOp?Notoh`G~Eq(nm>`RV>Jpf1n! z{W&y%l5G9T_I3+Xn!A2^eXLR@{NB$4-t%i#`@kjge5hu=%pV*eLK+fZG82_e3P)?s`4de~AWkg^W()A}TR>z5oYVLeyQ zUTJf-lUXKj?$|4$X|HMV`}60-X>oBNp}m?vZ*g0=25yM62HNA-#3R8`Hm#pbig$6bvM za@{7(V*<>ehodN}>L~nCZrUgmvUjnm=aHyO3$ge*8R_i9BesE5Q$FR{mw`yvxhF=d z+8x1u_^kKmW=GGRU0GG*HZxf|Y5M(66n?-V>eX0btt@DYPZ-ZYHOA_u@7E`AI`LE7HRzBPzOU&O?*m|7N6)i+Psl+odlUFB z!9;!eXUYu?GYKG*69Mcvb^5#ZmZP;Z%IN6*88=t@fP6vQScn6*+D+G6E6ZS!-bc6j zFauoTXFGp(ACJ$A*!+c6l}4jfdHqpY7co&>;6LPte`Gv@Psx_Xz2A-%_f(#UpI2mW zshEqJaj4NFFn!FFPeK82tn&DWNn;yc2Onhb0lUoYEF`^Ysi!DuqJPYk6@oa6;4p{H zRLjZ+n0!7+!lQP?oQT&TB=WkQnvvjl`T1W2#>K5zad7Oo#>eIBeyF@n*IlmdG&Xjm z&WLch2Py|c15uhEcCVa)bjZUkyZL6aL&9VvJ3CHra0zTI6tjn~<`)+CET--se;&SO z1H3SkyR|nkaC#?9zbddl857r}BC#~fg?Hsl*1xwW`DBZHOIef5Lu{c=2CX1I!7;1; zDrNcS;IfS?w(_XrB$86VcNb9MF-0i?G3Lc zd1j%f!jVOCVfouM%$NqJw~bvLE2FMhjIWB6T%8bI8?~Lv)Mr$Q&Gel?&%NK(Z;o&h z9K2m5b#<qE>SA6bZJ3#rV~(h$C}4kK1W~hyV$o=c)@a{~H&)CjSfB zf;*+|lSo~!eZ%$D)l-f2Ot%1H9!?&N+m$HFnmrBSIp%TxsyQ2%Dl0}@J;gvll!4~dOuD=*0|Ba>B~=PX^&Om^GhF3hq;pB=mf zi*H#EqFlato%#4NQv7>pQljrKe!Z~*@~2AQ!BsnYmSx79nWIgb5@J`Wu2RP98P6-X z{Qh}})F^ddXNZuWYdGoHv1H&4_AJ89x(~bE@$n-|^HCy2D6 zsW)Zgq3`p_f2oR{JI-(-hjIFk#|UcxK4By@l4N0gruk#BY0j(fZYLk@q%r`d$bR*1 zBV%~@B8H;ITfhv;EIH&E$m?T-NY5rO8KoavoP zVYfTTtoOg;9$5skA2+Hh11^F`acu^p8!lH&Ysi8*OAOA>Za0DQnX#>7B$6S)`x-j=aQO6KODqlX8-v!OEo-% z!}WB#Ojt1*sun5EdP|FmcNgT=1_u%Xp8lM8*Y-YKhti}x*S+IYcx!n}8BxVyhC#(} z30p*cSxeHDwtl(;N%?_YrQ2a@+LDlvz6a=}yON{q^$tt8PPXtovx!F<4*WWw(ny_# z-+I`ABlvOS>Ed2+?i!lNrT3x9z?l8a7N#o1)shpO<*l1HaAeM3<(Q@DepP}RR@<$8 zuZ3gXp(T{P4;)_5#1X(ivWN+556D7MCMbIQ2r^k8CFpOFLF+v?h&=YK!-%=uFvBLF zZM=IN8}qxpx(9aqC-Mz2wpOhaGgfV>&^QijJlv&Y8S?CgMwXY#gf4I9lDV-run6Pk z@zlR%QhU=EB!#cC7Z;ZDBgOTX&<`5N)ID05fm67NiSAAYB9D*#C*f%a7DY1;3?~*| z-ge5Ti0M^DupW#{@2vQg68rtNd#k7jQ?tIfFV^`NjNksu^K+qx&BjcOT@5VcG2uCX zDs29=>q%c*4%+<5Y)Jd~x5_Q5hTBSDG)G)_VkyNRIN!=^m9~3)fS@h(5-P@%<>F%G z*A2yvF5L$`-X2?aE^~a8nmqUz*k*9HYoR!3)%c9iIr=zt!1ia&@aw*wn*h$JOWye1 z)-?s6Uw_I?v-fd5u4(I3vPN|Xetsubt;bKadn9(JpY7!OUfh^z<7GhUx2EyTBTyEH zcbfI61T>sesw^R@4J#GPHqDtBFRGt6=Hj2Z%t+)Md*8FUg&ArG4ves>31fSp&1hd6 zFY_xs%70JQ`M7coY*b%3H{*SVZB#25D1Q6W>S-(gE~xlH*qkc`WD8n0axSTZjrcWd zT##?`^;N{N4mku_n0gUwW4gNZ^>H-LnJ^!!r60}dT>93usnwNQ#fYW_HCZsP4Ul&R z<1fDvh&vhb(;f7zTS=@w-R!M$7BK;V=I^n#HZVY^4Vuo~;5p?5&cG!vREF!;zWwHN zF8qTGW#gLxvN<-@q8X%O^RIwAK#zM38f2QTp~XMwG%+^GFDem4jv6(Sj?W%4F!ekV zP#*U%bp@xDXGbZw>DQ89+=y`XQj%QEE=Op)S~>e7X=fQIXB&Ml;YR(|O^5p7$PcZi zMyj#(%{O7if8CcRr`fsNk}6Hm{*6C27d1TvoCCFY%|9fnu+8Q<+C1Vz$a3_^Y9$Yc zzqorYrLkb}I>r8a<^0r0?`%`$oVrTq?DEgMHfFDjf1T~_!iELo$V4Vh%P$H$>W!qBwge10Ct*u~+1)2Mo~Eq{Zts?i4#_e{M|G z@KaCVVNOq9-f0ahl62&~_@{pxGt_5~kN+Mf;uvnebOkr(ZA7>gUF(Q&dXA#@3wxyH z=cC%MW+p4;sXmV8+A}bK-k`V{e?=q=%2r2YhdowF6%|f9(m7kc^ZvLLNrV{XNvr&{`I*OH#Gs-bh+qBC1~X_vFzWl zY)tLaKNm7JLu5$p7~`+xv8I&+9g~>e2e99Go@XCZ`d!a~R~sZ4A7lN`p5JkNmz3W} zKcVY*!5w*K#zi={uM_yI@vjoG>G;uRb;SsgEK5%IE_dm&2zk7O3HNMm4moHL7UOvL z_Ud>>JGMAlGcU&VB}nb`QWs6x5im#YE}`bj5XXFb`o#{NXa*oiP4s<2=-l_B#U% z{dMS1{0JCC@K}^`{gS-CjJH*zoioR|MEK^_O3jrh;0Nncxgq^JQ*Ua85GKXH-Q%~= z+b0B<+lzI37T~m>LerMa51(t_)Y{fRh6+V}gbT3j^rJHWoX_fe!v`%>ww4?{6zHxK z+r}D3hU_r&++>);`r*_8wNrNYl;x`0HQYx ze(|cfg1EH;i4g_&rcvT`<`A*K6T0iRXC&S>y^#IRyPb~`M#dbwpb3wvu6zC~yY8wx ztG7fP_hy%n;wC7n@!DF>0%c8Jl3PcHYjO4xe>c&fQ3O^0+Z&p4><7}io4d!ylAZdi z@vf)S)aR$8D9K2+6UnYeqx8K1@M#cuCvsiaWX>sT=Gu1GA;PGG}t~fkAv1Y3?Uu5ob3cgMdZ+Y%~3cr^98NH z1Nw)cIdyB=COnP~e8B^DYY8Ud$K;R?RpxPq^$g%N>*F@lH(Agb3Qx4~(|2c-zztRm zgD7V*!d{zS_6$M$3aeLz(s2qql14RgtYXiY>aE|7(nPoLBxY={-Xmswg||TsvEOT+ zAfna=dEj#yz2<_p6QFX*y&Bbkt3zX!6X?c3$Y4RrSbSw8hRKCCv=HgRUJD-y4$zI< zQZ6lOK;=?+6)$}ubN%V#5}XXP#E9ZWovzJ2V`hBvE4y#bgMviA;q?c}saNK$T-jJq z!y+e)8xcckP!UEls6U+693(I^L}?Id-2r*%ZyNnfa%q;TjW^V+hB&!&06^ZSvbG1Z zjZ?0HWg*QL15V;WF^2#Q39_>Z;x-QbOxZUOn28|`IW)xtvB>P?B}*_vGk$-O=&rzR z9xlQLbAH*RWx!t5PDVap*KWb{YvxDL%iN~PSut0l?{7t0r-;_9MLsCfYWc&oN-9;Z za`m-Y8SJKY+AYrD{dur2E+4b<<7szb=BgA#L%UDz-&N|Ul!K2COx)yTH1wV)`_;5! z$|kL!zmg?2;We#Z!9buW_h!)KSZKHvH;)?s^zcVb&eYPdTY}~Y-lgFtup?q6@KbD= zYzOg_w`O$5wn3?0_F|vyPFUe0o&0j(pS<1^hAmnnchn|%9M--QomGlx@YHI0A=uwS zsQq)xraMZLH>6qI`@STu-ea5svVvY(F|2d2iv_)M(QpagKiQ&D98*~siT3wbfL=+1 zciq1@_aQVv-}Idj&WK5v3{SUr6yn@}9Y1iNW7wQWF@{8U*oySXd0c*yKBk#{)im-N zBzVCfSgK8}^LPG;>J7I!0| z)hrHL&2U=!{6Fj!7i>LpW%!0@O?#t?Y3zixC{0b)%^m*)YB<&XN!TGPyx12KWVzKq zGh{iaUIUe5dBl!oHP7Ja?=43h*x%^KLDZ3~uK0y@5!l}c)Z=R%jt;$Q#Au3&8d(4f z8@~Afd@S|0rsa;kS+2Q*{nyD%W1)M!(=ULI6fru3h8M)mflhzp!T*iCu3Hx-ZvH|< z)*b&!8>hm*tH+j(+#BlD)C50+h?NzdRa1}7;MVB%PRSbNX0{oLmCDa@(H#`2i;^~< zl9A*-R5UP9KoRy-L(%h0QYO4<`q#0PjTa!%5Wjn&8XSZjV!&RPTN+_R7eeT8uqVYS3@VFeV1FjX+JXP(qR0M`UA_G6+;BZw;ss#rWXB3uRof-t__w_>a%2C*H7%J$n?bE`t{2O}Em zoT6z0%s^SQ`1v&itTA4Jsx%Ms==oKlYIG51Akuk!9DM#Q@BTbpRf`9Ck<6q-ns~Ex ziwAy77G1m*Lqf=3vTq@s+tMmDsb*hD7x5qT|336L>dHYMx(8)DD_kMqAf3;!xKv#{ zQ6oYK%<v&82l7XtX@;=5m)<)8*OhvtvLWgmnO%IaQlJw<<)WaO6DB1 zJ~~EN#}|}6J&2)C0hMy}ROA&Hz-<_H@DbpOP}iGZw=M6Yr+$jZ_TDz&kaXF1& z5I{yedhSHx|HxpgL026~riZ{-qx)|g-!SyvT9b^M(WU)W`oHE8l};?t7;uomXINb- zgS}xIJxh+6Jv(fUgC6*{N2F^_(yE^Aot97++8fr}b)^W{h-FT`5s`RTO}|585jcn; z(m zT;XM*GTKHu6ho<#2?Kgxt8pI$r^3_?tc;LzNqxK5a;T^i4h)?PU3D zy_XOVfi2b;aG+-75gGK)t?@~W^T#mhe~>Q{8@TkLIDwkS0hP!b$vB0Crbv)|^ppCr zK_evTe{v)Ru8>Al4#PPe4ZBVat(X8xs&BUiD%MoQ8SlVTN|j;Ke<2}cA6RuzBDUjr ztOHq*%AoG`xdKw(ZV+@O&AfBpGIufyaCK28^u~-uhe@BeG%;@IR=!2)WafLXE!HiE z{wYWLti?-Uqu>71q`&D8do$mp%>p@jHJa;Hl(Y$Nw}@4k^eb2&*Ci>3;fHMkhY4ua zxsz-d-E1C6B&)3d$-3y}eTl=Hv+ezBkBOs$0y1D>T=M?hHc z6UyOV>9AHF@~1K=;7ieJY{xzF&){XE18Mk82B`8l3YtoA{B7DbmUt9oRntLQGhe>Z zeT|IUKVj+5v$ue$hA7N>`U2nDtB99G<7a!JIJCm)eU|?%e~im-VydVr=;vRf5Kl}6 z7=Jeg6NxJb_+Bfll>;+(J%9Na9VDf;pwbQ_DUqdhZ*BjaQ^}>q*lgF6^z}PB*x=-E z>2GSo*7npi7a?5TK7cET3??BXaG>!tJ31wxJ-L#b#e-grg?4`*!Fbp(&3OxVYHA1K z=~>vc7gLT`a*7k-3D3>q+)2X|{h5Q4p@>Yxp3XS80*(TFxpxHzLPkzI3zTgRR3lj{ zY42F+O3Y38|DYM+e2$2fz4yNZ-w?XrZ!Rvqo`ly6c5!8-ajU-#qw78KK!Zv&ykiY; z`Y?T;*3oHHkNCwXWW=x()&q>tLdONWSk|4WM0R)_ehui2=?X4AiN}nPRI_EL@8>FI zH{r@QT;=!$JhO59S9f%9k7&NLp@htPm!;}AO;O+_L{KSR6z+Q$cn%iT#wk4v%@%9O zdzY3Fh~T$pQxYjhV{623MsMSdzBsp%%0##r(0nt3N^b=s#LoszpolcV5#zIEuOiEM z0+3vz-_jHA2=SisnYgJgWBsl1EA<$ft=4^S)+AcFPE^TDOWBTcaF(F`%>N{CVx6K| zNeaA1l3Cjlod%YerRS)2LB!Uay?{%NUCMgISiPY&5M@iw%tbnKU3q+e+P-}DA zLLe>(2JRi%kY{3~wOqzulYksKjx>y3tI-;FeSTu6_dV}I<(hs?M#sE~U|!Ajh6-P% zIfw>n^*q}C49~JY7D)KIrG5rf(4gB4LU5eI7# zgv`Ox4F?yF@tres{MShI5Xh^?TR53tK{Wiv(J36`l$aq?za*qEKybYB+pNcQmd)j# zi7P)CLIhwa#0kgv+hBOEG5tmf)yQAaT50!YEiRku5Zpjw$T2I)CsUhO7&P|~M7P2P z5GuEnrzJscRdW=9FqtLF5|u9g_2(G3Dm-&pCV86sSe6uLK4O{oZcEiao1-jhb$QT2 zrgDg-Knp5Guygu71dOQx>j6(U8cu8%<1*H>C4}8gacZz3T zua`_6haO@-QJec@9?izVN*_n|*LB2GI{rpYtGN@=CdpM41Yr8^=@zQr9~lZqToJ4I zf{GrrGZ+ui#rS1vJoN%TpeRwMMAySM@`p1>w;2vpiTF4`CT9~zlG4d>HM;C zY_@w;Llid-8S!zhP12Rc26)_;pwKb*1YbD!2F0&AM1S$a$le8RmYE{9oxC_;BfbxbT7@J|ASE5lutBWhbnH?O5-&rv-VwwO!;A>qBX;1q;Z%fN)&{Q zps{Q!xdb|iV}wi@VxuAekbh!ZqA^?#7D!++k|F}`aL>s7OBV8cR14Vm)#xX{I0UmI zfi4!~t&;`FlX16QFZ=yneI>eaV$Bqvbd_|^E_OElYak$~rGLldr0QJ_Xikh!IW|fW ziP@F#iU1>s8cbspE~L$lKwlIjXY)wX$7n$D4s zx*>wIdfod$pc|*yOz}n+?dV!9UtlW@*VEN2LzyW+fGTnyu(YjB$->qt*oCSs)`&|+ z6pS-90b||K$AFRZXNB1G(sxIzbxF=3ck^j1I01ch0ItQgg{yae`!dGk14?aE2=POL zlb=3DQU@SW>y%o7bkm}xc7%Fi$Lw&7BolgH;->ZN0sy*A>y8l+ zBkmFaI6kq`$!BdEifbH_*XTfMj~C!Dg2x4j>-)J**`AbRKsKjUPMya3LSF_}c0UkQ z1L{-TgdHsm^$d#}G(s(Cf=fqC|1WrXsxD~4CUhw4Zspou9T{&?^9jxR>WA)ws>o31 zMM3)$@L_W+;jx`uJfmOdd-2FZfuH>>+bucBCKP0Wu@y8WhOkiBYB>J3SIt740vvly zJn|yW6fm*>($F1q(fdF-9{nc9VW;fWHt|}w-aPxK-}QDPTzMLAVfa^EPT46 zRwA{xa_zhhBVu?FUj0Read}o8ctDro^dfPuFI%itkBjLPHxE&b#kRhB$RebFN$$2D z&)}PlVcZ-;p#^@)*h?FWqM-%U3Z;^uw+xslDtU{$Wfb;W$UE6r>0hS1t-oms!poPb zg6I?~QD zF+&l|SMLJG)S~e?SieV%lq-6S^Cvaq)dPOw>mM;ATciTW2%0@K@?$GPzW{(?O@IS+ zG&u(=L)3`*4iMhR8>5B+y6h=pCWnFBZ~Yz74QXbcvD>cy3v~>72x|1uQjP>|44_PZ zhPgl)Ox<>B`Cp^aL%4r+*D`EG(*mSMkCZ0?ZeA_F_uuz)5+pwyRe-7ZdbK}zh~Q^r zOVlmyrbV({Nzn>oN6fz?7$EW~x*61})L}$RvBgl>Gu1nPeK4rN%K{yDzJ&bSnO&%YWY88sy0OLzw!Ia&-LaPkWP^C-1WnjoG=O)a7#{^< ztbxluTSzp-O+wtFNcirY4DgVj&*g0jDxvcz=HKuB^~4O+@xpT}iJ$_V9HZk#zOj`l zm%9RfqO6%@{tQ=Glmh(ptJ6HPPKDv6`)cVAlHi5ye#PNeF8~Q|#ufUmmv){HWpdi|` zndsQ9$ixU0EczVCkumDk&$mhnUyiW^l2SJYbjmpY>u2~o%@Oc$F!o~0R-+2VWsgNZ(RY z&kab_dW6tdbonj$64h~rbW*5cnaW(OFNIQ!3FImUeB=5<8bJ0oYq4nE1e$Tu%oIr$ zBH`uujqA@}0-a`z_D@Ugfkq%;fUhg5`8EDapL78CjGF1#@B31VB?)tVkD0!H7IzgH zCw-QSGL&A|1DU+n%4&uNd?0sI%c?-_qJpf7j@Q}KMHBwl8m2Hf5I2`nxmUgq~~u7XT(bSboZAAeTvVnq}mKXSZ)l(S~{F` z24ZppZdc9>)o9!`5M+g{r{Pzl;A~nqX8sr7?ms>&D4?l8&E^h^<(;D`d-To73ABzx z2W-$-AYjSoWc_VCRHreTT>ALSA5Q3ujZdKkNjhOS?A_Lc8tqPCn$^zFHx=3zXt{I6 zuy#^`Pbfj+XblVJZ+4Z*SB9GaR@lKquPpphPV=%?;X#lE#{thu`&(>PJ=Nx6jH!67 zS)O;A-W>@*hLzEQWmtKe#~HDNT^8UEM+`HTGhv(a9WQ*vh1R5ZzTD1Ra1l8} zF~sZpGVse{2M?a}0tjZebnv@b53hdWci*mKS<;e1X#RC(Jg|R|;y31dmiyeL zV`2GrFz}@D!TF|Kg*$3#a+?fmMI^Zv4$#Oj&W2wf;Ur#^WzoXO@r!!&)F&St!25BR zc1-A+I*)7stQ5CgKlB?6qZ=cKY;2V1^f$W`A3cm z74)|6aD%dV-LP8Z@|1jRO^S_K%#8UvuLyU<9(Gyq$|$|{Fui>PTG$gi@mR;0w^~I- zFu+FzHhppC!DJih-YUg!cdI1n%1JaYO8Gwh)0c~{q;T@b2y`ewb{83EoFxaHckWg~ z-Q*eiq8KvOE+GX6f(w5bv0gcJc@ddd-@szWstsQ?Om9m>cw>Hx_1l1KM`w6I^hjuT zb3QF64Wp<9Ft8Zs8*sq9NE?yBfI)8Wbgz^UMT^GWc!#!NJB*%PkzY^|0uUx^qSG9R zNn9bC@->8&i86UEK7vy#l z5_W){RR1SnkadL}ycct&(Fy3O?QLWGf5OjmMt2RYu+91+blS9B@ss!nr_^$Xl7T#m)UpG|1MBsH`w#o1t_irjfujb$Kq)x2R0V@2b0u3z)m&4K)PU?(kGmL=NOw!Tl z48R`kcd`b07e^2ziB{93^kF6uSWw!0^S%?CX;vESnX7$!zNt9biqstD;L*6bIN$nW zR9Z7Y2L}b;6A-@}g`g8Lq|=+cnCNfQfheCY31TO)6lLOjPZF*fH+rrcX92|`Xxi}i zHw4q8tRWa<Jx z*}_9I;u0DrCU@Rrd-$}eNOL70Ntpl`r~b~*{S`Khxc7 zsDP)!=%m(&HhD&OS(lsUoL?LsPx3;x-TWi~SRvZf8vO0FN4>J#2*d&F>nE8%zxn!y z)v|Xpgws0#j?GfCy!M199VbcIPQ6ST-_seM1B-^iXsWZq5s-SB<4ny_dWekSPu0l= zq;6_~U2PYKqh+A)>KN*ROe_<7Ipqe_-bVKVYO!6ivlXI7K!5=&A|&$umArBz0D&WB z!x#Z7G!LDr)y^6yN@qnya|JK$8Ogdkuv?TqPI@O+5`2l$%$eO{;jl^|1=_rC!E=e) zUv8CdZEV0-?rr2#RaC%fMCxzWTG}NRkzJf8#B0P1=snqZm%QMOXksLsL}};KsZc)l z*M!By$Rz?xJ>z4Zz}he_Fd8o89tJ&+Pcoj)FEE;fo&QJFdj}-JeUHOvYR(?_Y`AcP zXhy>_CrOy8Fqku#1K-d(!hLE$}+D&BzP-SoQ z+000a{|GEjJ21uw>D*u;IhI8blcg8OfWzMuc_W8oHs%83!Y($hN*;D6ul?n9*l zF;{$?O;0YrOuct^C0u4+a_sqicn+>4CK2SGJs1o^B}A%-?V=!gIX(*0BtnaKXOOjUBEx!P2JAWNz-1S(pt)kR3%*f;mC8swHabO zcNRR7Qxa3@n#%41pPWI}dh%dQD)1&11OMN;X2;JDpg<41l}`}xzv>r>e2`Q!(`>B4 zeBcPm`Q+=umq{FOXv)Y}UB!yl)Fk?N2v)2Ow1c@Mu+f+kiO|_4V}~dOi8;06)wCbA zYzMcSg30(4WeTeE3fMQ)^as_Zev5fC$+vHjFmEH;gb7#7d+oT_O8~14A1=P*faA5` z_AhUn#F3oAf%UKNlcyB7cr}=i%o?pLeFD}sA@P?<8MYCNX63Jc69cR0d;63PrklCD zTM9SYq=s@SU=1ytx@(U;ls9HpW~FW!oEUE|I%L!7$LR3*Ea2*lCY`Ca8lhUzFI15)GfJGi}K2zd@U>i z?4uhQ9+5ed`PjqcH`a)IbfHBBfHgIhE_$j-+YA%WYYd35SDE88zr{P-Y;4T5xqmtS z{lR#4o-}9jm>kB;<@=+p3?ngSLNbkCge_!G*a*r_L;`!fB5CWUuUM5w<>j|2PR|@; z@(G$Mt|^YFMq%HxU{3)DZ#NUQ4q|ISQ&6^l^(ml>eMkYv(8$_&sK5evX0V;EC&6fh zFsSpBqP3{IXe+3 zfJWVFcl{cUgtVEtm2n*c{{HhjQZ4_1u^Mm(XATz`!$X!wO(hN*b=z5_G<@$VItgSZ zR8ELM@FkRTNl{8g^#DhzM|0N=^+?X@LUaE4N<1%yGi#Ji*d(^-N=59eD?KbIHR1ep49qq8Q^vPcSci%D9@Gq6hrRwcp{Ul~WSba{AG8 zX~KmWwtV4?=&bS6b6wuI)+U=>cYOZx(uKl}ND%pwNlqMYN34(}u|T!uowYNIzUM*fnf%J|i^ z52;Fumo^hJO3$o_Y6S4HBwtckJjOXe>5Zk@1L8D9;;Q1ae_fsxq`ks zNOyb^D4je%JZO?t1U2Joae@dg{EU=4oajQAv#VmRcU=x7)a!B^)qt)LY5=@}l7Qj} zba7q5PqyQTiw9p@j#hvy;-2{IxbOe0<^+C@e-(682D9a{0*L|Tb!ZR{n7}~j8S@TR zK5eJ!3csLM;73+t`6zcm^lpLx#*yFNz*^u+2#4Z>VI)Z zAOhDtB07YHz~%3hydKZL|3{Hd!U;$Uh-J}NX*Ev|{)ryYw16cyu9VenzEdD&nJ~Dr zM_B_g?i7<6@t7=>_2>GT5AQ5CUhfnmYxWMuW6lO?IcR1jd0t?b=QHtD|U1>odRa?K(?dCxGXT;t>&(dJxrM za~~~zTJNTHU8_Aiy}zse^LNw}1p>$%vS2}|HBe^%PbG1d6F(l1H*#A6_qT)2+^W9% zxIVg|k_K=`2Yet^p13NagT-15N-m)9{Zpi5t%DJ+sdx&w+NiXd ze{X;$&VEK))r{DMFu=wkyFuo6%l>Uk>Ml#mXiyST=j2Y5u4W%m_QXC<>)X<|c~}pA z#NW{3d!*NESb--Q1S)na@v(c9A#`>VhL*6B&K2e_)jXSf@l_Y*@?V?w4@? zg9SR1H39n5PQ$l-^E!4ZUMX)Px>%&e1Ld9(sTWUGT@Z43TiwcT1)gpF48DqloNeeV zn>{Qnu-ARWu0M#&Tbjyi}Kgs#)qvFTOCsCJkcI5wmi>jZIrn*{s3$ zxc0&~8>%T&uC9DGOo&6OdhhOeMH?nFJ)Q3U$gPei1=Yn%06DYrISnjZH!P4u;Xbwe zRX8Na;5vyl;G=$?Wj==~dJ#d+#jm>kZ-(;DB#5%Wq{*!}qLO)8ESnhSN6UnO4DNV}<2Iy38I;S5#phCx*C#|l z%B;h4tsis^%C4AC+wp&J3-Sk*xE=M&S2*ehnbV#k9$4)8S=v*?SUyjRT`<&pjuYSi zh2-`bRzN1+nq-n~qH;?Nu2v0+PJry2S9^B24{Q2rie}T0v6Lbv@!1Ve{jll^#JZUgpYHoQ zr{0LcK&7CZ`3Mb>qPee0Fm*|hr;N@d@SD47cC+6s!;Oe&h2B@3c-k8|S67iHEY|!z zvIm`=i;xY0mVkAqGSX+dr1euq{Dkl3H5=6~b25P@e_bH4U8r`bt2S{7nE6Lw=FQud zp_4nGu2JQ~K%KqRmU&I|-ZMtLvLEc3y6a$?NX+UNK59c`N6UairJ=GPS)mVm{SY}O zc}l}D^%;2Hf1OQ8bTs`uB}sk8c(5)DCxC{`H35Gap*y;AINky6qH6;(KdT6QI!^Q$ zfFey!N z<*D{XVt}Ig0(frMME*FOxB~8e7_oR83Z#Y*a8G? zP}soZ*FIofzhY&}$Uog^=`?R@nkUhTy~%wwveg+2gmpkO?8n*`!_8>W*oS!g5FK=) zASsT+b;Yd2HGn95pvm8*8B|uTDTB7(?Jvd~k^dfc{aPIC$GGSFmozLwxfhH~EU7y( z1N9Umhyr~Jf#vmc&(rksE(*7Dw+Y^A&;@Omj{p*wi+IKSp_*dn0yPJ{$NsfQ7(HD|^$af&BpIeWfUt=_UI2bkgdP`k= zQTNH0t!wh18$unv&&3w0rK_ccbg7uc?7_07tE5NlQc)9to*nFP)&U!J5uJ0GX3$HE zcDTM-SHoutnU)l76Y_FXbf}Na1}$2=%r`yk2d;uBqQKR~1e|`1*#LuGfwFseGFM0| zZYI;F)q_uqH6?8HRkDrR(M!4`FxJ8Vvi^Eea%e#8vLA=mfxmnW^5U)bY|0w?+OY+( zPpZQ@<=cl*^1?%a_|+}9fwGJEG2|$3QUj?V=eWTU2i{EWqU)NXvjswW^;|7jh=A^5 z&00eRmPPt7`s=(}AU*Lk`+^58V7B-<$WtCHiQS4@DNu_%o-^ zzX`^%L4}qJ)q%0xIdiM0+>LQxW>;xg)2%5FzW-qxw-1Mxk`C0>{am%U zb3O9T{;ZlPlD4E&a(8rr8unT-^N+-2+uFuWz`U!Xhd8lUkw_+d-(5BN5N@&+~{O4x) zeKFs!W?&>YxZSZ-flH(1_Jm$$jmWHIO!;lo^!RX&Y1&HdaN&cay12QSL?WiM2S2pS zk!BXbF+&qCbd8lgtfh+w;7I}=UwySR5iE>oL^f=Lv4XD#V5TJdecLVJG8h5CSG}tm>}MK%HP05*afS8rCvrfUkY#Vps$17H+weebZA7Anr!) z9>XYSYE|XksSXLdA7l}JTO+obLJ?+8J-8vg@({tgIJ}vR>r-i|_2R+H$#Iaz;tZ@0 zy^29l&s$h-COhd}A0^)G86~=DhLewMrpb{1Iq{ivfxWX3=u^FTC}!}<&^Yq$)`usJX8FfkFHJ9aC~kr5Gr#a-F6NV?r)=z6Mx zsV1pY3Uk}fV<#uu?(_6>r6SFnOZ;(=PqIUMwCrIR;vs7^@ltkv5>)nQ+n%}Pd#8J z+VXGJt0;2DJ{F>k)~jEu6V|yd^U1(s|4YfHlsX@V@=cDH2`D_vA;~(TDNZI+`TpHm zWrk47&Gzwxu$ua(Pc$d)c)2hSsaf0_muw=qb`tx#4X>IgsgYmIY=ZxxtLO|?Cf_U9 zv$w%0NGp@QD1rr^?6;msI4hWn)Z-kd4J)q&*;+_$JrTQ_OklnX zw7!&rUXv5KYEqelj!ZZEv3{DRD3w)#+TjZlY5@q z`EhlPdYdT8(s!aZJRXt+jI)LdV1dwJ9}14Mvp|UMP~S5eON!`re=6J&EJ?Ob`H7($ zDk8LiFwKZRrj*U#v)e<#qU3u6`h`4ThA9za|H%bD%QYN)fP7D&&RQvhE5Sr= z_08ykO>|@i1{r@e#~8a(E4&lPmtZU>YwfL&jeA4A@Q;PpsALnEK(~|e!%Npc5{aFn zF`aX8wa&b*r*6_#KKHF}8S@I>MCvJyj$=7(;f^JF!+Eg4d(-=mdAWb9b9MRmo!eul zT+;c=o!7^X=9O698j)l~&aMcg@Xo8pn)UCFJbPT{ zne60kP3b!ljkp)jSw{yw-J>jU@Soc#C=j&v7}~*Pdf-cJNt5#3>@P_su0_xV91y#=wJD z+&@Tr__GhtDO?d~r@P`Cld{4*JjZ}MJb&O9N5aEYQ(UNnt*N+|$(F}2J<;%Now705K9g)Aig#V=yWMpvegB0g zL*N4NFj|dnJ{n30yIL2E_ajzI1t2?u$4Scz~h1NNK;NT;f08Bv~EQ5Ldmh{1A-)^Ud)h_9P?u4@728vRHutAZEc>N&#Gr# z-7+^QmdL@}1KF@Z8L!DU+Rd8)tt&wLp&9=HHGLcv)1q8=i9dNNLHWn& z{Z^hPO8un!hbja65@uh@)R|R|%NfBUby8*#+HRr3?@WYtYik$Qqh|{w&p4xCX?O@Q z;-+UWOJ*Mzr|_+);sLYtU$|q^eL*Iv?M%*T?6&UI z<}q83UT`3cnJ(eGLltUxQs{-Q$|^8A(~>3lx6AgsVTJZ5t)DQ`l&{ZBEWJh~Ta0_d z>%Iy`AnOSuo{K|&b2vD5oXR70mmGNA*^9Dj0iJy8Y~ z7rcS2?-+U9`bnS zrgpX<=5SZ0M&ElACfe^TEH+Q*%RgR6UfrW6em1u8QU21izCBxDXM`%h$MqvgfBV7~qAQ^`5C`E)EiBatyF5#)u@g6FXioqFA)2%U@mqfS}=-1^XDL8IML1P}{TA^XZRL z51H{%++C>k3ue9HoArRoK}_DOGq}n-F$Ml9zX1i#ZnV2d?*Wf)puhIeilW0mec~~j zAn%-oG9{BdA<9~vLp7xZSBpH!<`=GZtoU~>rny&9H}?c%w-3RlM|b;)&(X3!Vo;gB zD_iJq{xf}!w7xkiA_HOK6|t%KWt*VbdA zb3uSPA5MWtZMUoM{$Pg~jX4zh7`;Ylz6?snvWO8%viK)%8j<*IWZ z^N+80FM-SOQ!A(JL7@mcXT95_W?8EH6NvKcrp5D|eFfDE7)bsFOzo2RB#I&!4KCv7 zsrgmWTHhBghWXGYy{~p*35J_;BHlR|z>)YyOSBOt&^0ta19LsWXj4wdn~wQ4HM$ZP zh!%|?>bTRp7LE!#EgmqIqg=Gr8569RGW164?1eKp14j(Kqm+2*I}#65-Or3YgP3H~ zQr9_NKG^vzm@sv`W7Ih8uZSj769sL^7!}9u_&8%Og2!}I?xr^^x+?H?g0V|<0kr8^ zoe$aKbZo)SmjdrwFHcnVLsNFCU5Djmx-&n85kAPZdz0T>q2dYxQl;9wUyc`*+)~{Z zOqn_!GZwm>rzq9$@9hF9gf>NTTrBU~IbHLWg0J^DLVmZORg|U061ZMpBpq(bn9qGZ zwud_H#LIZDp)%Gx2G#@auODHA8IODfJRF8O1>3@Bd#&35BpV2W{NjI~=kJ)ywD!Ei zDGlqBpj$^aXLa3hk=|PN3EiEcdp@zA(Run{i(AXdX5d`m)RoDjT270JW^$Jrb}#xR zd5`2u<$I%H;NL=1ZF7yr_QI^|pGvB{s*~XC*ML5YHpTeNLc+tOObT|k%DCYIUUk7Hr-OK-D!)Y=us&~P_6HGVXLdV`Cwp36_yU6cjXg&j$fO)-g z=DGbovGQP7?w+?g>utxo;{Ai!S`kOM5l%KK2|_;5-Q1f%Xb7j;?-K*ihnd1{-e`ET z`c;@$1P^NSZTy%)|C?8ZxLPzH2Zgp$aKuDA6YpJr!$o!r9_ff(Y8fVo-&A=PjgrgM zDYW0Tdm|%D_d8cu{857VP1FES-8PUEjbq^x9|0VCPEz5$Qhm^YEpCv$4!qnf$+Sc? zMS<+~Mdd8!9)>n2;9ajQ1r;;Wj?`)T^-PcD`mNvj8_Q{Usv)qB`McD&Uve5kytL#MU;Wmbv`>e@=z zb-?LNOWNTM?=ZdpEct~Q%30cHXbdhlVMeP&0c`?Q^8s} zU{bpC#m46rOgvD~7IFU~zacmlf}$9_mazg*FY8CDwr9Q1NzrY)E#>cnuC}3-N_I(G z(*3$hi>>Bi3r?EzuN9UidWr|uCLbJ$NVv2q7vQ7wHMv1K^J7T*%6E7|MFX?P-zQ4b zlCGn(bEu+1;{8YAd>?cT#FBnI+RKV@!{zeUM~(q-6*q20+hPKnytjF%g5^`k36q3Z zwN}j3z7^`qw*x{kAj++LqZl$0D-){5?pKR6Da*7TU4XWDkGOyP663R_@1%i|hRMn_}Is3%JLRG1>x#NnH&9#B^1JD5|R~E2Y+KqPL z`GL(^kYzmVo7}&|b6SwKD5tFGVI^J&z?sF?=s~w*FKRLax(-5bpK(M_Xm)~)R*A<* zn{5ru;X8+QUT>6ADv^4b#9)X9v9cK4SjIc>-|PEK zQSrm7gYcV?DY+ST`BtQ;{>}&tfP`b8gUsjt&AD)`ey^?7gejEar8s?>?B< z#GeXwrK>U%b$S6F$7Ey?Jb@eX`i>$;9TNVOf(gGUowjkDFja6{@5BbT*n4$RLn695 zOJpY(p)#2#<)mM6b;!Bw3YS=Ok@DnmjuxlC14pcgQA$2As!MS>xXGhXXlZLepD80m zk;iFM&WI?Y+q@;FlKoK9iik#J8~PnlH=*xPN*LaP!7nAu5VJGp(R66L1xHO8Uyu79 zy_zv~?tE%^cbwR1PJgn)>g6)SNpUxuU#KOgq&-i$op`Vw2;-A%TRT?e(F?Q~xK-`L zGOLK`Q@PHy<|I03U0J2d=D~Q{M$ywmh+s`?;$H&SraRv&P4F3rQqwjrt~xt0d~dID zy<=I0=W(^H^CviO%GD6ZXoOoDSz197qkw0wq>%4|Ex?0KE5?z0Mx};7@P1<`I~WFs z>!hG}-E+xz-*la+GEntSGDDLlNQ~hWg8J8Qqd3oIHjsGPf(7Y12=aypXP}0$1d{vCL>oIytLw^ zWjGdSTqbXKdL;xGKxQ&maQozx`wDBTa@bFCP=4k9xs@ujpMPb)oV$8HufBA!0$$*$@EWfLVb*50^jD&d z5_oz@&*bK34VEeLD62At9vs3sPj+a2XSBr^B=~-6DEa9tsln|S${m$+Txmsna8CiJ z+gWbW4Zbc*Te*0+eR~g2nok@yTW#-1j_$vedxalW>{6!MO|LTQ!*&(3IY# z6T4brj0s*~w}N7$erUuwRU0`uoo(!N(hW?w$0cqtGH(Fqzc4<#r1E-J)QN<@H)TKh z4Rlyn&t0>T+~MZM*$9#@o18t#b8~amZ0W#apYhTbmx<$ql$C$yI88%`@%p$)d&n0X z|69pTCnv7iObw6l88#|AaHj3V0F90abVS+U$3F0ibo~1el7LC#PMdVH(&tIolx_DH zG1iR|7W?Plhtctvn3H0YNx26*J3{CVjZ+!%jggVMrHeIN4ia$jvj70F@Y%1^)wTM)DRu@ zN5iGIKUUs(^tu_Phf7um5o^rFuoK!e8e@O-TtdR;YVqs$W)UxMX{W_qy2U9ES4V~A zz65p1PjVaqupSWi9-a_qLotc`f?h+7Xw)l|N``FcZIwvuStd7-t!)P|tfU$HDT#f8Ax3}Cl?O3&=;4EfUGe`GSL zDcweVDw^~N3+aF|MtNGyj`758u5!OVAla<5Qkfpp(_Z@m1NPeUM^h)cKvEoL)EJS$ zQL0@$;~V%uYi4_5K|5&I#gCcF@w(Yl9_K&&wOHKF?v*m+H5JcS;lk{X_IFkihO;Vd z6FS$@NJ00+{Qc3@!sO8iD7$vBUrH^{{G@HSJ6{$g4y1PFFSG*%d4bG34xysFOr&YqH*uG)@>ancum5$*r#nf&}K{oCG8h5oL&yxE&uy{>M+=V=rG>HCArn5kml zZaO#pFglj)TN+Dx{QaFZ55Q&r!nT`Y&w}O6Om%3Lz2~q$fOT;GwV347X7F==BoUjo zc4)gI^^y-C`-sv3IO|>WVTU67)Hf2Gf^a^`lu5a3N2PJog0Y+D?Vq_I#&SJW+m@*K z?f#N`GY4aV1rz*l=?rFVP>m$FxutPeobccCSE+(L)5kiN6g?_s%J8-M+HBDX7g%F< zWP~e;+#T`aPy5ppvk+?--Cyn%$siK-ZOc9KACrx9@_=uif6Jwed!C}6zcBn)Lfoe8 zJ%5a|0qKa2BleVP^lK`iSlL`VQK$5VrZn7xQ0ZCeg3Qxy0|-DTp(QOoc)7D&?l{pwXt#!HLdxbU zbos#kG@cDj_4#iK_+={I{Y7}tgrMB?F~V}ekcuz27*7=X@ez5Mma*fVJt35t##gx> zSKi{RK?E$lf#@l#xpZ*fixB!!*^+4OzVjLNR z8LrFCC=xEb<1=y%3z(`7KqDYx69j2M4t=H(XOEXXxgkKcJQr{J6z>5a_at zi+R=`_&}!QNtzcwdA$ZjqYZp z-Sf`;0OzB6z6ww6+ue<>L<9OFnMqa3Y3s*LmYZLAC@Bf-aq7YORx8HJ3q400D@^-0gk7Pz;a?3#es@;7P< z13nvEB%D2eY0y-J>ix^lW#o=?@3TeB2FFKJHqR?C0{-N#Zp*S*DOOB%b{boRVPe}; z6lr87v8Sh4-p*?$wmK>WtS2c5eVO#^VsCWyz>bAHMn$>qli`rdjox6U8Ys3$?MfT&l=iLBHl&EqFmHUGe2s7s8KR2|ZXn)rcvI2hgq zDb*kI;}s!>nF;%Hhy$S^YIV%ovv7c2DTPL|i^4ponjz5BlzOO;8;}l=!hojDAxr+R z5CEkzo$Oiogq^4mmdCYC3MRW0dwG^Pk#Kc8R#eHGO14himI)PUi3+@z>_Ng7c_94K z=|AK<{g>6uqSM=^6^H?&34}NHka+auDdVUs2VOe7mv6EJa_=sQQq_LnrJ!!#f)~vEpXMS4)G7JM1%~Ds>oJgsU*f?9y+)E%HeFAFNRo9oy`5@|ZD)+%!zb zI`_%3EYk!^GVn^gvwq+Qz5yuqrBTdxBAx}BnBk`o>nO)2GubC(rzQN=%Q7YvVtcv) zi)t%d8f@=x6V>HTT@c$nJ^2FVjXU3EJdExB<9@m;`0OqKJ53&%X*`+jqz(C_ApGOg z+&(cnO*b@=l|mlVp4wTzeOT~I^$5lpCqQV8h+L+qPTuB>IkQvl%-gUT;H6+!aScZa zD5SH3{POq(CDUX73hKJ!NTxkoD%Wv`Zph6>#zQEWYeMbk7!w(PK;0%BOYB2leFWBz zliNI6u2K7Tu#W;Rg=>XT$>YWx2d7~Q@g-A^M`TXGkul3On(nd0uvrzDIB>1i(c#th z?lX-uiIn8{PX6CdrhH&D!!I?f{=}E%0`8KWohX_|C8q(LFQF&KschsUVETv@N6Qym zgf#=g&)ZZ9v5<&0FzM|^#m)P+D()7dwdacBIn66I1uvcPRn$$zk+}NIHZN_R-%8U8 zkw65#8dnzdY5A4vx3I)=Qce1CH)3^v!!)g}uG=DA!T2+~Z_5hrBJQCG|G` z&HFj`84Z=>Jx)9v9(3SjDYp(!R`M6lpsyQ9Vg!fw+++gSk$iYn*XO?UzQOLWn@ye9 zbeHT9Y(Zy%`q1RMA;)()fm5PTyVtIzSM>oyzX9>JGvrhg+$+UvE00t$ob_p32m*=m96R zr83puR!rrK%ecUi|Ge2fbao>yUT}gh^Bqw6%mJg@XcQE`9d- zVR27km7qlMJ?>iL%qKF%BaqruD z@Z#-+=3~#)rWxM*$-?=*m!UW?09A z)+KW>>3*{Kw@KrHcraX}_*P z*a!EUtevDj)DovRh%D#1C(BA@yy484RhrL+MwZ}%WU$V++A^v6k83_4=)v4s!cK9z zb&$2;5VZSYjnA3m_Z|Uh`uM6psmu;C;u$jI&;x=vu)RBQbQDM884@yh3@W)0cr;LN zaeK6jMvwasdVbSmamSxET1;7)HD2yf9IiQCV&H#>oqAu{n2T5-Pl*}^)oj1E)|&AG znE4+N5y3ixKOTA%DzPyH&2pV#$5I)+>H8#*Ft^`>Jix?Q!z+)g_JDH|dec_aXHgyQ zvA;iESOhKcs1($bk~0cw51;-()C4S_&pOl}hO3AqfkuAA1=LA#)e^7DH_5SJm1E*tE z*6UJ53?GQel^5MI^BZa??La^z_!-xe-$02eL;@d#t{(3*giU)@1Bqs5V~8)#j$g9l zUvv)#1pqGMgg;lWRZxw{F)54M;YSB^Ga#zQoXO@s%_c z*?)anvfd3+=8`6SRO-;wBSNpxYi;?MQ>w` zf}RTV*y_9%Q|a4=jmnkMY!N_ZTth=v$e7@8zT*P|Sxt>`57WkuqE$wKu?!vdFVEB( zl9CTXSFLcaow;K1V3GH}Ku?eKRlK|YjmH)`=-j`?3@>Yzxn%)Icc19IMy&?DSOt5- zL1@cq*<-otx_>T*2mJZ;K<`ulcN=cJ+)#FM!5la>N_5jU%GmH{VQflYKOrkR3zKwz zWqY^(={`Nj~`ZM^dCx~B~!ecUdf^T2v4#^K&G90@g#9#u6uAauto&d5F>Z0#eLbA zLu(p7pppD?!0Eo$a}liugzMg0P2K?wt_s|Ea;{4Y9VMtKC07%;PSHD=UQs|w%k*&N zbbza`Mvc#P4YmPLTE|W9^KPzCxe**1ncznplm3!UTRCq0X0^77k%^If&Xtd&mIuGL z&))B52rMQY8`@{r1m42YR7{|ZX$!+VftpNFYl238x2fBwQ>2Wgh~opdbfHO9A9d;2 zzHU_3e0p;VqZf)z5;qJ)SFS0pnMJ5{`f>GfyP50QiwB{ymIc(Bilk=?3kVi>K?+GMC*u|Oog{;#r85N!cCQ00bc`eA4X_GR#+Zd7pm(;5d)AwvXWut#nf_KfsBbJ zh}O9FFh+tt?a?v|6+9nj&_l-;q)hU!fke9D`?(9%Z~0ourY~UUPfBe(Hybdui+%y^ zR#PtbsGzlj6W8Zm)GPjz1lqZC1g*^oJT&kzfUIQTTa{k=pQO-JIwX~tsStZuV@x+1 zH^-Zb9p}GWX>UPW#d0WQiYK?1GalCoDoi64SDH@|6D`^6M>1FVc_x_s4heUOa-Ra6 zW!$y{`INGhhyEI#&3{WBc^NsEcxRJz9*jmws(=g?H?_Hw#}t&EMj9{M+<6X0EMxiF z8kMD_pP(4kg3{AS&gEtY*~5}e?l46d{LdE_@TMZ~9@4IH6O?tNv^iI_mgULX1oEt4(= zC9%;XGZ0W(!GFC`IrGu=D#n{B-P5?aq+7(X%S~~8Wy%fLW|faErFnQahPueU-^=~C zLp%87l7)uC;?uF*s5!T$!YIKOXfY-*Q_wd#=Bq?>yUWMJKFd$M{RWAhZwYv z?HigA*t2fbZ#fwE?M1D`IK?jG?i#f3ea_M0(hF6($~b*(zH3i1VHsH-%My1)|3z(6 zS9Y@`G<9M7Iv8JK{P%~C;Y+49Q<|0&U8pOE({6_g_<%~uaB};hwaIes0If@htTEI% zsfs6rdauAAVKR;T7+|nzRS$XZXaP;R>WS)!(w&zzf{^K9fwou0qBl?1a7BC=_ts7l zX;;4A(w&vUGEC%HVuf)u{)mYODRwwIFe3lliLwi(MXg@utg!D5 zKVoKq_g@qE)=)jTeb?#sBai?4JSeaV-RAlUis)f2ije~!{kER{1O;9T2@)yoMI!!X zP^75VcwQNIRKnlHw{I5T^U(sq)=h8I>h-Gze5vL^`W6@&B+-S}gL${=03F$5nV5P5)Kp@ez>w6OeoCjgZMUn@jX}F+J&!ik4~_QWLX$L33hSeZIyhtYo zxEu>C)ZkoPlyg`$iWy)8c^2<+^=VZ@dCS#9>C;f}LakWfq@w>g^JpL!FlSI@;c>rW|WR=l$}Yz9*+yy3}*1=pvLimzx3 zCZiu@gi<{+o^wvX)DsLl&mHT|nrIc-Ko-?UwZ)COP-pgkMEeECyq;&F9?q==Qg+eO zThQB4YKI^@3+Gg7{7jpKibE?iG3?criyS)}H)ML~NB zUjvNuH18{?oFuwa{PS)>0t8+mj~(lxdk8l$MgBpC?FZhmUJBxihNt9D^^fXCW9NAN zF^<>Xy%F8b6J8=edS{&+?(8c4j82YgxDb`MsF(>RM3$J!nS7RhYF%w)vQi^?b}M&p zs$ko1_OUz1yd=#-p}UO2kZGioxf)2uXfrJ@X$1QWp;mE1V?G zwzrYUnprTz>EW_9_C(KoZmsLY+~|vZ5?Lu7CS4sS_rYUSMKgMqN)WNCG85ZZ$DrVu z=?mBJodubREO#(dKRzH;k@UdD;>IGsCx)+kmy&)gQaqo8*52<}B^hlr%d%6Odrzs5 zX-(^ni8jyUI!zrlPfn)b`SIm-$~U}K~5nwC5o-2vhb zQJY^g{bSw@XZwfJsr>BCkhw$F7HXU^bUB_yWU)DeMQlIg=^Uhje`- z8?MlR{yp@MYI%~(G0Q^9&#nC0^++FD<5go;>&?2^fxZg?1Y6S6;EvTY_VAJ+v&do4 zu?mv%=i~J-m9K?D`Y131@%8b9RM{I*!QLq(=WOV#{UUdscp7&k#{f-SlS`JNqug1` zpg1u5zB)Ic;jV3&MPGZAGbbMhOQ!-uuBAMVA+?C`{9JEparE@_&MyPw(sRc-XM3!Y z`(Alh-4SVe{C3w9JyQKO{NLV{U5Xl0A+{>8&r_9497`SW9Mz-hw0OHAkVJRP z*jz4;V6UX?P104|+cI1MFArxbtnW>v74{z<9(MuowFu;`t(VXwJZM!@aY#=_FsF11 zOs`{x^$v^@>ecacCcyf**JABz`2{;AWpzm8E5cSQqOd17A$TH9Ax(%VboeI6jImNQ zo$<@y+VZ)3;=oA;{zz2|U60>;+jM3SQ}xPdUwHI6Ub~4gF0K_P8%_7i=@Ma?qo*t6EkE01p{gGPi6iy;moU$@; zPt!EJ?_7&X)NKOLF7-0P8zJ~!212_jR4ubS@OEfObTkeVn8Ar+xC)z8#-mnPwdyd# z=L7u%;cd|n7a~p1hwBL_!Gfvw>AjhY#%Z_$w6}075nUOVkLqU=M(JfNc-X%YyKbz6w0PSR(bXk#YiWI>eC7OGzWX?;;E{oG zrc-PGN3d~Y%YWHQ#`o4cRQpw+_3;QTB}GP`?H?@H0v~+=(P9_cHVq6bcELNbeY)e> zHHYi04lK94xw2EI)XZ&bY!Di z0z?>p7<2g#Utbb1JAX!iJmHst?KTARx!W zvtS%YswDo(ti6yl;00ZqI)5b*Px}G67J%X6S=8yZ8lz!FnhDq-`Mni8CUOtccw#TgK&hE*IO$qVJ;h5T58uAwXLELvzJ7$1GF2dP2oky)x z0m&bl%+k|jDdnL4VvJh;xZoBB1N$q~lf02{0Fw-2kYk|sCy0|+SsSkC((;@3mH`={ zvSPOjg`diGD@Zij!da-lsCzK!e>PQ22wNHINu3&~VJ9I`;TfRgjL3)2LO!{G0rm}Zu`G+1m~Gr z>z<|eG+B(T;}}z-Dlj zE{uxQL5~@g4io2!Im@EL zxvDa2_UBEOGkWnHgQL#z^%yy}7qpN=|DD;?D18Eo#&}MN4*698B3c;MmC$k;*vS*B zayoTq0YU7(Rau_XYrB!Zzpdpk} zC|$(q!QAt*BCNu*V&o`X3?k=?BaVS7`Z3Y0fUtx!5QJt`nGpaD1QQ2FgR@bED7`v7 z&Kw=>n=6`w57SC>(9xVuuA#;R0}i~L`l)bffW1t*zS&doFyr!lh|TA_~Q zTNhxo;>`Xj)_ErpcDS}ep)RFYU7Y=IQS`H&ZLbz3WAI|Hiv@6k$@s?V{byLGw}X1SE^?u5ca>=^40^p zaOGg;6NbB4tP8N~IcJ4*YZOP2^d+UO;#q0RaXa3ac>_*2ys>U|I@Z2^(n)7bXwZrr zIbaaAwG}w{g1<;K(7B4waj3Xlf@Sg@Jx`vwL4*t4ZEc)z@M z+Q8-meON7R%w`u0v5qzztoe;q3BCgmud0YYsMV;6vk=)rb5f*J4K(q1cZgsBcJv%+ zj1Tf8z{GChFZ{+N9i@0~Jnl7xo4h?0T}fg;O0nJyAnMm=(2yA&)e&q&h;>;i1_ zCbZ>h(&p5EAX`P^0ag!pje6t65~hiC&1Q`dlyM+?@8ptZEPV`AdJLOJDr2c&?Ks2so>UZ^t-3R!Mxt*9s?;K65ef^mggQ zv5;bQv~C9g%T0?bf5F}yv$<-(T&dFNQKG>>%LeF~RWe#zv6lW$w^>^FZ?dLnR?Y^< zO*jOO){HLJYco=-T5tAgv0?L)P59rqE&amrUJ@fFFm9x^Pt^XM(2;#j%c8%Mu>%H3 z4dR9W`3u`(+1~B{{?L?RMW3HI@&KtS~-i_o&R&1pcR zBjkMx=Pf>gRpmg5dJAlcrEWa8q!njf*7*ngUMa>2yQ4)kOv_qJ$=Z4V*o!aQ`I8a| zlBN?%r_ja;jX$yLI7NM1Lq?Wd^nkOUADepc!qlzz_Z9>to)AN8(2Wu<`Nmyz7=P{6 zUu)VbMf5CWN;GT9ih|M7kkze!?pOh$)H8v`*Z;ma!4DH>QUaG`#FYd5!BeVnJo>*c zRwfCN81m_G#23=ccx(UA?bqoAMjA#m{=}$V3?l*AiKa|oD$oK8nLbpN!wb`}Ccv_Yfi%#JX=n#6Wb7O8Nae)a#w5^}hJx8RkMO`+VQuwqe@ebB>MT zjCpd4-=n3E3IAEm+=96Sdfgp)tAK-+->Nw$S(*WitIJ|g-#NiA=l?funloVqoWd^u z66?^IQZ|SRy9jU}m7KT=#;6QAXgPUSnnwGOibkIKJJw;d_oeIrw;eaAU+GRX1Yk3+ zTZYZbU8=8q3}mteT&Q=UH_{|9{?h~&)K zPT%k6yH`o&mw5107FbBo$4mWX3sTx-e;9udFwyt4u-bK3I;fr2-Z2tw-Si#_gn_f% z4L0(1hD{mM6T2wan~!%#%eqpxQ@0ngdAt_<@VwWw>GQDQF2v+_e>CLe@XGfCt<$%8 zncv6r^<{~avjeys*zfwA;ICeRm*pLI-=~YYBgp!z<_~SgybZy%t|xB@{NZK}=W9{& zpQoz@@cL?7d=~_w?%{Uvw9qzjHh3racyn?4VBhT9e#_)_m+c5T@f(c4o2sg&vQiXW z>B{Uu@LqEA_*ajHu%2@>^qezyy$lL(td#sf<@u<7Tq*F{c*vBeXWl})Uo<1TM(qBz z6cXH&)*z6xbw;w|FrGEr@?e(uof8RRkh#v)u~vbnZ*(@ozWz+%>3H9eu+r!7m&((3 z7v{ey%=kVC@C8rDui<((FOZY2NvFIiFG+XOmlrp1BFTN%`B~+=V#ThtY1*5cPVXkq zSI4`rOR%7}s!ykSyF|ks029sVR^iM^gWKW)C}FcS+7wDGNX6d98WM6<_} zT;b(Zg%t!v!h8GgY?7Rf1)iV#uiPm5`Vzh@ex65I2#@!Ft)5s{6ml+f7aIMSHMxrY zSn7ZH*mRZV_qg}6)5f$I{qbXt=hKAZ6t^37mrtvochk$07x?A8Ys2=XTrlK|bOJu{ znwfhR78B>>V`y9GgpsTD1cg0%^$vj=7eufrdS)bM@@8U5C3bS2#vZrG+SsM}=S~c-w35gu-T=cSEO|t5dC)pPlzF{(1^CkC}_a*a6L^l5tU%i>|8H;DJHi zObas^Q*fmA_`ED@YnQFsdG+EQT9?mb&C87&*a3XKzYbBfAA#KXRxd&MRICpxTy>NN zMNRrhY$9=1*j00JAssVLV>NZ^?Sj8hYZ7X}!yb&sw%u=-BVRm9?6<HZ*m8J?!Ob9QD`pQf!F)8C?Qt9wSu)^`16LGY7X`m zJpI0m32l&AzC-)_W=(EIX+x()rtA*RB`yc!KXS|FgSZInSy-LB>6h?~JHYHJ%{fbT z)PJP10ts?%zKT$e!gfP?3av_mBm)-=j<(emUeA~T?O4|)<_}N-kj&N1wyh{@;v~N z(#PSV+3WEisk0H#dG}6UL$k!#KCGFs*AH2eW65MQwtRU*~BBWxJ}P!HxBu z$1Yg{a7{Jkgaj!D97vBv)?TspGg{+JC5fI>B8FpcsPnZ7WlTOVs|CxqR()bL_Dx38 zwps&kJfx}qz1o2cEv%M1o%EIBFWw*d;{GXKaB9toC}hubE}YY^w*S7upeFb&2)laS z=*OH@VsNY!Zo2Pg)5*3AMQOAEjpE#)QOTulc2(?LD2kn3Js8Q0w)H*>=d+l-gieoZ zm=DTlbI(#jl|OQTZWKz@mf0TS2>8~EkAKgyDR8yamBhC(wHW9xel